,id,ticker,title,category,content,date,provider,url,article_id
122466,343981,BDX,Fallout from money manager Kenneth Fisher s remarks tops  1 billion in lost assets,news,By Tim McLaughlin and Ross Kerber BOSTON  Reuters    Fallout from Kenneth Fisher s alleged insensitive remarks about women escalated on Friday when a large Iowa pension plan cut ties with the money manager  whose firm has lost more than  1 billion in assets under management in the last week  The Iowa Public Employees  Retirement System was the latest to notify Fisher Investments that it will terminate its contract with his firm  Fisher Investments manages  386 million of IPERS   34 billion trust fund  Iowa joins pension funds run for Boston  the state of Michigan and Philadelphia in cutting ties with Fisher   IPERS staff has taken time to evaluate this situation  and it is our opinion that Mr Fisher s comments have damaged the credibility of the firm and its leadership   the Iowa pension plan said in a statement   As a result  the risk to IPERS is that the firm could lose investment talent  and or it may be unable to recruit high caliber talent in the future  Furthermore  the negative publicity will probably continue to be a major distraction to Fisher investment personnel   Fisher Investments did not immediately comment  In a video posted Oct  9 on Twitter  Alex Chalekian  chief executive of a financial advisory firm  called attention to comments Fisher made at a financial conference last week  Chalekian said Fisher made derogatory comments about genitalia  picking up girls and financier Jeffrey Epstein  among other topics  Epstein committed suicide in August while in jail awaiting trial on sex trafficking charges  In a memo to his firm s employees sent to Reuters earlier this week by a spokesman  Fisher said   It pains me to know that my comments have caused you grief  concern  and indignation  I sincerely apologize   SEI Investments Co on Friday said it was reviewing its business relationship with Fisher  SEI serves as a trustee and sponsor on investment portfolios managed by Fisher for dozens of retirement plans that have included Becton Dickinson  NYSE BDX  and Co  Blue Cross Blue Shield of Minnesota and Nextera Energy Inc  according to U S  Department of Labor disclosures    The comments made do not reflect SEI or our core values   the company said in a statement   As the trustee of certain trusts advised by  Fisher   our fiduciary duty requires us to focus on and protect the interests of the investors in those trusts  We are engaged in a due diligence review of  Fisher  and will make decisions that we believe to be in the best interests of investors after that process concludes   Several other clients of Fisher  including Fidelity Investments  have said they are reviewing whether to keep his firm as a money manager   The Kansas City Public School Retirement System  which has  78 million with Fisher Investments  will also review its relationship with the firm  Executive Director Christine Gierer said on Friday  Gierer said she expects the situation will be discussed at the system s next board meeting  on Nov  4  Fisher s setbacks come in the wake of the  MeToo movement  which has exposed widespread sexual harassment or abuse of women in multiple spheres of American life and ended the careers of dozens of powerful men in media  politics  entertainment and business ,2019-10-20,Reuters,https://www.investing.com/news/stock-market-news/sei-investments-reviewing-relationship-with-money-manager-kenneth-fisher-1999448,1999448
122472,343987,BDX,Fallout from money manager Kenneth Fisher s remarks tops  1 billion in lost assets,news,"By Tim McLaughlin and Ross Kerber
BOSTON  Reuters    Fallout from Kenneth Fisher s alleged insensitive remarks about women escalated on Friday when a large Iowa pension plan cut ties with the money manager  whose firm has lost more than  1 billion in assets under management in the last week 
The Iowa Public Employees  Retirement System was the latest to notify Fisher Investments that it will terminate its contract with his firm  Fisher Investments manages  386 million of IPERS   34 billion trust fund 
Iowa joins pension funds run for Boston  the state of Michigan and Philadelphia in cutting ties with Fisher 
 IPERS staff has taken time to evaluate this situation  and it is our opinion that Mr Fisher s comments have damaged the credibility of the firm and its leadership   the Iowa pension plan said in a statement 
 As a result  the risk to IPERS is that the firm could lose investment talent  and or it may be unable to recruit high caliber talent in the future  Furthermore  the negative publicity will probably continue to be a major distraction to Fisher investment personnel  
Fisher Investments did not immediately comment 
In a video posted Oct  9 on Twitter  Alex Chalekian  chief executive of a financial advisory firm  called attention to comments Fisher made at a financial conference last week 
Chalekian said Fisher made derogatory comments about genitalia  picking up girls and financier Jeffrey Epstein  among other topics  Epstein committed suicide in August while in jail awaiting trial on sex trafficking charges 
In a memo to his firm s employees sent to Reuters earlier this week by a spokesman  Fisher said   It pains me to know that my comments have caused you grief  concern  and indignation  I sincerely apologize  
SEI Investments Co on Friday said it was reviewing its business relationship with Fisher 
SEI serves as a trustee and sponsor on investment portfolios managed by Fisher for dozens of retirement plans that have included Becton Dickinson  NYSE BDX  and Co  Blue Cross Blue Shield of Minnesota and Nextera Energy Inc  according to U S  Department of Labor disclosures 
 The comments made do not reflect SEI or our core values   the company said in a statement   As the trustee of certain trusts advised by  Fisher   our fiduciary duty requires us to focus on and protect the interests of the investors in those trusts  We are engaged in a due diligence review of  Fisher  and will make decisions that we believe to be in the best interests of investors after that process concludes  
Several other clients of Fisher  including Fidelity Investments  have said they are reviewing whether to keep his firm as a money manager 
The Kansas City Public School Retirement System  which has  78 million with Fisher Investments  will also review its relationship with the firm  Executive Director Christine Gierer said on Friday 
Gierer said she expects the situation will be discussed at the system s next board meeting  on Nov  4 
Fisher s setbacks come in the wake of the  MeToo movement  which has exposed widespread sexual harassment or abuse of women in multiple spheres of American life and ended the careers of dozens of powerful men in media  politics  entertainment and business ",2019-10-21,Reuters,https://www.investing.com/news/stock-market-news/fallout-from-money-manager-kenneth-fishers-remarks-tops-1-billion-in-lost-assets-2000734,2000734
122473,343988,BDX,Becton Dickinson  BDX  Q4 Earnings And Revenues Surpass Estimates,opinion,"Becton Dickinson  NYSE BDX  came out with quarterly earnings of  3 31 per share  beating the Zacks Consensus Estimate of  3 30 per share  This compares to earnings of  2 93 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 0 30   A quarter ago  it was expected that this medical device manufacturer would post earnings of  3 05 per share when it actually produced earnings of  3 08  delivering a surprise of 0 98  
Over the last four quarters  the company has surpassed consensus EPS estimates three times 
Becton Dickinson  which belongs to the Zacks Medical   Dental Supplies industry  posted revenues of  4 58 billion for the quarter ended September 2019  surpassing the Zacks Consensus Estimate by 0 34   This compares to year ago revenues of  4 40 billion  The company has topped consensus revenue estimates two times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Becton Dickinson shares have added about 15 7  since the beginning of the year versus the S P 500 s gain of 22 8  
What s Next for Becton Dickinson 
While Becton Dickinson has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Becton Dickinson was unfavorable  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  4  Sell  for the stock  So  the shares are expected to underperform the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  2 96 on  4 35 billion in revenues for the coming quarter and  12 92 on  18 13 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Dental Supplies is currently in the top 39  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-11-05,Zacks Investment Research,https://www.investing.com/analysis/becton-dickinson-bdx-q4-earnings-and-revenues-surpass-estimates-200482164,200482164
122474,343989,BDX,Becton Dickinson  BDX  Up 2 6  Since Last Earnings Report  Can It Continue ,opinion,"A month has gone by since the last earnings report for Becton Dickinson  NYSE BDX   Shares have added about 2 6  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Becton Dickinson due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  Becton  Dickinson Beats on Q4 Earnings  FY20 Guidance SolidBD reported fourth quarter fiscal 2019 earnings per share  EPS  of  3 31  which beat the Zacks Consensus Estimate by a penny  The bottom line also improved 13  on a year over year basis and rose 12 3  at cc The company raked in revenues of  4 58 billion  surpassing the Zacks Consensus Estimate of  4 57 billion  The reported figure increased 4 1  from the year ago quarter  At cc  revenues rose 6 2  Segment DetailsBD MedicalIn the quarter under review  the company reported worldwide revenues of  2 44 billion  up 3 9  from the year ago quarter and 5 3  at cc  Per management  the segment s results were driven by performance in the Medication Management Solutions  Medication Delivery Solutions and Pharmaceutical Systems units BD Life SciencesWorldwide revenues in the segment totaled  1 13 billion  up 2 3  year over year and 6 9  at cc  Per management  the upside was driven by solid performance in the Diagnostic Systems and Biosciences units BD InterventionalThis segment generated worldwide revenues of  1 01 billion  up 6 9  from the year ago quarter  At cc  revenues grew 7 7  on strong performance by the Urology and Critical Care and Surgery sub units Geographic ResultsUSIn the fiscal fourth quarter  revenues in the United States improved 4 6  to  2 56 billion  Revenues grew 4 9  at cc  Per management  growth in the United States was driven by good performance by the BD Medical  BD Life Sciences and the Surgery and Urology and Critical Care units within the BD Interventional segment InternationalRevenues outside the United States grossed  2 02 billion  up 3 5  from the year ago quarter  At cc  the segment grew 7 9   Per management  international revenue growth in the fourth quarter was strong in APAC and EMEA Margin AnalysisIn the quarter  gross profit amounted to  2 27 billion  up 8 3  from the prior year quarter tally  Gross margin was 49 4   up 190 bps from the prior year quarter Operating income in the quarter grossed  111 million  down significantly from the year ago quarter s figure of  576 million  As a percentage of revenues  operating margin in the quarter was 2 4   significantly down from year ago quarter s 13 1  Adjusted operating income amounted to  902 million  up 26 2  from the year ago figure GuidanceThe company expects fiscal 2020 revenues to increase 4 4 5  year over year and 5 5 5  at cc Adjusted EPS is expected between  12 50 and  12 65  indicating growth of 7 8 5  from fiscal 2019  At cc  growth is expected between 9 5  and 11  
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in estimates review  The consensus estimate has shifted  10 74  due to these changes 
VGM Scores
Currently  Becton Dickinson has a strong Growth Score of A  though it is lagging a lot on the Momentum Score front with an F  However  the stock was allocated a grade of C on the value side  putting it in the middle 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  Notably  Becton Dickinson has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-12-04,Zacks Investment Research,https://www.investing.com/analysis/becton-dickinson-bdx-up-26-since-last-earnings-report-can-it-continue-200490371,200490371
122475,343990,BDX,The Zacks Analyst Blog Highlights  Royal Dutch  TOTAL  Becton  Dickinson  Workday And TransDigm,opinion,For Immediate ReleaseChicago  IL  December 26  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Royal Dutch Shell  LON RDSa    TOTAL   NYSE TOT    Becton  Dickinson   NYSE BDX    Workday   NASDAQ WDAY   and TransDigm Group   NYSE TDG   Here are highlights from Tuesday s Analyst Blog Top Research Reports for Royal Dutch Shell  TOTAL and Becton  DickinsonThe Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Royal Dutch Shell  TOTAL and Becton  Dickinson  These research reports have been hand picked from the roughly 70 reports published by our analyst team today You can see Royal Dutch Shell s shares have outperformed the Zacks International Integrated Oil industry year to date   0 9  vs   0 5    The Zacks analyst believes that the Anglo Dutch company s position as a key supplier of liquefied natural gas should further benefit its long term cash flow growth on the back of attractive growth opportunities Europe s largest oil company s Q3 earnings was ahead of analysts  expectations  driven by strong performance from the Downstream and Integrated Gas units Moreover  its dividend is safe and secure  However  there are worries over drop in its cash flow excluding working capital while the company s poor reserve replacement ratio raises concerns about future production  Moreover  Shell s  1 7  2 3 billion impairment charge is expected to increase gearing  Hence  investors are advised to wait for a better entry point  You can  Shares of TOTAL have gained  8 3  in the past three months against the Zacks Integrated International Oil industry s rise of  0 7   The Zacks analyst believes that the company continues to benefit on account of strong contribution from startups and the expanding upstream portfolio that has above industry average exposure to the faster growing hydrocarbon producing regions of the world Strategic acquisitions and divestment of assets that are not in sync with its long term objectives are going to boost performance and further strengthen the company s cash flow generation capability  Cost saving initiatives are also aiding it to boost margins However  TOTAL s operations in some politically troubled regions and increasing competition might affect profitability  Due to its global presence  the company is exposed to risks associated with pursuing business abroad  You can  Becton  Dickinson s shares have gained 10 2  over the past six months against the Zacks Dental Supplies industry s decline of  10 5   The Zacks analyst believes that solid performance by the core BD Medical and Interventional segments instills optimism in the stock Domestic revenues increased year over year in recent times  driven by segmental strength  Growth in Europe and APAC is an added positive  Expansion in gross margin is also encouraging  BD has issued a solid guidance for fiscal 2020  which is indicative of bright prospects A series of product launches is expected to boost the stock further  On the flip side  a drop in operating margin raises concern  Management expects unfavorable foreign currency to partially mar BD s bottom line in fiscal 2020 and first quarter fiscal results  Competition in the MedTech space is stiff  The stock is overvalued at the moment  You can  Other noteworthy reports we are featuring today include Workday and TransDigm Group The Hottest Tech Mega Trend of AllLast year  it generated  24 billion in global revenues  By 2020  it s predicted to blast through the roof to  77 6 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early Media ContactZacks Investment Research800 767 3771 ext  9339 Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-12-25,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-royal-dutch-total-becton-dickinson-workday-and-transdigm-200494958,200494958
122479,343994,BDX,Can Becton Dickinson  BDX  Keep The Earnings Surprise Streak Alive ,opinion,"Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report  Becton Dickinson  NYSE BDX   which belongs to the Zacks Medical   Dental Supplies industry  could be a great candidate to consider 
When looking at the last two reports  this medical device manufacturer has recorded a strong streak of surpassing earnings estimates  The company has topped estimates by 0 64   on average  in the last two quarters 
For the most recent quarter  Becton Dickinson was expected to post earnings of  3 30 per share  but it reported  3 31 per share instead  representing a surprise of 0 30   For the previous quarter  the consensus estimate was  3 05 per share  while it actually produced  3 08 per share  a surprise of 0 98  
Price and EPS Surprise

For Becton Dickinson  estimates have been trending higher  thanks in part to this earnings surprise history  And when you look at the stock s positive Zacks Earnings ESP  Expected Surprise Prediction   it s a great indicator of a future earnings beat  especially when combined with its solid Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Becton Dickinson has an Earnings ESP of  0 59  at the moment  suggesting that analysts have grown bullish on its near term earnings potential  When you combine this positive Earnings ESP with the stock s Zacks Rank  3  Hold   it shows that another beat is possibly around the corner 
When the Earnings ESP comes up negative  investors should note that this will reduce the predictive power of the metric  But  a negative value is not indicative of a stock s earnings miss 
Many companies end up beating the consensus EPS estimate  but that may not be the sole basis for their stocks moving higher  On the other hand  some stocks may hold their ground even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2020-01-06,Zacks Investment Research,https://www.investing.com/analysis/can-becton-dickinson-bdx-keep-the-earnings-surprise-streak-alive-200496690,200496690
122497,344012,BDX,Becton  Dickinson declares  0 73 dividend,news,Becton  Dickinson  NYSE BDX  declares  0 73 share quarterly dividend  in line with previous Forward yield 1 43 Payable Sept  29  for shareholders of record Sept  8  ex div Sept  6 Now read ,2017-07-25,Seeking Alpha,"https://www.investing.com/news/stock-market-news/becton,-dickinson-declares-$0.73-dividend-509899",509899
122498,344013,BDX,Becton  Dickinson FQ4 revenues down 2   non GAAP EPS up 13 ,news,Becton  Dickinson and Company  NYSE BDX  fiscal Q4 results   M   Revenues  3 166   2 0    Medical  2 115   5 4    Life Sciences  1 051   5 5   Net Income  289   999    EPS  1 24   999    Non GAAP EPS  2 40   13 2   Fiscal 2018 Guidance  Revenue growth  5   6   non GAAP EPS   10 55   10 65  Impact of Hurricane Maria in Puerto Rico could be   40M  to revenue and  1   to non GAAP EPS growth Now read ,2017-11-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/becton-dickinson-fq4-revenues-down-2-nongaap-eps-up-13-762665,762665
122499,344014,BDX,Becton  Dickinson gets Warning Letter after FDA inspection of New Jersey facility,news,The FDA has sent a Warning Letter to Becton  Dickinson   Company  BDX  0 4   following an on site inspection of its New Jersey site  The letter cited several violations of federal law  including marketing significantly modified versions of certain Vacutainer blood collection tubes without agency clearance and failing to submit medical device reports to the FDA in a timely manner The inspection also revealed that the company failed to evaluate and investigate a complaint involving variability in test results performed on blood samples collected in Vacutainer tubes with Magellan Diagnostics   VIVO  2   LeadCare systems The FDA conducted the inspection as part of its investigation into the cause of inaccurate blood lead test results performed on the LeadCare analyzer BDX has until February 1 to inform the FDA on its actions to address the violations or it will face additional actions Previously  Meridian s Magellan unit slapped with FDA Warning Letter related to lead testing gear  shares down 4   Oct  23  2017 Previously  No link identified between BD s blood collection tubes and inaccurate lead test results   FDA  Aug  18  2017 Now read ,2018-01-11,Seeking Alpha,https://www.investing.com/news/stock-market-news/becton-dickinson-gets-warning-letter-after-fda-inspection-of-new-jersey-facility-1094348,1094348
122500,344015,BDX,FDA OKs BD s new HPV assay,news,The FDA approves Becton  Dickinson and Company s  NYSE BDX  BD Onclarity HPV Assay  The test detects 14 types of high risk human papillomavirus  HPV  from cervical cancer screening specimens Now read ,2018-02-13,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-oks-bds-new-hpv-assay-1236727,1236727
122501,344016,BDX,Age bias law does not cover job applicants  U S  appeals court,news,"By Jonathan Stempel  Reuters    A divided U S  appeals court on Wednesday dealt a setback to older job applicants  saying they cannot invoke a federal law against age bias in employment to challenge hiring policies they believe have a discriminatory impact  In a 8 4 decision  the 7th U S  Circuit Court of Appeals in Chicago said the  plain language  of the Age Discrimination in Employment Act   ADEA    which forbids discrimination against people 40 and older  showed that Congress intended that law to cover current employees  not outside job applicants  The decision reversed a 2 1 ruling last April by a panel of the same court  It also reinstated a federal district judge s dismissal of Illinois resident Dale Kleber s disparate impact claim against CareFusion Corp  a unit of medical device maker Becton Dickinson and Co  N BDX   Kleber claimed in his lawsuit that CareFusion decided not to interview him after he applied for a job as a lawyer in 2014  when he was 58 years old  and instead hired a less qualified candidate who was only 29  The job description required that applicants have  no more than 7 years  of relevant experience  less than Kleber had  Lawyers for AARP Foundation Litigation  which represented Kleber  did not immediately respond to requests for comment  CareFusion and its lawyers did not immediately respond to similar requests  People 55 or older comprised 22 4 percent of U S  workers in 2016  up from 11 9 percent in 1996  and may account for close to one fourth of the labor force by 2022  according to the Bureau of Labor Statistics     Wednesday s majority opinion was written by Circuit Judge Michael Scudder  an appointee of President Donald Trump  Scudder distinguished the ADEA from Title VII of the Civil Rights Act of 1964  which Congress has amended to cover job applicants  He said that body remained free to similarly extend the ADEA  which  the judiciary cannot  do  Circuit Judge David Hamilton  an appointee of President Barack Obama  dissented  saying extending ADEA protections to job applicants tracked the U S  Supreme Court s view of Title VII  Hamilton also faulted the majority for offering no plausible policy reasons to ignore the  more sensible and less arbitrary  interpretation of the ADEA  
The case is Kleber v CareFusion Corp  7th U S  Circuit Court of Appeals  No  17 1206 ",2019-01-23,Reuters,https://www.investing.com/news/economy-news/age-bias-law-does-not-cover-job-applicants-us-appeals-court-1755796,1755796
122504,344019,BDX,Stocks   Alphabet  AMD  Gilead Slide in Premarket  Est e Lauder Soars,news,"Investing com   Stocks in focus in premarket trade Tuesday 
  Alphabet  NASDAQ GOOG  stock sank 2 01  by 8 00 AM ET  13 00 GMT  as the company reported sharply higher fourth quarter spending on video content  employees and facilities which outweighed better than expected quarterly earnings 
  Advanced Micro Devices  NASDAQ AMD  stock slumped 3 11  as Mubadala Investment said it would sell its current stake of 34 9 million shares in the company  Mubadala will also convert 75 million warrants to common shares and hold those  leaving it with a 6 9  stake in the company 
  Gilead Sciences  NASDAQ GILD  stock lost 3 33  after the company reported fourth quarter profit that missed consensus 
  Viacom  NASDAQ VIAB  stock fell 1 66  after quarterly revenue missed analysts  expectations 
  Archer Daniels Midland  NYSE ADM  stock slid 1 78  as fourth quarter results missed on the top and bottom lines 
  Est e Lauder  NYSE EL  stock soared 9 58  after the company reported better than expected fiscal second quarter results and lifted its full year guidance 
  Seagate Technology  NASDAQ STX  stock tumbled 6 10  after giving a current quarter sales outlook below analysts  estimates 
   Canopy Growth   NYSE CGC  stock dropped 0 56  after the company increased its stake in Canopy Rivers  OTC CNPOF   Rival pot stocks added to a rally in shares for a second day with Aurora Cannabis  NYSE ACB   Tilray  NASDAQ TLRY  and  Cronos  Group  NASDAQ CRON  all pressing higher 
  Becton Dickinson  NYSE BDX  gained 1 55  as the company reported fiscal first quarter results that beat on the top and bottom lines 
  Energizer  NYSE ENR  stock could see movement in the regular session after the company raised its full year earnings guidance  Its quarterly profit beat consensus  although revenue missed ",2019-02-05,Investing.com,https://www.investing.com/news/stock-market-news/stocks--alphabet-amd-gilead-slide-in-premarket-estee-lauder-soars-1769521,1769521
122513,344028,BDX,FDA Resets PAD Guidelines  The Road Ahead For Device Makers ,opinion,Following the FDA s last week announcement of its renewed guidance on the treatment of peripheral artery disease  PAD   medical device companies sound upbeat about the development so far More precisely  the updated guidance for the physicians is related to the benefit risk profile of peripheral paclitaxel devices intended for the treatment of PAD The FDA StatementEarlier in 2019  the FDA had notified health care providers about a late mortality signal in patients treated for PAD in the femoropopliteal artery with paclitaxel coated balloons and paclitaxel eluting stents In its revised guidance  the regulatory body has provided the advisory panel s analyses and recommendations for healthcare providers  It has also laid an emphasis on taking additional steps to address this signal including coordination with manufacturers on updates to device labeling and clinical trial informed consent documents for incorporating information about the late mortality signal Among the recommendations  the FDA noted that health care providers should discuss the risks and benefits of all available PAD treatment options with patients  This is because for many patients  alternative treatment alternatives like paclitaxel coated balloons and paclitaxel eluting stents mete out a more favorable benefit risk profile The FDA has also asked the clinicians to determine whether the benefits of using a paclitaxel coated device  in patients at particularly high risk for restenosis and repeat femoropopliteal interventions  outweigh the risks of late mortality MedTech Makers  RejoinderMedical device major Boston Scientific Corporation   NYSE BSX   is pleased about the FDA s recommendation as this will allow physicians to continue accessing the company s Eluvia Drug Eluting Vascular Stent  DES  System  Per Boston Scientific  Eluvia has already demonstrated an excellent safety profile and a very low revascularization rate of 12 9  at two years in the pivotal IMPERIAL trial including many complex PAD patients Medtronic   NYSE MDT   too is optimistic about the FDA s guidance  which it claimed has fueled the company s growth in the PAD treatment market  According to the company  its IN PACT Admiral drug coated balloons  DCB  have clear benefited the clinical outcomes and improved the quality of life across multiple randomised controlled clinical trials  Per the IN PACT SFA trial result  three of the four DCB patients remained intervention free through five years  While those requiring a repeat procedure  the time to reintervention was more than two years However  as a major setback  Becton Dickinson   Co    NYSE BDX   has announced that post the FDA Advisory Committee meeting on paclitaxel  the regulatory agency has notified that it is not going to grant any PMA  Premarket Approval to the company s Lutonix drug coated balloon catheter for use below the knee Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-08-14,Zacks Investment Research,https://www.investing.com/analysis/fda-resets-pad-guidelines-the-road-ahead-for-device-makers-200455549,200455549
122514,344029,BDX,Teledyne Technologies  Netgear  Boston Scientific  Medtronic And Becton Dickinson Highlighted As Zacks Bull And Bear Of The Day,opinion,For Immediate ReleaseChicago  IL   August 16  2019    Shares of Teledyne Technologies   NYSE TDY   as the Bull of the Day  Netgear   NASDAQ NTGR   asthe Bear of the Day  In addition  Zacks Equity Research provides analysis on Boston Scientific Corp    NYSE BSX    Medtronic   NYSE MDT   and Becton Dickinson   Co    NYSE BDX   Here is a synopsis of all five stocks  During the recent market turmoil and amid fears of a looming recession as signaled by the inversion of yields on short and long term Treasury securities  there s been renewed interest in defensive stocks that are naturally resistant to changes in the economic cycle The reasoning is that companies that provide the goods and services that people  companies and even governments buy in all economic situations will maintain share value even as tech companies who are much more dependent on the business cycle suffer Health Care and Pharmaceutical stocks are an obvious choice  as are Consumer Staples and Utilities  Sometimes overlooked  the Defense Industry also generally holds up well during tougher economic conditions Teledyne Technologies offers the predictability of the Defense stocks  but also offers diversification into adjacent businesses that are minimally economically sensitive  Though it was initially focused on the defense industry   especially aerospace   Teledyne now provides cutting edge technology for medical imaging  deepwater oceanographic exploration and research  manufacturing automation and air and water testing With annual sales north of  3B  Teledyne receives about a quarter of revenues from the US Government  with the remaining 75  spread fairly evenly among Offshore Energy and Marine Instrumentation  Electronic Testing and Measurement  Commercial Imaging and Aerospace Industrial Since 2000  the company has increasingly diversified its lines of business  even as it divested operations in less profitable businesses like Aerospace Engines and Printed Circuits  The result has been a steady increase in gross margins Teledyne constantly seeks to reduce complexity and overhead  emphasize key customers and products and improve pricing on niche products For the past two decades  Teledyne has delivered consistently rising revenues  net earnings and cash flow  Over that period  the shares have risen more than 3200    easily outpacing the S P 500 and the Aerospace industry average Thanks in part to a stellar earnings history   including 20 consecutive beats of the Zacks Consensus Earnings Estimate  Teledyne shares have marched steadily higher  even shrugging off much of the recent trade and interest rate related volatility While sales growing in high single digits and earnings in the mid teens might not sound spectacular  it s a very comforting pattern in uncertain times  Last quarter s 17  beat of the Zacks Consensus Earnings Estimate was a standout in an earnings season that mostly saw more modest increases Estimates for full year 2019 earnings have risen from  9 35 share to  9 95 share in the past 30 days   a 12  increase over 2018  Those recent revisions earn Teledyne a Zacks Rank  1  Strong Buy  Teledyne s corporate slogan  Everywhereyoulook  is a nod to the company s industry leading imaging equipment as well as the ubiquity of its instruments and equipment in a wide range of modern equipment The company s proven track record  consistent performance and continued opportunities for growth and margin improvement make it a sound choice to anchor a portfolio during uncertain times  It s not a great time to be in the network equipment business  The US China trade dispute threatens to increase prices for firms which are heavily dependent on Chinese manufacturing and a threatened global economic slowdown would mean significantly reduced demand for finished products Netgear now finds itself stuck between the proverbial rock and hard place  with planned tariffs potentially increasing the cost of its products   manufacturing of which is outsourced to several other companies  primarily in China and Vietnam   just as demand for its commercial networking equipment seems likely to wane The products Netgear makes for the home consumer market tend to sell consistently  regardless of economic conditions  but the businesses that purchase more expensive switches  network appliances and storage solutions tend to ramp up their spending during boom times and cut back sharply when times are tougher The e commerce industry in particular tends to need additional network equipment immediately when sales are booming and is generally not price sensitive because they can make back the investment quickly by having fast and reliable networks  In lean times  however  there s generally plenty of network capacity and delaying the purchase of upgraded equipment Enterprise network equipment also typically has a usable life in excess of the length of time the owner needs it  It becomes obsolete before it wears out  Unfortunately this means it s a cash cow for equipment resellers who can repurpose pre owned equipment from large businesses as an upgrade for smaller businesses at a much lower cost than buying new Netgear shares are down more than 35  so far in 2019  badly lagging the S P 500 and the Hardware industry  A bottom line earnings beat in July breathed a bit of new life into the shares  but when you break down the report  it wasn t really all that strong Quarterly net revenue of  231M was the lowest level in more than two years  Operating margin of just 4 4  was more than 50  lower than the previous three quarters and though net earnings of  0 28 share exceeded already lowered expectations  that number was also down more than 50  than the previous quarter Each of Netgear s three global regions showed a decline in revenue  The Americas were down 9 9   Europe  Middle East and Africa were down 10 6  and Asia Pacific was down 6 3  Overall sales in 2019 are expected to be  1 05B   25  lower than the previous year   and 2020 is only a bit better at  1 08B Negative momentum on analyst revisions earn Netgear a Zacks Rank  5  Strong Sell  Additional content FDA Resets PAD Guidelines  The Road Ahead for Device MakersFollowing the FDA s last week announcement of its renewed guidance on the treatment of peripheral artery disease  PAD   medical device companies sound upbeat about the development so far More precisely  the updated guidance for the physicians is related to the benefit risk profile of peripheral paclitaxel devices intended for the treatment of PAD The FDA StatementEarlier in 2019  the FDA had notified health care providers about a late mortality signal in patients treated for PAD in the femoropopliteal artery with paclitaxel coated balloons and paclitaxel eluting stents In its revised guidance  the regulatory body has provided the advisory panel s analyses and recommendations for healthcare providers  It has also laid an emphasis on taking additional steps to address this signal including coordination with manufacturers on updates to device labeling and clinical trial informed consent documents for incorporating information about the late mortality signal Among the recommendations  the FDA noted that health care providers should discuss the risks and benefits of all available PAD treatment options with patients  This is because for many patients  alternative treatment alternatives like paclitaxel coated balloons and paclitaxel eluting stents mete out a more favorable benefit risk profile The FDA has also asked the clinicians to determine whether the benefits of using a paclitaxel coated device  in patients at particularly high risk for restenosis and repeat femoropopliteal interventions  outweigh the risks of late mortality MedTech Makers  RejoinderMedical device major Boston Scientific Corp  is pleased about the FDA s recommendation as this will allow physicians to continue accessing the company s Eluvia Drug Eluting Vascular Stent  DES  System  Per Boston Scientific  Eluvia has already demonstrated an excellent safety profile and a very low revascularization rate of 12 9  at two years in the pivotal IMPERIAL trial including many complex PAD patients Medtronic too is optimistic about the FDA s guidance  which it claimed has fueled the company s growth in the PAD treatment market  According to the company  its IN PACT Admiral drug coated balloons  DCB  have clear benefited the clinical outcomes and improved the quality of life across multiple randomized controlled clinical trials  Per the IN PACT SFA trial result  three of the four DCB patients remained intervention free through five years  While those requiring a repeat procedure  the time to reintervention was more than two years However  as a major setback  Becton Dickinson   Co  has announced that post the FDA Advisory Committee meeting on paclitaxel  the regulatory agency has notified that it is not going to grant any PMA  Premarket Approval to the company s Lutonix drug coated balloon catheter for use below the knee Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better See these 7 breakthrough stocks now  Media ContactZacks Investment Research800 767 3771 ext  9339Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer   Past performance is no guarantee of future results  Inherent in any investment is the potential for loss This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit for information about the performance numbers displayed in this press release ,2019-08-15,Zacks Investment Research,https://www.investing.com/analysis/teledyne-technologies-netgear-boston-scientific-medtronic-and-becton-dickinson-highlighted-as-zacks-bull-and-bear-of-the-day-200455905,200455905
122515,344030,BDX,The Zacks Analyst Blog Highlights  Estee Lauder  Becton  Dickinson  Applied Materials  Regeneron And HollyFrontier,opinion,For Immediate ReleaseChicago  IL  August 21  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Estee Lauder   NYSE EL    Becton  Dickinson   NYSE BDX    Applied Materials   NASDAQ AMAT    Regeneron   NASDAQ REGN   and HollyFrontier   NYSE HFC   Here are highlights from Tuesday s Analyst Blog Top Analyst Reports for Estee Lauder  Becton  Dickinson and Applied MaterialsThe Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features updated research reports on 16 major stocks  including Estee Lauder  Becton  Dickinson and Applied Materials  These research reports have been hand picked from roughly 70 reports published by our analyst team today You can see Estee Lauder s shares are up  43 5  in the past year  outperforming the Zacks Cosmetics industry  which is up  25 9  over the same period  The Zacks analyst thinks that this is largely attributable to the company s robust sales and earnings history  backed by growth across most brands as well as sales channels The trend continued in the fourth quarter of fiscal 2019  wherein the top and the bottom line surpassed estimates and rose year on year  Performance in the quarter and fiscal 2019 was supported by growth in emerging markets  strong travel retail and online sales  Additionally  management provided an optimistic view for fiscal 2020 and for the first quarter However  the company is mindful regarding certain headwinds such as soft retail trends in the United States and the U K   costs related to Brexit  impact of tariffs in China as well as moderation of sales in China and travel retail network  Moreover  adverse currency rates are a concern  You can   Shares of Becton  Dickinson have outperformed the Zacks Dental Supplies industry in the past year  losing  0 6  vs   5 3   Becton  Dickinson  also known as BD  exited the fiscal third quarter on a strong note  The Zacks analyst likes the solid show by the core BD Medical and Interventional units Domestic revenues increased year over year in the quarter under review  driven by segmental strength  Growth was observed in China and EMEA  Expansion in gross and operating margins is another encouraging factor  BD kept its fiscal 2019 guidance intact  However  sluggishness in the core Life Sciences unit raises concern  International sales also declined in the quarter Contraction in operating margins is a concern  Management expects unfavorable foreign currency to partially mar BD s bottom line in fiscal 2019  Stiff competition in the MedTech space adds to the company s woes  You can   Applied Materials  shares have outperformed the Zacks Semiconductor Equipment   Wafer Fabrication industry in the past three months   14  vs   11 8    Applied Materials reported fiscal third quarter results wherein both earnings and revenues topped the estimates The company witnessed solid customer spending in foundry and logic  thanks to IoT  communications  automotive  power and sensor applications  The company also experienced solid momentum across United States and Taiwan during the reported quarter  The Zacks analyst remains optimistic about the price elasticity of NAND  which is expected to bolster NAND customer spending in the near term The company s expanding etch footprint bodes well for its semiconductor portfolio  However  market uncertainties remain a headwind  Softness in semiconductor and display markets on account of slowdown in memory and display customers  spending is major concern  You can   Other noteworthy reports we are featuring today include Regeneron and HollyFrontier Legalizing THIS Could Be Even Bigger than MarijuanaAmericans spend an estimated  150 billion in this industry every year  more than twice as much as they spend on marijuana Now that 8 states have fully legalized it  with several more states following close behind   Zacks has identified 5 stocks that could soar in response to the powerful demand  One industry insider described the future as  mind blowing    and early investors can still get in ahead of the surge Media ContactZacks Investment Research800 767 3771 ext  9339 Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-08-21,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-estee-lauder-becton-dickinson-applied-materials-regeneron-and-hollyfrontier-200457269,200457269
122516,344031,BDX,Why Is Becton Dickinson  BDX  Up 4 1  Since Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Becton Dickinson  NYSE BDX   Shares have added about 4 1  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Becton Dickinson due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers  Becton  Dickinson Beats on Q3 Earnings  Guidance IntactBD reported third quarter fiscal 2019 EPS of  3 08  which beat the Zacks Consensus Estimate of  3 05  The bottom line also improved 5 8  on a year over year basis and rose 14 8  at cc The company raked in revenues of  4 35 billion  surpassing the Zacks Consensus Estimate by 0 06   The reported figure increased 0 6  from the year ago quarter  At cc  revenues rose 5 7  Segment DetailsBD MedicalIn the quarter under review  BD Medical segment reported worldwide revenues of  2 31 billion  up 2 9  from the year ago quarter and 6  at cc  Per management  the segment s results were driven by performance in the Medication Management Solutions  Medication Delivery Solutions and Pharmaceutical Systems units BD Life SciencesWorldwide revenues in the segment totaled  1 06 billion  down 1 9  year over year but increased 5 4  at cc BD InterventionalThis segment generated worldwide revenues of  0 98 billion  up 2 8  from the year ago quarter  At cc  revenues grew 5 2   The segment s results reflect strong performance by the Urology and Critical Care and Surgery sub units Geographic ResultsUSIn the fiscal third quarter  revenues in the United States improved 4 4  to  2 44 billion  Revenues grew 5  at cc  Per management  growth in the United States was driven by performance of the BD Medical and BD Interventional segments InternationalRevenues outside the United States grossed  1 91 billion  down 1 6  from the year ago quarter  At cc  the segment grew 6 5   Per management  international revenue growth in the third quarter was strong in China and EMEA Margin AnalysisIn the quarter  gross profit amounted to  2 07 billion  up 2 9  from the prior year quarter tally  Gross margin was 47 7   up 60 bps from the prior year quarter Operating income in the quarter grossed  626 million  down 22 3  from the year ago quarter  As a percentage of revenues  operating margin in the quarter was 14 4   up 240 bps year over year Adjusted operating income amounted to  716 million  up 9 6  from the year ago figure Guidance ReaffirmedFor fiscal 2019  the company continues to expect revenue growth of 8 9   At cc  revenues are anticipated to increase 5 6  Adjusted EPS is expected between  11 65 and  11 75  indicating growth of 12  at cc  However  this includes unfavorable impact of foreign currency 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates 
VGM Scores
At this time  Becton Dickinson has a nice Growth Score of B  a grade with the same score on the momentum front  Charting a somewhat similar path  the stock was allocated a grade of C on the value side  putting it in the middle 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  Notably  Becton Dickinson has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-09-04,Zacks Investment Research,https://www.investing.com/analysis/why-is-becton-dickinson-bdx-up-41-since-last-earnings-report-200461868,200461868
122517,344032,BDX,Will Becton Dickinson  BDX  Beat Estimates Again In Its Next Earnings Report ,opinion,"Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report  Becton Dickinson  NYSE BDX   which belongs to the Zacks Medical   Dental Supplies industry  could be a great candidate to consider 
This medical device manufacturer has seen a nice streak of beating earnings estimates  especially when looking at the previous two reports  The average surprise for the last two quarters was 0 88  
For the most recent quarter  Becton Dickinson was expected to post earnings of  3 05 per share  but it reported  3 08 per share instead  representing a surprise of 0 98   For the previous quarter  the consensus estimate was  2 57 per share  while it actually produced  2 59 per share  a surprise of 0 78  
Price and EPS Surprise

For Becton Dickinson  estimates have been trending higher  thanks in part to this earnings surprise history  And when you look at the stock s positive Zacks Earnings ESP  Expected Surprise Prediction   it s a great indicator of a future earnings beat  especially when combined with its solid Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Becton Dickinson currently has an Earnings ESP of  0 61   which suggests that analysts have recently become bullish on the company s earnings prospects  This positive Earnings ESP when combined with the stock s Zacks Rank  3  Hold  indicates that another beat is possibly around the corner  We expect the company s next earnings report to be released on November 5  2019 
Investors should note  however  that a negative Earnings ESP reading is not indicative of an earnings miss  but a negative value does reduce the predictive power of this metric 
Many companies end up beating the consensus EPS estimate  but that may not be the sole basis for their stocks moving higher  On the other hand  some stocks may hold their ground even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-10-17,Zacks Investment Research,https://www.investing.com/analysis/will-becton-dickinson-bdx-beat-estimates-again-in-its-next-earnings-report-200475161,200475161
122529,344044,BDX,Becton Dickinson to buy CareFusion for  12 billion in cash  stock,news,"By Deena Beasley  Reuters    Medical equipment supplier Becton Dickinson   Co  N BDX  has agreed to buy CareFusion Corp  N CFN   a maker of infusion pumps and other medical devices  for  12 2 billion in cash and stock  marking the latest multibillion dollar healthcare sector deal 
Becton said on Sunday it would pay a total of  58 00 a share    49 00 in cash and 0 0777 of a share of Becton Dickinson   for each share of CareFusion  This would represent a premium of 26 percent to the closing price on Oct  3 
The acquisition  recommended by the boards of both companies  would aim to combine the two U S  based companies  complementary products for preparing  administering and monitoring medications and would also extend the companies  geographic reach 
Becton Dickinson makes products to deliver and administer drugs  like disposable needles  syringes and intravenous catheters  while CareFusion makes products to store the drugs and to deliver them  such as infusion pumps 
 The combined entity will offer a  one stop shop  solution for hospitals  which are looking for sourcing efficiencies as they navigate a tough healthcare environment   ISI Group analyst Vijay Kumar said in a research note  He said the new company will be a market leader in the  20 billion medication management segment 
A combined company  could improve patient safety plus reduce costs at the same time   said Vincent Forlenza  Becton Dickinson s chairman  chief executive officer and president in a telephone interview 
Cost related healthcare reforms  including those mandated under President Barack Obama s Affordable Care Act  have spurred consolidation for U S  health systems and hospitals  the main customer for suppliers of medical equipment 
 This is an industry that from a customer perspective is consolidating   said Kieran Gallahue  CareFusion s chairman and CEO   Healthcare systems around the globe are looking for companies that can bring greater scale to them   it is a way to drive down costs while improving safety  
Forlenza said Becton s geographic reach   around 60 percent of its sales are outside of the United States and 25 percent of sales are in emerging markets   offers a strong platform for products from CareFusion  which currently relies on the domestic market for 75 percent of its revenue 
Becton said the transaction is expected to provide double digit earnings growth  on an adjusted basis  in the first full year  and will be accretive to net earnings in fiscal year 2018 
Kumar estimated that in its first year  the deal would increase Becton s cash earnings per share by 15 percent  On a  fully synergized  basis  he expects the deal to be 40 percent accretive to cash EPS 
Healthcare companies have been merging at a record pace  with year to date activity topping  346 billion  compared to  212 billion in the year ago period  Thomson Reuters data showed as of September 
Medical device maker Medtronic Inc s  N MDT  planned acquisition of Covidien Plc  N COV  for  43 billion is another recent deal aimed at increasing supplier leverage in negotiating sales to hospitals 
Other recent large deals in the healthcare sector have included AbbVie Inc s  N ABBV  planned  54 billion acquisition of Shire Plc  L SHP   AstraZeneca Plc  L AZN  fended off a  118 billion takeover attempt by Pfizer Inc  N PFE  
Each of those transactions involved so called  tax inversion  in which U S  companies look to avoid high taxes by acquiring overseas assets and reincorporating in countries with lower tax rates  In reaction  the U S  government last month took measures aimed at limiting the benefits of redomiciling overseas 
The Becton CareFusion deal is not a tax inversion   CareFusion is based in San Diego  while Becton is headquartered in Franklin Lakes  New Jersey 
The deal  subject to regulatory and CareFusion shareholder approvals and customary closing conditions  is expected to close in the first half of next year 
At closing  the companies said Becton Dickinson shareholders will own around 92 percent of the combined company and CareFusion shareholders will own around 8 percent 
Goldman  Sachs   Co served as financial advisor to Becton Dickinson  and Skadden  Arps  Slate  Meagher   Flom LLP provided legal counsel  Perella Weinberg Partners LP and Barclays Plc  served as financial advisors to CareFusion  while Wachtell  Lipton  Rosen   Katz acted as its legal advisor 
 Reporting By Deena Beasley  Editing by Chizu Nomiyama ",2014-10-05,Reuters,"https://www.investing.com/news/stock-market-news/becton-dickinson-to-acquire-carefusion-for-$12.2-billion-in-cash,-stock-311888",311888
122530,344045,BDX,Becton Dickinson wins reversal of  340 million syringe award,news,By Jonathan Stempel  Reuters    A federal appeals court on Friday threw out an antitrust verdict that ordered medical device maker Becton Dickinson and Co  N BDX  to pay rival  Retractable Technologies Inc   A RVP   340 million in damages over its marketing of safety syringes  Shares of Retractable tumbled more than 50 percent and hit their lowest level in roughly 3 1 2 years  The 5th U S  Circuit Court of Appeals in New Orleans called Retractable s claim that Becton violated the Sherman Act by trying to monopolize the U S  safety syringe market  infirm as a matter of law   Writing for a 3 0 panel  Judge Edith Jones also called  unsupported and incoherent  the allegation that Becton  tainted  the market for retractable syringes while secretly plotting to offer its own once Retractable s patents expired   RTI has not demonstrated that BD engaged in predatory or anticompetitive conduct   Jones wrote  But the appeals court agreed that Franklin Lakes  New Jersey based Becton could be held liable for falsely advertising that its needles were sharper and wasted less medicine  It ordered a lower court judge to decide how much profit Becton should give up as a result  Safety syringes are designed to protect patients from needlestick injuries and contamination  Both Retractable and Becton  and their law firms  did not immediately respond to requests for comment  Shares of Retractable were down  1 26  or 51 4 percent  at  1 19 in afternoon trading  after earlier falling as low as  1 15  Becton shares were up 0 4 percent at  165 36  Retractable  based in Little Elm  Texas  accused Becton of trying to thwart competition by offering loyalty discounts and rebates  or requiring that customers not buy syringes elsewhere  In September 2013  a federal jury in Texas awarded Retractable roughly  113 5 million in damages  which was later tripled  That verdict later became the basis for an injunction requiring Becton to tell customers about its false claims  Jones voided that injunction  but said a substitute based on the false advertising violations was  theoretically possible   The case is Retractable Technologies Inc et al v  Becton Dickinson   Co  5th U S  Circuit Court of Appeals  No  14 41384 ,2016-12-02,Reuters,https://www.investing.com/news/stock-market-news/becton-dickinson-wins-reversal-of-$340-million-syringe-award-445322,445322
122531,344046,BDX,Becton  Dickinson declares  0 73 dividend,news,Becton  Dickinson  NYSE BDX  declares  0 73 share quarterly dividend  in line with previous Forward yield 1 56 Payable June 30  for shareholders of record June 9  ex div June 7 Now read ,2017-05-23,Seeking Alpha,"https://www.investing.com/news/stock-market-news/becton,-dickinson-declares-$0.73-dividend-487762",487762
122532,344047,BDX,Europe M A surges but U S  slows sharply amid uncertainty,news,"By Greg Roumeliotis and Pamela Barbaglia  Reuters    Acquisitions of European companies surged in recent months  amid optimism about the region s economic prospects  but global deal making subsided and the total value of U S  deals fell sharply due to uncertainty about President Donald Trump s tax reform and deregulation agenda  Mergers and acquisitions in Europe rose 45 percent year on year to  234 billion in the second quarter  as companies bet the region s economies will bounce back  according to Thomson Reuters data released on Thursday  Global M A dropped 12 percent to  771 billion  however  and U S  M A dropped 36 percent to  281 billion    The EU recovery is happening and has made companies more attractive even if there are increased regulatory hurdles   said Hernan Cristerna  global M A co head at JPMorgan Chase   Co  N JPM    In the second quarter  Italian toll road operator  Atlantia  SpA  MI ATL  made a 16 3 billion euro   18 64 billion  offer for Spanish peer  Abertis  Infraestructuras SA  MC ABE   while chemicals companies  Huntsman  Corp  N HUN  and  Clariant  AG  S CLN   of the United States and Switzerland  respectively  agreed a  14 billion merger  The United States also saw some big deals  including U S  medical equipment supplier Becton Dickinson and Co s  N BDX   24 billion acquisition of peer  C R Bard  Inc  N BCR    But U S  M A volume  as measured by the total value of deals  was down  The number of deals stayed almost flat year on year  but the average size of transactions decreased   Some U S  companies are in wait and see mode because they are still seeking clarity on the tax and regulatory reforms that the Trump administration has been promising  This kind of uncertainty is a major obstacle to mega deals   said Bill Curtin  global head of M A at law firm Hogan Lovells  Coupled with high stock market valuations  the uncertainty around U S  President Donald Trump s policy agenda reduced the appetite of many North American chief executives for major deals   Corporates are still actively acquiring  but they are taking less risk  so there are fewer transformational deals and the mix of M A has shifted toward more mid sized transactions   said Matt McClure  head of Americas M A for  Goldman Sachs Group  Inc  N GS   Regulatory risks to deals closing has been another factor weighing on deals  The European Commission has been flexing its antitrust muscle  while expectations that the Trump administration will adopt a more merger friendly stance have yet to meaningfully materialize  Nevertheless  for some companies the adverse environment offers a window to make a bold acquisitive move with little competition  For example  Amazon com Inc  O AMZN  clinched a  13 4 billion deal for U S  grocer Whole Foods Market Inc  O WFM  earlier this month  which has yet to trigger any rival offers   There is a subset of companies which view the current environment as an opportunity  There is a little bit of a  dare to be great  mentality   said Michael Boublik  chairman of Americas M A at  Morgan Stanley   N MS   In the Asia Pacific region  M A volumes were almost flat in the second quarter at around  207 billion  Many dealmakers say global activity could increase in the second half of the year  particularly if there is more macroeconomic certainty in the United States  
 Our outlook for the second half remains positive  Economic activity is strengthening  corporate earnings are robust  and financing markets remain very attractive   said  Barclays  Plc  L BARC  Americas head of M A Larry Hamdan ",2017-06-29,Reuters,https://www.investing.com/news/stock-market-news/europe-m-amp;a-surges-but-u.s.-slows-sharply-amid-uncertainty-500815,500815
122533,344048,BDX,FDA OKs BD s new flow cytometry system,news,The FDA grants 510 k  clearance for Becton  Dickinson and Company s  NYSE BDX  BD FACSLyric flow cytometer system for use with BD Multitest assays for immunological assessment of patients having or suspected of having immune deficiency The bench top analyzer is also available in Europe and certain other geographies Now read ,2017-07-19,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-oks-bd's-new-flow-cytometry-system-507231,507231
122550,344065,BDX,Merit Medical Acquires Brightwater Medical For  35 Million,opinion,Merit Medical Systems  Inc    NASDAQ MMSI   recently announced the acquisition of Brightwater Medical for a deal value of  35 million  Notably  Brightwater Medical s flagship product  the ConvertX  is expected to complement Merit Medical s products like Resolve drainage catheter  InQwire guide wires  Advocate PTA balloons and other vascular products Following the announcement  shares of Merit Medical rose 2 3  to close at  59 10 on Jun 17  indicating that investors at Merit Medical consider this a strategic deal More on the AcquisitionFor investors  notice  California based Brightwater Medical s ConvertX Nephroureteral Stent System recently received FDA approval for the treatment of ureteral obstructions Management at Merit Medical expects revenues from the ConvertX product of approximately  1 million in 2019  with expectations of growth to around  25 million in the fifth full year of sales  Additionally  upon the transfer of the ConvertX manufacturing operations to Merit s Pearland facility  management anticipates adjusted gross margin in the 70 75  range  Upon receiving a CE Mark for ConvertX  the company expects an additional gain of  15 million in revenues However  management at Merit Medical expects the buyout to dent earnings per share by 5 cents on a reported basis and by 3 cents on an adjusted basis Other Significant AcquisitionsEarlier this year  Merit Medical closed the purchase of assets from Becton  Dickinson and Company   NYSE BDX     The assets acquired are soft tissue core needle biopsy products sold under the trade names of Achieve Programmable Automatic Biopsy System  Temno Biopsy System  Tru Cut Biopsy Needles  Aspira Pleural Effusion Drainage Kits and Aspira Peritoneal Drainage System  These products will be sold by Merit Medical s global direct sales force and distribution partners  Notably  the transaction is expected to expand Merit Medical s operating margin and increase its cash flow in 2019 Apart from this  Merit Medical recently acquired a small U S  based entity  Laurane Medical  with manufacturing operations in Europe  The acquired company specializes in the bone biopsy business A Peek Inside Merit Medical s Product PortfolioThe recent acquisition is expected to broaden Merit Medical s product offerings It is encouraging to note that in recent times  the company has launched products like EmboCube Embolization Gelatin  basixTAU Inflation Device  Prelude Prestige Splittable Sheath Introducer  Prelude Ideal Sheath Introducer and PreludeSYNC Radial Hemostasis Device Merit Medical s HeRO product line has been another key contributor to growth  HeRO Graft  Super HeRO Adapter and HeRO Ally Revision Kit are the three platforms within the company s HeRO family of dialysis devices  which see robust demand Price PerformanceOver the past year  shares of this Zacks Rank  2  Buy  stock has rallied 16 9  against the  s 2 6  decline  The current level also compares favorably with the S P 500 index s 3 2  rally Other Key PicksOther top ranked stocks in the broader medical space are DENTSPLY SIRONA   NASDAQ XRAY   and Masimo Corporation   NASDAQ MASI    each carrying a Zacks Rank  2  You can see  DENTSPLY s long term earnings growth rate is expected at 11 5  Masimo s long term earnings growth rate is projected at 16 1  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-06-18,Zacks Investment Research,https://www.investing.com/analysis/merit-medical-acquires-brightwater-medical-for-35-million-200432486,200432486
122551,344066,BDX,Becton Dickinson  BDX  Q3 Earnings And Revenues Top Estimates,opinion,"Becton Dickinson  NYSE BDX  came out with quarterly earnings of  3 08 per share  beating the Zacks Consensus Estimate of  3 05 per share  This compares to earnings of  2 91 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 0 98   A quarter ago  it was expected that this medical device manufacturer would post earnings of  2 57 per share when it actually produced earnings of  2 59  delivering a surprise of 0 78  
Over the last four quarters  the company has surpassed consensus EPS estimates three times 
Becton Dickinson  which belongs to the Zacks Medical   Dental Supplies industry  posted revenues of  4 35 billion for the quarter ended June 2019  surpassing the Zacks Consensus Estimate by 0 06   This compares to year ago revenues of  4 28 billion  The company has topped consensus revenue estimates two times over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Becton Dickinson shares have added about 4 9  since the beginning of the year versus the S P 500 s gain of 13 5  
What s Next for Becton Dickinson 
While Becton Dickinson has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Becton Dickinson was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  3 34 on  4 57 billion in revenues for the coming quarter and  11 68 on  17 28 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Dental Supplies is currently in the top 32  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-08-06,Zacks Investment Research,https://www.investing.com/analysis/becton-dickinson-bdx-q3-earnings-and-revenues-top-estimates-200451266,200451266
122563,344078,BDX,Here s Why You Should Hold Becton  Dickinson Stock For Now,opinion,"Becton  Dickinson and Company   NYSE BDX    also known as BD  is expected to benefit from a slew of developments and a strong guidance for fiscal 2019  However  raw material pricing pressure is anticipated to mar the company s prospects The stock currently has a Zacks Rank  3  Hold  Price PerformanceShares of BD have rallied 16 4   comparing favorably with the  s decline of 1 2  in a year s time  The current level is also better than the S P 500 index s 3 2  rally What s Deterring the Stock BD expects raw material pricing pressure  which increased in 2018  to accelerate into fiscal 2019  primarily due to resin price increases owing to a supply constrained market  Although pressure from raw materials partially eased in the fiscal first quarter  management expects a 2  headwind from it in fiscal 2019 Additionally  BD expects a 1  headwind from tariffs in 2019  Customer ordering patterns are also expected to negatively impact second quarter results Why Should You Retain BD BD has reiterated its guidance for fiscal 2019 On a reported basis  BD continues to expect fiscal 2019 revenue growth of 8 5 9 5   primarily owing to the C  R  Bard acquisition  At cc  the same metric is anticipated to increase 5 6   The Zacks Consensus Estimate for the same is pegged at  17 45 billion For fiscal 2019  adjusted EPS is projected between  12 05 and  12 15  reflecting growth of 13 14  at cc and 10  compared to fiscal 2018  The midpoint of the latest guidance of  12 10 is in line with the Zacks Consensus Estimate The company has also seen a slew of developments in recent times In the first quarter of fiscal 2019  BD announced the launch of two cloud based applications  BD HealthSight Data Manager and BD HealthSight Diversion Analytics  which enable an enterprise wide connected medication management system  Notably  both form part of the BD HealthSight platform Moreover  in the BD Interventional segment  WavelinQ was made available for sale in the United States in the first quarter  This product provides a minimally invasive nonsurgical option for creating critical AV fistulas for hemodialysis procedures Last December  BD announced the FDA 510 k  clearance of its BD MAX enteric viral panel  a molecular diagnostic test for the direct qualitative detection and differentiation of enteric viral pathogens that cause viral gastroenteritis   Read More   Which Way Are Estimates Headed For the fiscal second quarter  the Zacks Consensus Estimate for earnings is pegged at  2 59  reflecting a decline of 2 3  on a year over year basis  The same for revenues is pinned at  4 22 billion  showing a decline of 0 1  year over year Becton  Dickinson and Company Price and Consensus
    Key PicksSome better ranked stocks in the broader medical space are Cardinal Health   NYSE CAH     Merit Medical Systems  Inc    NASDAQ MMSI   and Surmodics  Inc    NASDAQ SRDX   Cardinal Health s long term earnings growth rate is projected at 6 2   The stock has a Zacks Rank  2  Buy  Merit Medical s long term earnings growth rate is projected at 13   The stock has a Zacks Rank  2 Surmodics  long term earnings growth rate is expected at 10   The stock flaunts a Zacks Rank  1  Strong Buy   You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-03-05,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-hold-becton-dickinson-stock-for-now-200394665,200394665
122568,344083,BDX,Stock Market News For Mar 15  2019,opinion,Wall Street closed mixed on Thursday as investors  remained anxious about the delay in sealing a U S    China trade deal  Moreover  weak earnings data from the United States and China also dented investors  confidence  However  stock price movements in either direction were largely marginal  The Dow managed to end in the green while both S P 500 and Nasdaq Composite finished in the red The Dow Jones Industrial Average  DJI  closed at 25 709 94  gaining 7 05 points  However  the S P 500 Index  INX  decreased 0 1  to close at 2 808 48  The Nasdaq Composite Index  IXIC  closed at 7 630 91  shedding 0 2   A total of 6 69 billion shares were traded on Thursday  lower than the last 20 session average of 7 37 billion shares  Decliners outnumbered advancers on the NYSE by 1 24 to 1 ratio  On the Nasdaq  decliners had an edge over advancers by 1 33 to 1 ratio   The CBOE VIX increased 0 7  to close at 13 50       How Did the Benchmarks Perform The Dow ended in positive territory for the second consecutive day  Notably  20 stocks of the 30 stocks blue chip index finished in the green while ten ended in the red  The S P 500 also closed in the red after three straight days of gain  The Materials Select Sector SPDR  XLC  and Communication Services Select Sector SPDR  XLB  lost 0 7  and 0 4   respectively  Notably  seven out of eleven sectors of the benchmark index closed in the red while four finished in the green The tech heavy Nasdaq finished in the red reversing three days of winning streak owing to weak performance of large cap stocks  Shares of Facebook Inc    NASDAQ FB   declined 1 9  following global outage of Instagram and WhatsApp and other major apps of the company  Facebook carries a Zacks Rank  3  Hold   You can see  Weak Economic Data On Mar 14  the Department of Commerce reported that U S  new home sales declined 6 9  in January  New homes sold at a seasonally adjusted annual rate of 607 000 in January  missing he consensus estimate of 619 000 Economists largely blamed the 35 day long partial government shutdown and stock market reverses in the fourth quarter of 2018 for such weak numbers  However  new home sales in December revised upward from 621 000 to 652 000  Similarly  new home sales in November were also revised upward from 599 000 to 628 000 The Department of Labor reported that U S  initial jobless claims for the week ended Mar 9 increased by 6 000 to 229 000  higher than the consensus estimate of 224 000  The number of people already collecting unemployment benefits  known as continuing claims  increased by 18 000 to 1 77 million Meanwhile  China s value added industrial output grew 5 3  year over year in the January February period  This marked the slowest growth rate for the first two months of any year in seventeen years Delay in Trade DealInvestors are concerned that closure of a new trade deal between the United States and China is unlikely to happen this month  China wants a trade deal to be announced in the upcoming summit between President Trump and Chinese leader Xi Jinping slated to take place late this month  However  U S  officials are still not satisfied with all pending trade related issues which are part of bilateral negotiations  In that case  the meeting between the two Presidents may be delayed Delay in Brexit On Mar 14  British lawmakers voted in favor of a delay to the Mar 29 deadline when Brittan is scheduled to quit the European Union  On Mar 13  the UK parliament voted against a no deal Brexit  On Mar 12  British lawmakers rejected the proposed Brexit deal submitted by British Prime Minister Theresa May Stock That Made HeadlineBecton  Dickinson and Co    NYSE BDX    also known as BD  recently announced the FDA premarket approval for its Venovo venous stent device  the first one indicated to treat iliofemoral venous occlusive disease    Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ,2019-03-14,Zacks Investment Research,https://www.investing.com/analysis/stock-market-news-for-mar-15-2019-200398208,200398208
122570,344085,BDX,BD Introduces New Product To Reduce The Risk Of Sepsis,opinion,Becton  Dickinson and Company   NYSE BDX    popularly known as BD  recently introduced BD BACTEC platelet control media that will enable microbiology laboratories  blood banks and transfusion services in the identification of contaminated platelet units  This new quality control media is likely to significantly broaden the scope of the company s BACTEC portfolio The company is optimistic about reducing the occurrence of sepsis among patients requiring blood transfusion following the introduction of this product  BD also claims that this new quality control media will decrease the patient s expenses owing to sepsis BD BACTEC platelet control media  which is an FDA cleared product  will help in carrying on the company s legacy in providing specific and cost effective solutions through BD BACTEC portfolio Platelet Transfusion and Sepsis at a GlancePlatelet transfusion is a process wherein platelets are transferred to patients having low platelet counts or those who have platelet dysfunction and are bleeding or at a high risk of bleeding Going by  s definition  sepsis is a typical response of body to infection which can prove life threatening  More specifically  this is body s overactive and toxic response to an infection which primarily results from contaminated blood transfusion BD BACTEC Platelet Control MediaThe newly introduced product is part of an all inclusive solution that leverages the automated BD BACTEC FX technology and BD Synapsys microbiology informatics solution  These in turn help laboratories to cater to the culture based platelet testing requirements Clinicians are set to benefit from this product as it will help in lowering the risk of sepsis through culture based methodology to identify platelet contamination Industry ProspectPlatelets are more susceptible to bacterial contamination owing to storage conditions  In comparison to any other transfusable blood component  platelets have a higher risk of sepsis and any associated fatality With respect to detection of bacterial contamination in platelet donations  the guidelines and protocols issued by The World Health Organization  WHO   U S  Food and Drug Administration  FDA  and American Association of Blood Banks  AABB  is likely to lower septic transfusion reactions and related fatalities by an estimated range of 50 70  According to a report published by   increasing number of blood transfusions  rising prevalence of rare infectious diseases and growing elderly population base will drive the demand for platelets and plasma  Per this report  Platelets and Plasma Market will exceed  6 5 billion by 2024 Benefits of the InnovationThe addition of the product will boost BD Life Sciences segment  which primarily deals in products for the safe collection and transfer of diagnostic specimens along with instruments and reagent systems to identify a wide range of infectious diseases  healthcare associated  HAIs  and cancers In the context of enhancement of this segment  the launch of BD s new automated flow cytometry sample preparation instrument with CE IVD certification deserves a special mention Zacks Rank and Share Price MovementBD carries a Zacks Rank of 4  Sell  Year to date  the stock has underperformed the   The stock has gained 11 4  compared with the industry s growth of 12 8   The current level is also lower than the S P 500 Index s 14 9  increase Key PicksSome better ranked stocks from the same space are The Cooper Companies  Inc    NYSE COO    Invacare Corporation   NYSE IVC   and DENTSPLY SIRONA Inc    NASDAQ XRAY    Each of these stocks carry a Zacks Rank  2  Buy   You can see  Cooper Companies has a long term earnings growth rate of 10 8  Invacare Corporation has earnings growth rate of 29 3  for the next quarter DENTSPLY SIRONA has a long term earnings growth rate of 9 6  Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-04-08,Zacks Investment Research,https://www.investing.com/analysis/bd-introduces-new-product-to-reduce-the-risk-of-sepsis-200405199,200405199
122574,344089,BDX,The Zacks Analyst Blog Highlights  Eli Lilly  Altria  Becton  Dickinson  T Mobile And General Motors,opinion,"For Immediate Release
Chicago  IL   April 11  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Eli Lilly   NYSE LLY    Altria   NYSE MO    Becton  Dickinson   NYSE BDX    T Mobile   NASDAQ TMUS   and General Motors   NYSE GM   
Here are highlights from Wednesday s Analyst Blog  
Top Stock Reports for Eli Lilly  Altria and Becton  Dickinson
The Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Eli Lilly  Altria and Becton  Dickinson  These research reports have been hand picked from the roughly 70 reports published by our analyst team today 
You can see 
Buy rankedEli Lily s shares have outperformed the Zacks Large Cap Pharmaceuticals industry year to date  gaining  10  vs   1 9   The Zacks analyst thinks Lilly s revenue growth in 2019 will likely be driven by higher demand for its newer drugs including Trulicity  Jardiance  Taltz  Verzenio as well as new migraine drug  Emgality as some older drugs like Cialis face generic competition 
In 2018  Lilly made significant pipeline progress with several positive late stage data readouts  multiple approvals and regulatory submissions  Emgality could emerge as a significant contributor to long term growth  Lilly has also added promising new pipeline assets through business development deals 
However  generic competition for several drugs including Cialis  rising pricing pressure  currency headwinds and the impact of the failed Lartruvo study are expected to put pressure on the top line  Estimates have gone up ahead of Q1 results  Lilly has a positive record of earnings surprises in recent quarters 
Shares of Altria have underperformed the Zacks Tobacco industry over the past three months   12 7  vs   19 8    The Zacks analyst thinks the company has been steadily gaining from the popularity of Smokeless products  To further bolster this category  the company recently invested in JUUL and Cronos  Altria has also applied for converting its non voting interests in JUUL to voting securities 
Pricing also continues to drive the company s revenues  It has also undertaken cost reduction initiatives to counter interest burden  Altria plans to deliver annualized cost savings of nearly  575 million by the end of 2019  However  the company grapples with persistently declining cigarette shipment volumes  Stern FDA regulations combined with increased health consciousness are taking a toll on the cigarette category 
Going forward  management expects cigarette industry volume to decline in the range of 3 5 5   Further  the company s wine category has been sluggish  thanks to stiff competition 
Becton  Dickinson s shares have outperformed the Zacks Dental Supplies industry over the past year  gaining  12 5  vs   1 5   The Zacks analyst likes the solid performance by the core BD Medical and Life Sciences units  Domestic and international revenues increased year over year in recent times 
Management is optimistic about the C R  Bard buyout which has consistently proven to be accretive  Notably  a series of product launches and regulatory approvals in recent times continue to boost the stock  The company has kept its fiscal 2019 guidance intact 
On the flip side  contraction in gross and operating margins in recent times is worrisome  Customer ordering patterns are also expected to negatively impact fiscal second quarter results  Management expects unfavorable foreign currency to remain headwinds in fiscal 2019  Stiff price competition in the MedTech space adds to its woes 
Other noteworthy reports we are featuring today include T Mobile and General Motors 
Zacks  Top 10 Stocks for 2019
In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year 
Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  

Media Contact
Zacks Investment Research
800 767 3771 ext  9339
 
 
Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit for information about the performance numbers displayed in this press release ",2019-04-10,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-eli-lilly-altria-becton-dickinson-tmobile-and-general-motors-200406048,200406048
122575,344090,BDX,Can BD Medical Drive Becton  Dickinson s  BDX  Q2 Earnings ,opinion,"Becton  Dickinson and Company s   NYSE BDX    popularly known as BD  second quarter fiscal 2019 results are scheduled to release on May 9  before market opens  While the results are likely to show steady growth in the core BD Medical segment  weakness in BD Life Sciences may partially mar results  Notably  BD has a positive average surprise of 1  in the trailing four quarters  Which Way Are Estimates Treading  For the quarter to be reported  the Zacks Consensus Estimate for BD s earnings per share is pegged at  2 59  suggesting a year over year decline of 2 3   The same for revenues stands at  4 24 billion  indicating an increase of 0 5   Let s see how things are shaping up prior to the earnings release  BD Medical Likely to Drive Q2 Earnings BD Medical  one of the major revenue drivers of the company  is expected to drive fiscal second quarter results  Strong year over year growth in revenues from needles  syringes and intravenous catheters for medication delivery  prefilled IV flush syringes  syringes and pen needles for diabetes care and others are likely to boost the segment  It is encouraging to note that for the second quarter  the Zacks Consensus Estimate for the segment s revenues is pegged at  2 21 billion  suggesting a rise of 1 7  year over year  Notably  BD recently launched two cloud based applications  BD HealthSight Data Manager and BD HealthSight Diversion Analytics  which are likely to contribute to the segment s results  Additionally  management expects the sub segments     Medical Surgical Solutions  Pharmaceutical Systems and Diabetes Care   to drive the unit  The Zacks Consensus Estimate for Medical Surgical Solutions  fiscal second quarter revenues stands at  975 million  calling for a year over year rise of 1 8   The growth is expected to be driven by strength in vascular access and infusion disposables  For Pharmaceutical Systems  the Zacks Consensus Estimate for second quarter revenues is pinned at  344 million  suggesting a year over year rise of 12 8   Management expects strong demand for core products  and increased customer ordering For Diabetes Care  the Zacks Consensus Estimate for second quarter revenues stands at  262 million  suggesting a drop of 8 7  year over year  Timing of orders in the United States and the EMEA is likely to affect sales in the sub segment Becton  Dickinson and Company Price and EPS Surprise
 
 
   Other Factors at Play BD has seen a slew of developments lately  which might reflect on its fiscal second quarter results  In the BD Life Sciences segment  the company received FDA clearance for the BD Phoenix CPO Detect test and the BD MAX Enteric Viral Panel which will broaden the suite of diagnostic solutions offered by the unit  However  the Zacks Consensus Estimate for the unit s second quarter revenues stands at  1 06 billion  indicating a year over year decline of 3 3   BD also launched WavelinQ  a solution that provides a minimally invasive nonsurgical option for creating critical AV fistulas for hemodialysis procedures  This is expected to boost the BD Interventional segment  Notably  the Zacks Consensus Estimate for the unit s second quarter revenues is pegged at  974 million  mirroring a sequential rise of 0 4   However  BD expects unfavorable foreign currency movements to severely impact fiscal second quarter results  This apart  BD expects unfavorable impact from raw materials and tariffs to add to the woes  Reflective of these  management expects revenue growth to be below the full year guidance range by about 100 basis points  Adjusted earnings per share in the quarter to be reported are expected between  2 50 and  2 60  Lastly  a normal flu season is expected to pose a 1  headwind in fiscal 2019  most of which will be pronounced in the fiscal second quarter  What Does Our Model Say  Per our proven model  a stock needs to have a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to deliver a positive earnings surprise in the quarter  However  this is not the case here  Earnings ESP  BD has an Earnings ESP of  1 15   You can uncover the best stocks to buy or sell before they re reported with our   Zacks Rank  BD carries a Zacks Rank  4  Sell   Please note that we caution against stocks with a Zacks Rank  4 or 5  Strong Sell  going into the earnings announcement  especially when the company is seeing negative estimate revision  Stocks Worth a Look Here are a few stocks that are likely to post a beat this earnings season  Cardinal Health   NYSE CAH   has an Earnings ESP of  1 13  and a Zacks Rank  3  You can see   Aurora Cannabis   TO ACB   has an Earnings ESP of  55 88  and a Zacks Rank  3  HEXO Corp    TO HEXO   has an Earnings ESP of  2 78  and a Zacks Rank  3  Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3   This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-05-03,Zacks Investment Research,https://www.investing.com/analysis/can-bd-medical-drive-becton-dickinsons-bdx-q2-earnings-200416689,200416689
122600,344115,BDX,What s In Store For Cardinal Health s  CAH  Q2 Earnings ,opinion,"Cardinal Health  Inc  s   NYSE CAH   second quarter fiscal 2019 results are scheduled for release on Feb 7  before market opens  While results are likely to show impressive growth in the core Pharmaceutical segment  headwinds in the Medical Gloves sub segment are likely to mar prospects Fiscal Q1 Results at a GlanceIn the last reported quarter  Cardinal Health delivered first quarter fiscal 2019 adjusted earnings of  1 29 per share  which beat the Zacks Consensus Estimate of  1 06  Adjusted earnings increased 18  year over year Revenues increased 7 9  on a year over year basis to  35 21 billion and beat the Zacks Consensus Estimate of  33 54 billion Cardinal Health has an average positive earnings surprise of 9 3  for the trailing four quarters Which Way Are Q2 Estimates Treading For the quarter to be reported  the Zacks Consensus Estimate for earnings is pegged at  1 09 per share  reflecting a year over year decline of 16 8   The same for revenues is pinned at  36 3 billion  indicating growth of 3  from the year ago quarter Let s see how things are shaping up prior to the earnings release Pharmaceutical to Drive Fiscal Q2Cardinal Health s Pharmaceutical segment is the second largest pharmaceutical distributor in the United States  The segment s products and  services comprise pharmaceutical distribution  manufacturer and specialty services as well as nuclear and pharmacy services  which are expected to majorly drive second quarter results In the last reported quarter  the segment accounted for 89 2  of net sales  Revenues at the segment increased 8 6  to  31 42 billion on a year over year basis However  it is encouraging to note that  for the quarter to be reported  the Zacks Consensus Estimate for the unit s revenues stands at  31 92 billion  reflecting a year over year rise of 2 5  Cardinal Health  Inc  Price and EPS Surprise
    Other Factors at PlayCardinal Health expects to see notable contributions from its Medical unit  For investors  notice  the segment manufactures products such as single use surgical drapes  gowns and apparel  exam and surgical gloves  etc   which are likely to boost sales in the quarter to be reported In the last reported quarter  the unit contributed 10 8  to net sales  Sales at the segment improved 2 1  year over year to  3 80 billion For the quarter to be reported  the Zacks Consensus Estimate for the unit s revenues stands at  4 08 billion  mirroring a year over year rise of 1  However  Cardinal Health s lackluster expectations from its exam gloves segment are concerning  Notably  in the last reported quarter  commodity pricing  inflation and supply disruptions created headwinds for the segment What Does Our Model Say Per our proven model  a stock needs to have a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to deliver a positive earnings surprise in the quarter  However  this is not the case here Earnings ESP  Cardinal Health has an Earnings ESP of 0 00   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Cardinal Health carries a Zacks Rank  3 Please note that we caution against stocks with a Zacks Rank  4  Sell  or 5  Strong Sell  going into the earnings announcement  especially when the company is seeing negative estimate revision Stocks Worth a LookHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter Masimo Corporation   NASDAQ MASI   has an Earnings ESP of  1 04  and a Zacks Rank  3 Quidel Corporation   NASDAQ QDEL   has an Earnings ESP of  5 26  and a Zacks Rank  2  You can see  Becton  Dickinson and Company   NYSE BDX   has an Earnings ESP of  0 49  and a Zacks Rank  2 Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-02-04,Zacks Investment Research,https://www.investing.com/analysis/whats-in-store-for-cardinal-healths-cah-q2-earnings-200383180,200383180
122618,344133,BDX,BD Brings HealthSight Diversion App To Combat Opioid Crisis,opinion,Becton  Dickinson and Company   NYSE BDX    also known as BD  recently launched the HealthSight diversion management application to help hospitals and health systems identify drug diversion  This is likely to boost BD s Medication Management business apart from fighting the opioid crisis in the United States Following the announcement  shares of BD rose 0 6  to  250 10 at close  Over the past year  the stock has rallied 9 6  compared with the  s 1 8  rise  The current level is also higher than the S P 500 index s 4 5  increase The stock carries a Zacks Rank  3  Hold  For investors  notice  drug diversion is the illegal transfer of prescription drugs to patients who are not prescribed  It leads to addiction to prescribed drugs among patients which might eventually cause overdose More on BD HealthSight Diversion Management AppBD HealthSight diversion management is a cloud based application which is part of the BD HealthSight platform  The application is designed to support enterprise wide medication management and assist with opioid drug diversion investigations The solution uses data from existing BD products  including the BD Pyxis ES system and the Electronic Medical Record  EMR  The U S  Opioid CrisisThe opioid crisis in the United States began in the 1990s which has been causing death waves across the nation  In fact  the epidemic has reduced the overall life expectancy of the country Per new data from Centers for Disease Control and Prevention  it led to more than 70 000 drug overdose deaths in 2017 As a prevention measure  MedTech bigwig McKesson Corporation   NYSE MCK   reports controlled substances transactions via the automated ARCOS drug reporting system  Notably  ARCOS is an automated  comprehensive drug reporting system which monitors the flow of DEA  Drug Enforcement Administration  controlled substances Medication Management Segment at a GlanceBD s Medication Management unit enables many solutions that can help clinicians streamline and automate medication and supply processes  BD Alaris infusion also deserves a mention in this regard Notably  in the last reported quarter  the segment grew 21 3  year over year Key PicksSome better ranked stocks in the broader medical space are Integer Holdings Corporation   NYSE ITGR   and Veeva Systems   NYSE VEEV   Integer Holdings has an earnings growth rate of 31 2  for the next quarter and a Zacks Rank  2  Buy   You can see  Veeva Systems  long term earnings growth rate is estimated at 19 3   The stock carries a Zacks Rank  2 3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ,2018-11-29,Zacks Investment Research,https://www.investing.com/analysis/bd-brings-healthsight-diversion-app-to-combat-opioid-crisis-200363959,200363959
122619,344134,BDX,Becton  Dickinson s MAX Enteric Viral Panel Cleared By FDA,opinion,Becton  Dickinson and Company   NYSE BDX    also known as BD  recently announced the FDA 510 k  clearance of its BD MAX enteric viral panel  a molecular diagnostic test for the direct qualitative detection and differentiation of enteric viral pathogens that cause viral gastroenteritis  This is also likely to boost BD s Diagnostic Systems apart from fortifying its foothold in the infectious disease diagnostics market However  the latest development failed to drive BD s shares  which dipped 1 5  to  214 26 at close More on BD MAXFor investors  notice  the BD MAX enteric viral panel is designed for targeted detection of the viral cause of infectious diarrhea symptoms in all care settings  Notably  it runs on the BD MAX system  which is a fully integrated  automated molecular diagnostics platform In fact  earlier this year  the company obtained CE Mark for molecular screening test for antibiotic resistant carbapenemase producing organisms  CPOs  on the BD MAX System   Read More   BD Diagnostic Systems at a GlanceBD Diagnostic Systems provides products and instruments for detecting a broad range of infectious diseases  healthcare associated infections and cancer  BD MAX majorly drove the segment s revenues in the last reported quarter With the latest development  BD now has a wide portfolio of solutions for the detection of infectious diseases Last month  BD s Phoenix CPO detect test received FDA 510 k  clearance   Read More   Market ProspectsZion Market Research predicts that the global infectious disease diagnostics market will reach a worth of  21 28 billion by 2024 at a CAGR of 5 4  Hence the latest development has been a well timed one for BD Shares Shine BrightOver the past year  shares of BD have rallied 3 7  against the  s 11 4  decline  The current level also compares favorably with the S P 500 index s 8  fall Zacks Rank   Key PicksBD currently has a Zacks Rank  3  Hold  Some better ranked stocks in the broader medical space are Veeva Systems Inc    NYSE VEEV    Integer Holdings Corporation   NYSE ITGR   and OPKO Health  Inc    NASDAQ OPK   Veeva Systems  long term earnings growth rate is projected at 19 5   The stock currently flaunts a Zacks Rank  1  Strong Buy   You can see  Integer projects earnings growth rate of 31 2  for the fourth quarter  It currently carries a Zacks Rank  1 OPKO Health s long term earnings growth rate is projected at 12   The stock presently sports a Zacks Rank of 2  Buy  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-12-27,Zacks Investment Research,https://www.investing.com/analysis/becton-dickinsons-max-enteric-viral-panel-cleared-by-fda-200371553,200371553
122620,344135,BDX,Here s Why Investors Should Retain Athenahealth  ATHN  Stock,opinion,"athenahealth  Inc  s   NASDAQ ATHN   strong product portfolio  solid network expansion strategies and unique business model buoy optimism  However  the company faces cutthroat competition in the MedTech space In the past year  shares of this Zacks Rank  3  Hold  company have lost 3 2   outperforming its  s 18 5  decline  The current level also compares favorably with the S P 500 index s 7 6  decline Here we take a quick look at the primary factors that have been plaguing athenahealth and discuss the prospects that ensure its near term recovery Cutthroat Market Competitionathenahealth s EHR solution faces stiff competition from the likes of Allscripts Healthcare Solutions and others  MedTech behemoths like Cerner offer long standing seamless products integrating inpatient and ambulatory care systems Further  SaaS based models put athenahealth s pricing under pressure  Stringent hospital budgets also lead to weak pricing  which will continue to hurt athenahealth s profitability Why Should You Hold the Stock athenahealth s portfolio comprises a wide array of products that include electronic health records  revenue cycle management  medical billing  patient engagement  care coordination  population health management and Epocrates athenaInsight  an online news hub that reports on U S  healthcare activities and trends of healthcare providers and  de identified patients   has also been fortifying the company s footprint Last year  athenahealth rapidly expanded its patient record sharing capabilities with CommonWell and Carequality  Notably  athenaClinicals is the company s first economically sustainable  service based electronic medical records  EMR  system   Among other activities  athenahealth purchased Proxsys  LLC   a care coordination company   and launched athenaCoordinator  now athenaCoordinator Core  for order transmission and care collaboration with secure text message These apart  athenahealth recently announced that it has entered into a definitive agreement under which to be acquired by Veritas Capital for approximately  5 7 billion in cash  Under the terms of the deal  athenahealth shareholders will receive  135 in cash per share  After the completion of the acquisition  athenahealth is expected to be combined with Virence Health   Virence     the GE Healthcare Value based Care assets   that Veritas acquired earlier this year  The transaction is expected to close in the first quarter of 2019 Which Way Are Estimates Headed For the fourth quarter of 2019  the Zacks Consensus Estimate for earnings is pegged at  1 14  up 2 7  year over year  The same for revenues is pinned at  358 3 million  mirroring an increase of 8 9  year over year For 2019  the Zacks Consensus Estimate for revenues is  1 35 billion  The same for earnings stands at  4 20  up 69 4  year over year athenahealth  Inc  Price and Consensus
    Key PicksA few better ranked stocks in the broader medical space are Veeva Systems Inc   NYSE VEEV    Becton  Dickinson and Company   NYSE BDX   and OPKO Health  Inc   NASDAQ OPK   Veeva Systems  long term earnings growth rate is projected at 19 5   The stock currently sports a Zacks Rank  1  Strong Buy   You can see  Becton  Dickinson s long term earnings growth rate is projected at 11 5   The stock carries a Zacks Rank  2  Buy  OPKO Health s long term earnings growth rate is projected at 12   The stock sports a Zacks Rank of 1 Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2019-01-16,Zacks Investment Research,https://www.investing.com/analysis/heres-why-investors-should-retain-athenahealth-athn-stock-200376596,200376596
122621,344136,BDX,Cerner Picked By Remi Vista For Behavioral Health Technology,opinion,Cerner Corporation   NASDAQ CERN   announced that Remi Vista selected Cerner Integrated   a behavioral specific electronic health record technology   to improve the mental well being of the people acrossits facilities in Northern California Per management  Remi Vista will leverage on Cerner s exclusive solutions of health IT applications and services  optimized for behavioral health  These solutions are formulated for optimal health and wellness through data driven  preventative  and supportive solutions and services Apart from Cerner Integrated  Cerner s revenue cycle solutions will help reinforce Remi Vista s financial operations What is Cerner Integrated Cerner Integrated is an electronic health record platform that brings together health data from a person s mental and physical well being for curing mental crisis Cerner Integrated s web based portal enables individuals and families to engage in the care process by viewing vital health data  sharing self reported information  scheduling appointments and communicating with their care team Behavioral Health Market ProspectsBehavioral health is the scientific study of emotions  behaviors and biology related to a person s mental well being Per Future Market Insights  the global behavioral health market is projected to reach  156 3 billion worth by 2028  growing at a CAGR of 3 4  from 2018 However  America is one of the most affected countries  in terms of mental illness and behavioral health issues Price PerformanceCerner lost 22 9  in a year  wider than the  s decline of 12 7    Bottom LineCerner continues to gain from its Population Health  Revenue Cycle and ITWorks platforms Cerner s EHR platform and revenue cycle management solutions have recently been implemented by a number of health facilities like the Illinois Rural Community Care Organization   IRCCO    Capital Region Medical Center   CRMC    Rankin County Hospital District and others  Additionally  the Department of Veterans Affairs   VA   announced that it signed an agreement with Cerner Government Services  Inc   a wholly owned subsidiary of Cerner Corporation  Management confirmed that Cerner saw continued activities in the area in the third quarter of 2018 California based Kern Medical too has selected Cerner to implement Cerner integrated EHR and Cerner HealtheIntent to support improved health outcomes  In fact  in the third quarter of 2018  management confirmed that 30  of Cerner s bookings came from its core Millennium installed base Stock to ConsiderThe stock currently carries a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical space are Veeva Systems Inc   NYSE VEEV    Becton  Dickinson and Company   NYSE BDX    and OPKO Health  Inc   NASDAQ OPK   Veeva Systems  long term earnings growth rate is projected at 19 5   The stock currently sports a Zacks Rank  1  Strong Buy   You can see  Becton  Dickinson s long term earnings growth rate is projected at 11 5   The stock presently carries a Zacks Rank  2  Buy  OPKO Health s long term earnings growth rate is projected at 12   The stock currently sports a Zacks Rank of 1 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-01-18,Zacks Investment Research,https://www.investing.com/analysis/cerner-picked-by-remi-vista-for-behavioral-health-technology-200377039,200377039
122658,344173,BDX,Why Is Becton  Dickinson  BDX  Down 2 4  Since Its Last Earnings Report ,opinion,"It has been about a month since the last earnings report for Becton  Dickinson and Company   NYSE BDX    Shares have lost about 2 4  in that time frame 
Will the recent negative trend continue leading up to its next earnings release  or is BDX due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts 
Recent EarningsBecton  Dickinson posted second quarter fiscal 2018 earnings of  2 65 which beat the Zacks Consensus Estimate of  2 61  Earnings also improved 7 8  year over year at cc BD posted revenues of  4 22 billion  surpassing the Zacks Consensus Estimate of  4 12 billion  Revenues rose 5 7  at cc  On a year over year basis  revenues surged 42 2  buoyed by synergies from the acquisition of C  R  Bard Segment DetailsBD MedicalThe segment posted worldwide revenues of  2 17 billion  up 4 2  at cc  Per management  the strong results were driven by the Medication Delivery Solutions  Diabetes Care and Pharmaceutical Systems units BD Life SciencesWorldwide revenues in this segment came in at  1 18 billion  reflecting an increase of 7 3  at cc Revenue growth reflects strong performance in the Diagnostic Systems and Biosciences units   However  growth in the Preanalytical Systems unit was negatively impacted by a production issue in one of its product lines which was resolved in the quarter The segment s growth was aided by flu related revenues in the Diagnostic Systems unit as a result of a stronger flu season in comparison to the prior year BD InterventionalIn the reported quarter  this segment posted worldwide revenues of around  1 billion  up 7 1  at cc  The segment s results reflect strong performance by the Peripheral Intervention and Urology and Critical Care units and solid growth in the Surgery unit Geographic ResultsUSSales in the United States came in at  2 33 billion  up 4  at cc in the second quarter The BD Medical segment accounted for revenues of  1 18 billion in the United States BD Life Sciences accounted for  498 million of revenues  while BD Interventional recorded  649 million in the United States InternationalSales outside the United States came in at  1 9 billion  up 7 9  at cc The upside was driven by strong performance by the BD Medical  BD Life Sciences and BD Interventional segments Internationally  BD Medical posted revenues worth  994 million  BD Life Sciences raked in international revenues of  600 million  while BD Interventional contributed  303 million Margin AnalysisIn the reported quarter  gross profit totaled  1 6 billion  up 14 8  year over year BD posted operating income of  183 million  down 59  GuidanceBuoyed by the solid fiscal second quarter performance  BD raised its fiscal 2018 guidance  The company expects adjusted earnings per share of  10 9  11 05 on an increase in the estimated benefit from foreign currency  This represents growth of approximately 15 16 5  over fiscal 2017 The company raised the revenue growth guidance for fiscal 2018 to 5 5 5   which is also at a high end of the previous guidance 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  There have been three revisions higher for the current quarter compared to seven lower 
Becton  Dickinson and Company Price and Consensus
    VGM Scores
At this time  BDX has an average Growth Score of C  however its Momentum is doing a lot better with an A  The stock was allocated a grade of B on the value side  putting it in the top 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Based on our scores  the stock is primarily suitable for momentum investors while also being suitable for those looking for value and to a lesser degree growth 
Outlook
Estimates have been broadly trending downward for the stock and the magnitude of these revisions indicates a downward shift  Interestingly  BDX has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-06-04,Zacks Investment Research,https://www.investing.com/analysis/why-is-becton-dickinson-bdx-down-24-since-its-last-earnings-report-200321825,200321825
122659,344174,BDX,Zacks Industry Outlook Highlights  Becton And Dickinson  Johnson   Johnson  Cigna And CVS Health,opinion,For Immediate ReleaseChicago  IL   June 15  2018   Today  Zacks Equity Research discusses the Industry  Medical Devices  Part 1  including Becton  Dickinson and Company   NYSE BDX    Johnson   Johnson   NYSE JNJ    Cigna   NYSE CI   and CVS Health Corp   NYSE CVS   Industry  Medical Devices  Part 1Link  The global medical device industry has demonstrated strong and sustainable growth in the recent past  Banking on an aging population  increasing incidence of chronic and lifestyle diseases  increasing adoption of artificial intelligence  AI  and big data applications  upbeat consumer sentiment and increased business investments  this sector appears to be in the pink of health Going by KPMG data  the medical device industry s global annual sales is forecast to rise more than 5  a year to reach nearly  800 billion by 2030 A CISION report says that the United States is the largest medical device market in the world at present  raking in more than  180 billion in revenues  Despite several socio political hazards and economic dips  U S  medical device companies have been riding high on R D innovation  increasing consolidation  emerging market expansion and tax cuts Undoubtedly  it has been a very profitable investment space of late Here are a few major developments Abolition of MedTech Tax The bipartisan two year suspension of the Medical Device tax  which imposed a 2 3  excise tax on MedTech manufacturers  marks a temporary relief  It will be again put into effect from Jan 1  2020 The repeal is expected to boost hiring and investment at 9 000 America based medical device manufacturers  thus instilling investor optimism The ratification of the tax repeal amendment has encouraged massive investments in the sector M A Uptrend ContinuesApart from the tax relief  the MedTech fraternity has also been riding high on the ongoing merger and acquisition  M A  trends in the space  In fact  various reports suggest that M A has been the key catalyst driving the U S  healthcare space of late  Per data provided by BioSpectrum Asia  M A activity in the MedTech space surged 50  in 2017  increasing the value of aggregate M A to more than  200 billion Some of the major acquisitions in the recent past include Becton  Dickinson and Company s acquisition of C  R  Bard and Johnson   Johnson s buyout of Actelion PBM Health Insurers ConsolidationLately  health insurers have been looking to collaborate with pharmacy benefit managers in the MedTech space to streamline costs in the drug supply chain Buoyed by continued capital inflow  strategic M A policies by key medical device players have expanded customer bases  moderated leverage and enhanced cash flow  These have also alleviated pricing pressure and competition in the MedTech space In this regard  the latest buyout announcement of Express Scripts by Cigna  which comes just three months after drug chain and pharmacy giant CVS Health Corp s announcement to acquire the nation s third largest health insurer  Aetna  NYSE AET   is important Digital Revolution and MedTechLatest trends like robotic surgeries  Big data analytics  bio printing  3D printing  electronic health records  EHR   predictive analytics  real time alerting and revenue cycle management services in the U S  MedTech space are gaining prominence Various reports suggest that the strategic application of AI in every sphere of healthcare can provide an impetus to productivity  Companies that adopted AI technologies have witnessed a 50  reduction in healthcare costs and have also experienced improved patient outcome of more than 50  This along with a rise in minimally invasive surgeries  higher demand for liquid biopsy tests and use of IT for quick and improved patient care  and the shift of the payment system to a value based model have been driving profits at medical device companies of late Trade War Fears Grip MedTechThe 10 sectors that have been identified by Trump for imposition of higher tariff are now on investors  radar  Healthcare  including medical equipment  is one of the sectors  likely to bear the brunt of the trade dispute Going by data provided in an article by Christian B  Jones in Mondaq  MedTech firms in the United States currently sell  4 7 billion annually to China  while the nation imports from China a total of  5 billion in medical device  U S  exports of medical devices last year totaled  52 billion  creating a  1 billion worldwide trade surplus  Needless to say  the medical device lobby is extremely apprehensive about the proposed tariffs on Chinese products as it could significantly affect international trade Strong Stocks that Should Be in the NewsMany are little publicized and fly under the Wall Street radar  They re virtually unknown to the general public  Yet today s 220 Zacks Rank  1  Strong Buys  were generated by the stock picking system that has nearly tripled the market from 1988 through 2015  Its average gain has been a stellar  26  per year  Follow us on Twitter   Join us on Facebook  NASDAQ FB    Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Media ContactZacks Investment Research800 767 3771 ext  9339Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2018-06-14,Zacks Investment Research,https://www.investing.com/analysis/zacks-industry-outlook-highlights-becton-and-dickinson-johnson--johnson-cigna-and-cvs-health-200325232,200325232
122660,344175,BDX,Can R D Focus Drive DENTSPLY SIRONA s  XRAY  Q3 Earnings ,opinion,"DENTSPLY SIRONA s   NASDAQ XRAY   third quarter 2018 results are scheduled to release on Nov 8  The company s focus on Research and Development  R D  is expected to boost quarterly results Let s take a look at other major factors that will influence DENTSPLY SIRONAS  performance in the quarter to be reported Q2 Results at a GlanceIn the last reported quarter  the company reported adjusted earnings per share  EPS  of 60 cents  which beat the Zacks Consensus Estimate by a penny  However  earnings deteriorated 7 7  from the prior year quarter s level  Net sales increased 5  year over year to  1 04 billion  The figure marginally surpassed the Zacks Consensus Estimate of  1 03 billion DENTSPLY SIRONA has an average positive earnings surprise of 4  in the trailing four quarters DENTSPLY SIRONA Inc  Price and Consensus
     Which Way are the Estimates Treading For the third quarter  the Zacks Consensus Estimate for EPS is pegged at 46 cents  reflecting a decline of 34 3  year over year  The same for net sales is projected at  951 8 million  hinting at a fall of 5 7  year over year R D Focus to Drive Q3 ResultsDENTSPLY SIRONA s overall growth strategy rests on product innovation and R D focus  which is likely to drive the top line in the third quarter In Europe  new products like WaveOne GOLD  X Smart iQ  VDW and CONNECT Drive are expected to drive revenues Growing preventive and restorative product portfolio are expected to drive revenues in the third quarter  The company s diverse product portfolio and recurring revenue base are key growth catalysts in the long run In fact  in the second quarter of 2018  the company s operating expenses rallied 50 basis points  bps  owing to consistent investments in R D  We expect the trend to continue in the third quarter as well  For 2018  management expects capital expenditures to be around  200 million  with strong developments in the third quarter  For instance  DENTSPLY SIRONA s laser team is currently spending a considerable time on innovation  This is likely to drive the company s share and margin However  the company lowered full year guidance  DENTSPLY SIRONA expects adjusted EPS for 2018 in the range of  2  2 15 per share  down from the previous projection of  2 55  2 65  Revenues for 2018 are expected to decline 2  at constant currency  cc  in 2018  down from the previous expectation of 2  growth at cc Other Factors to ConsiderThe company s CAD CAM is a dental imaging platform is likely to be a key contributor to third quarter results DENTSPLY SIRONA acquired OraMetrix   a leading industry provider of innovative 3 D technology solutions   in the second quarter of 2018  Post the acquisition  the company has been providing an end to end digital workflow to dental professionals  Management confirmed that the company is likely to gain solid traction in the CAD CAM unit in the third quarter  particularly in the U S  markets However  the Technology   Equipment impairment is likely to post soft revenues and pressed operating margin rates for CAD CAM as well as Imaging reporting units  Per management  this is because of increasing competitive pressures and reduction in inventory levels Earnings WhispersPer our proven quantitative model  a stock needs to have a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to deliver a positive earnings surprise  This is not the case here as you will see below Earnings ESP  DENTSPLY SIRONA has an Earnings ESP of  0 98   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  DENTSPLY SIRONA carries a Zacks Rank  4 Please note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is witnessing negative estimate revision Stocks Worth a LookHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter ICU Medical  Inc    NASDAQ ICUI   has an Earnings ESP of  8 65  and a Zacks Rank  2 Quidel Corporation   NASDAQ QDEL   has an Earnings ESP of  10 55  and a Zacks Rank  3  You can see  Becton  Dickinson and Company   NYSE BDX   has an Earnings ESP of  0 43  and a Zacks Rank  3 Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-11-01,Zacks Investment Research,https://www.investing.com/analysis/can-rd-focus-drive-dentsply-sironas-xray-q3-earnings-200352941,200352941
122661,344176,BDX,What s In The Offing For DaVita  DVA  This Earnings Season ,opinion,"DaVita Inc  s   NYSE DVA   third quarter 2018 results are scheduled to release on Nov 7  after market close  While the company s Kidney Care business is expected to drive the top line  headwinds in the Rx and GranuFlo wings might be a concern Q2 Results at a GlanceIn the last reported quarter  DaVita reported adjusted earnings of  1 05 per share  beating the Zacks Consensus Estimate of 97 cents Total revenues declined 25 5  year over year to  2 89 billion but beat the Zacks Consensus Estimate of  2 88 billion The company has a positive average earnings surprise of 2 4  for the trailing four quarters Which Way Are Estimates Treading For the quarter to be reported  the Zacks Consensus Estimate for earnings is pegged at 90 cents  reflecting year over year growth of 11 1   The same for revenues stands at  2 92 billion  showing a year over year decline of 25 6  DaVita Inc  Price and EPS Surprise
    Let s delve into factors that are likely to impact DaVita s third quarter 2018 results Probable Gains From Kidney Care   Dialysis BusinessesAs an operating division of DaVita  DaVita Kidney Care focuses on setting worldwide standards for clinical  social and operational practices in kidney care  It has also been consistently cushioning the company s top line In the last reported quarter  Kidney Care revenues were  2 87 billion  up 7  year over year  Net dialysis and related lab patient service revenues totaled  2 67 billion  up 11 9  year over year Lately  DaVita opened a 150 000 square foot campus for DaVita Labs in DeLand  FL  with a view to serve DaVita dialysis clinics and their patients   Read More   Although it is likely to have little impact on third quarter results  it shows that management remains optimistic about the Kidney Care wing Possible DeterrentsDaVita is currently being plagued by headwinds related to DaVita Rx and GranuFlo units For investors  notice  DaVita Rx is a full service pharmacy specializing in kidney care and dedicated to the safety of patients  At the end of the last reported quarter  management at DaVita announced that certain unfavorable changes in the oral pharmacy space have hurt the economics of DaVita Rx Notably  for the second half of 2018  DaVita expects to incur an adjusted loss on DaVita Rx operations of  20 million to  35 million due to duplicative costs during the transition Additionally  a federal jury in Colorado handed down a negative verdict involving DaVita s use of GranuFlo  one of the components used to produce dialysis  by the end of the last reported quarter  This is likely to have a negative impact on the company s customer base  which might also hurt the top line Lastly  the company incurred some additional costs in the first half of 2018 and expects such costs to be significantly higher in the third quarter What Does Our Model Say Per our proven model  a stock needs to have a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to deliver a positive earnings surprise in the quarter  However  this is not the case here Earnings ESP  DaVita has an Earnings ESP of 0 00   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  DaVita carries a Zacks Rank  3 Please note that we caution against stocks with a Zacks Rank  4  Sell  or 5  Strong Sell  going into the earnings announcement  especially when the company is seeing negative estimate revision Stocks Worth a LookHere are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter Becton  Dickinson and Company   NYSE BDX   has an Earnings ESP of  0 34  and a Zacks Rank  3  You can see  Quidel Corporation   NASDAQ QDEL   has an Earnings ESP of  10 55  and a Zacks Rank  3 Patterson Companies   NASDAQ PDCO   has an Earnings ESP of  0 82  and a Zacks Rank  3 Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-11-01,Zacks Investment Research,https://www.investing.com/analysis/whats-in-the-offing-for-davita-dva-this-earnings-season-200354167,200354167
122662,344177,BDX,Why Earnings Season Could Be Great For Becton  Dickinson  BDX ,opinion,Investors are always looking for stocks that are poised to beat at earnings season and Becton  Dickinson and Company   NYSE BDX   may be one such company  The firm has earnings coming up pretty soon  and events are shaping up quite nicely for their report That is because Becton  Dickinson is seeing favorable earnings estimate revision activity as of late  which is generally a precursor to an earnings beat  After all  analysts raising estimates right before earnings   with the most up to date information possible   is a pretty good indicator of some favorable trends underneath the surface for BDX in this report In fact  the Most Accurate Estimate for the current quarter is currently at  2 93 per share for BDX  compared to a broader Zacks Consensus Estimate of  2 92 per share  This suggests that analysts have very recently bumped up their estimates for BDX  giving the stock a Zacks Earnings ESP of  0 17  heading into earnings season Becton  Dickinson and Company Price and EPS Surprise   Why is this Important A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises  and outperforming the market  Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank  3  Hold  or better show a positive surprise nearly 70  of the time  and have returned over 28  on average in annual returns  see more   Given that BDX has a Zacks Rank  3 and an ESP in positive territory  investors might want to consider this stock ahead of earnings  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here Clearly  recent earnings estimate revisions suggest that good things are ahead for Becton  Dickinson  and that a beat might be in the cards for the upcoming report Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-11-04,Zacks Investment Research,https://www.investing.com/analysis/why-earnings-season-could-be-great-for-becton-dickinson-bdx-200354724,200354724
122663,344178,BDX,BD s FDA Nod For Phoenix Test Boosts Diagnostic Systems,opinion,Becton  Dickinson and Company   NYSE BDX    also known as BD  recently announced the FDA 510 k  clearance of its Phoenix CPO detect test  This will allow hospitals to identify infections caused by carbapenemase producing organisms  CPOs  and help them contain the spread of antimicrobial resistance  AMR   The development will also likely boost BD s Diagnostic Systems Per management  all versions of Phoenix will be available starting January 2019 More on Phoenix CPO Detect TestIt is a new phenotypic test  representing a significant advance over conventional ones in rapid detection of CPOs  Notably  the test can detect the presence of CPOs in under 36 hours  compared to conventional phenotypic methods which may take up to 96 hours It gives laboratories an accurate and cost effective method to quickly identify CPO caused infections and support patient management This complements BD s diagnostics portfolio which also boasts BD Phoenix M50  an automated microbiology system used for susceptibility testing BD Diagnostic Systems at a GlanceBD Diagnostic Systems provides products and instruments for detecting a broad range of infectious diseases  healthcare associated infections and cancer In the recently reported fourth quarter of fiscal 2018  BD Diagnostic Systems grew 8 2  year over year  It grew 9 6   from fiscal 2017 Per management  growth was driven by BD s instrumented microbiology platforms  TB  and IDAST  strong Kiestra installations and BD MAX molecular platform Market ProspectsResearch by Market Watch shows that the global infectious disease diagnostics market is expected to exceed more than  21 billion by 2022 at a CAGR of 10  Hence BD s latest development has been a well timed one Price PerformanceOver the past year  shares of BD have rallied 6 3  compared with the  s rise of 4 2   The current level is also higher than the S P 500 index s increase of 5 6  The stock carries a Zacks Rank  3  Hold  Key PicksA few better ranked stocks in the broader medical space are Stryker Corporation   NYSE SYK    Masimo Corporation   NASDAQ MASI   and Veeva Systems   NYSE VEEV   Stryker has a long term expected earnings growth rate of 10  and a Zacks Rank  2  Buy   You can see  Masimo s long term earnings growth rate is projected at 14 6   The stock carries a Zacks Rank  2 Veeva Systems  long term earnings growth rate is estimated at 19 3   The stock carries a Zacks Rank  2 3 Medical Stocks to Buy NowThe greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ,2018-11-14,Zacks Investment Research,https://www.investing.com/analysis/bds-fda-nod-for-phoenix-test-boosts-diagnostic-systems-200359123,200359123
122664,344179,BDX,Here s Why You Should Hold Becton  Dickinson  BDX  Stock Now,opinion,"Becton  Dickinson and Company   NYSE BDX    also known as BD  is expected to benefit from solid fiscal fourth quarter results and a slew of positive developments  However  a few headwinds are anticipated in fiscal 2019 along with product recall issues The stock currently has a Zacks Rank  3  Hold  What s Deterring the Stock BD expects raw material pricing pressure  which increased in 2018  to accelerate into fiscal 2019  primarily due to resin price increases owing to a supply constrained market Additionally  headwinds related to the sale of Advanced Bioprocessing and the divestitures to Merit Medical are likely to keep margins under pressure In the last reported quarter  management declared that BD has decided to discontinue its insulin infusion sets owing to a moderately higher than anticipated rate of complaints associated with insertion that occurred during the pilot launch of the product Why Should You Retain BDBD recently reported solid fiscal fourth quarter results  Earnings per share came in at  2 93  beating the Zacks Consensus Estimate by a penny  Revenues totaled  4 4 billion outpacing the Zacks Consensus Estimate of  4 36 billion Notably  the company continues to gain from its core BD Medical and BD Life Sciences segments  Domestic and international revenues increased year over year as well A series of developments have been raising optimism as well The company recently announced the FDA 510 k  clearance of its Phoenix CPO detect test   Read More   Additionally  BD announced the safety and efficacy data from its LUTONIX Drug Coated Balloon  used for a below the knee  BTK  indication Last month  BD announced the availability of the BD MAX MDR TB panel in Europe Shares of BD have rallied 7 3   outperforming the  s growth of 3 7  in a year s time  The current level is also higher than the S P 500 index s 6  rise Which Way Are Estimates Headed For the current quarter  the Zacks Consensus Estimate for earnings is pegged at  2 66  reflecting an increase of 7 3  on a year over year basis  The same for revenues is pinned at  4 11 billion  showing an increase of 33 6  year over year For the full year  the Zacks Consensus Estimate for revenues is at  17 45 billion  reflecting a rise of 9 2  year over year  However  the same for earnings stands at  12 15  showing growth of 10 4  year over year Becton  Dickinson and Company Price and Consensus
    Key PicksA few better ranked stocks in the broader medical space are Stryker Corporation   NYSE SYK    Masimo Corporation   NASDAQ MASI   and Veeva Systems   NYSE VEEV   Stryker has a long term expected earnings growth rate of 10  and a Zacks Rank  2  Buy   You can see  Masimo s long term earnings growth rate is projected at 14 6   The stock carries a Zacks Rank  2 Veeva Systems  long term earnings growth rate is estimated at 19 3   The stock carries a Zacks Rank  2 Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ",2018-11-14,Zacks Investment Research,https://www.investing.com/analysis/heres-why-you-should-hold-becton-dickinson-bdx-stock-now-200359639,200359639
122702,344217,BDX,Becton  Dickinson  BDX  Down 1 3  Since Last Earnings Report,opinion,"A month has gone by since the last earnings report for Becton  Dickinson and Company   NYSE BDX    Shares have lost about 1 3  in that time frame 
Will the recent negative trend continue leading up to its next earnings release  or is BDX due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts 
Recent EarningsBecton  Dickinson and Company  popularly known as BD  reported first quarter fiscal 2018 earnings of  2 48 per share  which beat the Zacks Consensus Estimate of  2 40  Adjusted earnings increased 3 9  at constant currency  cc  on a year over year basis The company reported revenues of  3 08 billion  beating the Zacks Consensus Estimate of  3 05 billion  This represents an increase of 5 4  from the prior year quarter  or 3 7  at cc Segmental AnalysisBD MedicalThe BD Medical segment generated revenues of  2 04 billion  up 1 9  at cc on a year over year basis The segment s result reflects an adverse impact from the change in the U S  dispensing business model  However  BD Medical witnessed strong performance in the Medication and Procedural Solutions as well as the Diabetes Care and Pharmaceutical Systems units Medication and Procedural Solutions registered revenues of  925 million in the BD Medical segment  up 5  year over year at cc Diabetes Care reported revenues of  277 million  up 2 2  at cc on a year over year basis Pharmaceutical Systems reported revenues of  245 million  up 3 7  at cc on a year over year basis However  Medication Management Solutions reported revenues of  587 million  down 3 4  at cc on a year over year basis BD Life SciencesThe BD Life Sciences segment generated revenues of  1 05 billion  up 7 3  at cc from the year ago quarter  The segment s performance indicates strong numbers across the Biosciences  Diagnostic Systems and Preanalytical Systems units Preanalytical Systems recorded revenues of  375 million in the first quarter  up 4  at cc on a year over year basis Diagnostic Systems reported revenues of  381 million  up 12 5  year over year at cc Meanwhile  the Biosciences unit registered revenues of  289 million  up 5 3  at cc Geographic ResultsUnited StatesU S  revenues were roughly  1 66 billion  up 1 6  on a year over year basis Within the BD Medical segment  growth in the Medication and Procedural Solutions and Diabetes Care units was offset by declines in the Medication Management Solutions and Pharmaceutical Systems units BD Life Sciences segment results within the United States were primarily driven by Diagnostic Systems and Preanalytical Systems units in the reported quarter International RevenuesInternational revenues rose 6 3  to  1 42 billion at cc Both BD Medical and BD Life Sciences segment registered strong growth outside the United States   Within the BD Medical segment  growth was driven by strength in the Pharmaceutical Systems unit  aided by impressive results in the Medication and Procedural Solutions and Diabetes Care units GuidanceIncluding the accretion from C  R  Bard acquisition  BD expects fiscal 2018 revenues to increase in the range of 30 31  on a reported basis  However  revenues are expected to grow in the range of 4 5 5 5  Notably  revenues are likely to be affected by the change in the U S  dispensing business model The company expects adjusted earnings per share in the range of  10 85  11 00  up from the previous range of  10 55  10 65  The current range indicates growth of approximately 15  to 16  on a reported basis  or approximately 12  at cc 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in fresh estimates  There have been three revisions higher for the current quarter compared to two lower Becton  Dickinson and Company Price and Consensus    VGM Scores
At this time  BDX has a poor Growth Score of F  however its Momentum is doing a lot better with an A  The stock was allocated a grade of C on the value side  putting it in the middle 20  for this investment strategy 
Overall  the stock has an aggregte VGM Score of D  If you aren t focused on one strategy  this score is the one you should be interested in 
Our style scores indicate that the stock is more suitable for momentum investors than value investors 
Outlook
Estimates have been broadly trending upward for the stock and the magnitude of these revisions looks promising  Notably  BDX has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-03-07,Zacks Investment Research,https://www.investing.com/analysis/becton-dickinson-bdx-down-13-since-last-earnings-report-200296687,200296687
122703,344218,BDX,Cigna To Take Over Express Scripts  ESRX  For  67 Billion,opinion,Integrating medical care and pharmacy benefits under one roof  Express Scripts Holding Company   NASDAQ ESRX   recently announced that it is getting acquired by Cigna Corporation   NYSE CI    a global health insurance company  The acquisition is expected to be completed by Dec 31  2018  Post the acquisition  the combined company will invest  200 million in its charitable foundation to support the communities in which it operates Per the definitive agreement  Cigna will take over Express Scripts in a cash and stock transaction worth  67 billion  Notably  this includes Cigna s assumption of approximately  15 billion debt of Express Scripts  Express Scripts is the largest pharmacy benefits manager Express Scripts sports a Zacks Rank  1  Strong Buy   You can see   Express Scripts  stock has outperformed the industry in the past year  Specifically  the company s shares have gained 19 7  compared with the  s rally of 13 8  Under the terms of the deal  Cigna will pay  48 75 in cash and 0 2434 shares of stock of the newly combined company  Upon closure  Express Scripts  shareholders will own approximately 36  of the combined company The transaction will result in total cost synergies of  650 million and double digit accretion to earnings in the first year after closure  As a result  Cigna expects the deal to increase earnings per share from  18 to  20  21 in 2021  The latest acquisition has been undertaken solely to enhance customer base and improve  Patient Provider Alignment  Express Scripts Holding Company Price    U S  Healthcare Leads the M A GameMergers and acquisitions  M A  have been the key driver of the U S  healthcare space  lately  Glancing through the major acquisitions of the recent past  Becton  Dickinson and Company s   NYSE BDX   acquisition of C  R  Bard  and JOHNSON   JOHNSON s buyout of Actelion deserve a mention In fact  health insurers are trying to consolidate with pharmacy benefits managers to streamline and cut costs in the drug supply chain  Notably  the latest buyout of Express Scripts comes just three months after a drug chain and a pharmacy giant CVS Health Corp   NYSE CVS   agreed to take over the nation s third largest health insurer Aetna  NYSE AET  Coming to the post acquisition impacts  we believe that the latest development will pose a big threat to UnitedHealth Group Incorporated  NYSE UNH   the largest U S  health insurer  with its own pharmacy benefits unit  and CVS Health after it completes the merger with Aetna The move is also expected to nullify threats from Amazon com Inc  NASDAQ AMZN    which is making huge expansion in the world of pharmacy business  Recently  the e commerce giant announced a joint venture with JPMorgan Chase   Co  NYSE JPM   and Warren Buffett s Berkshire Hathaway  NYSE BRKa  to curb medical costs for their employees What are the Moody s Ratings for Express Scripts Moody s Investors Service  the rating services arm of Moody s Corporation  placed the Baa2 senior unsecured long term ratings to Express Scripts  Notably  obligations rated Baa are subject to moderate credit risk  However  the latest rating has been kept under review with a tag of  direction uncertain  by Moody s Moody s has not rated Express Scripts with high credit risk because of its solid position as a leading pharmacy benefit manager  moderate leverage and strong cash flow However  Moody s is worried about Express Scripts  high customer concentration and pricing pressure  Further  the company s ongoing dispute with Anthem  Inc   its largest customer   is a concern Per Moody s  Express Scripts experienced declining script volume and higher than typical customer losses  Other challenges include fewer generic drug introductions  softening mail order growth trends  client focus on cost savings and transparency The Hottest Tech Mega Trend of All Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ,2018-03-11,Zacks Investment Research,https://www.investing.com/analysis/cigna-to-take-over-express-scripts-esrx-for-67-billion-200297297,200297297
122704,344219,BDX,Trade War Fears Grip MedTech   3 Stocks On The Line Of Fire,opinion,"The trade war cacophony has spread far and wide  not sparing the investment world  The conflict between two of the world s biggest economies has led Dow to fall more than 1 100 point in just two days last week  Although it is gradually recovering  the market is still fraught with possibilities of other outbreaks The 10 sectors that have been identified by Trump for imposition of higher tariff are now on investors  radar  Healthcare  including medical equipment  is one of the sectors which might face the brunt of the trade dispute Current ScenarioUnlike what most economists had initially expected  China is fast adopting stances to square off America s advantage points in this import tariff game In response to Trump s proposed imposition of  60 billion in annual tariffs on Chinese products  Beijing has announced the initial  3 billion of reciprocal tariff on 128  roughly  imports from the United States and is supposedly preparing a bolder counter attack In the wake of the tariff threats  Nobel Prize winning economist Robert Shiller has warned of an impending economic crisis Meanwhile  a Bloomberg report states that the United States will maintain a lead in the trade conflicts with China  This is because the United States  to some extent  is a monopsony market with a large number of buyers  Thus  if the nation stops purchasing Chinese products  China will not be able to channelize that surplus to Canada or Indonesia at the same price  However  China will not be able to adopt a tit for tat strategy as it does not import on the same scale from the United States Accordingly  following last week s crash  the market is slowly looking up  The news that the nations are likely to resolve the issue mutually is fuelling the recovery  However  whether the talks will extinguish the possibilities of a trade war completely is yet to be seen  Meanwhile  investors are caught in the  America First  and  Made in China 2025  web Is Medical Device Caught in the Storm As stated earlier  U S  Trade Representative Robert Lighthizer has identified healthcare as one of the 10 sectors which are subjected to the  60 billion U S  tariff  More specifically  Trump has considered biomedicine and high performance medical devices  which include China s advanced chemicals and medical equipment  respectively Needless to say  this has triggered a decline in the sector  Following the news and with chances of China s retaliation  losses were widespread in the Medical device sector with bigwigs taking severe blows  We note that  the sector has gained significantly from profits earned by a number of medical device companies from the BRIC nations Going by a Market Realist report  companies like Medtronic plc   NYSE MDT    Becton  Dickinson and Company   NYSE BDX    Abbott and others saw considerable weakness on Mar 23 as talks of a U S  China trade war started doing the rounds Although these stocks are gradually reviving on rising chances of the two nations negotiating certain terms  investors consider them still extremely vulnerable and widely exposed to the trade conflict given their huge business network in Mainland China We have shortlisted three stocks that are facing the brunt of the tumultuous market conditions Zimmer Biomet Holdings  Inc    NYSE ZBH    This Zacks Rank  5  Strong Sell  lost 6 5  on Mar 23  We note that  the company has been investing heavily to cash in on the Chinese Reconstructive and Trauma markets  Strategic investments in these regions over the past several quarters to improve operational and sales performance are yielding results  In the fourth quarter  the company witnessed improvement in its Asia Pacific business on solid distributor orders  China particularly demonstrated strong growth  Thus  any form of retaliation by China will impact the company Zimmer Biomet Holdings  Inc  Price
    Medtronic  In the last reported quarter  Medtronic s businesses in China showed strength  growing double digits  According to the company  within the next decade  China is expected to be its biggest health care market  Needless to say  this Zacks Rank  3  Hold  company is expending large amounts of cash to strengthen its business in this market  The company is focused on developing public and private partnerships as well as executing channel optimization strategies  You can see Medtronic PLC Price
    Over the last few years  Abbott   NYSE ABT   has been leading the emerging market investment trend  with about 50  of total sales coming from this region  This Zacks Rank  3 stock s core Established Pharmaceuticals Division   EPD   business operates solely in emerging geographies  with leading positions in Chinese pharmaceutical markets for branded generics  In the last reported quarter as well  China demonstrated double digit growth in EPD  Trade war or not  these stocks are in an extremely vulnerable position with a broad network and diversified business base in China Abbott Laboratories Price
 

   Breaking News  Cryptocurrencies Now Bigger than VisaThe total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved Zacks  has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ",2018-03-27,Zacks Investment Research,https://www.investing.com/analysis/trade-war-fears-grip-medtech--3-stocks-on-the-line-of-fire-200301454,200301454
122705,344220,BDX,What s In Store For DENTSPLY  XRAY  This Earnings Season ,opinion,DENTSPLY SIRONA Inc  s   NASDAQ XRAY   first quarter 2018 results are scheduled to release on May 7  before the market opens  The company s CAD CAM imaging platform is expected to boost results in the quarter to be reported and improvement in other units are tailwinds as well In the last reported quarter  DENTSPLY posted adjusted earnings per share  EPS  of 82 cents  beating the Zacks Consensus Estimate by a penny  However  the metric declined 22 4  year over year  Net sales increased to  1 091 million from  996 5 million in the year ago quarter  Also  the figure surpassed the Zacks Consensus Estimate of  1056 0 million and rose 5 3  at constant currency  cc  exchange rate Currently  the Zacks Consensus Estimate for earnings in the quarter to be reported is pegged at 42 cents per share  reflecting a decline of 14 3  year over year  The Zacks Consensus Estimate for net sales is projected at  944 7 million  showing an improvement of 4 9  year over year Let s delve into major factors that will influence DENTSPLY performance in the quarter to be reported What to Expect From DENTSPLY in Q1 The company s CAD CAM unit is likely to drive the top line in the first quarter  The CAD CAM is a dental imaging platform and a major foundation in global dental markets In the last reported quarter  DENTSPLY announced that consistent focus on sales force effectiveness is likely to boost results  At present  there are 30 plus sales force and close to 5 800 people employed globally in sales and sales support In the quarter to be reported  R D prospects and innovations will be other growth drivers  Recently  the company announced its plan to redirect industry leading R D budget toward high impact projects that provide a better competitive position DENTSPLY SIRONA Inc  Price and EPS Surprise    DENTSPLY confirmed that it has undertaken measures to reduce its interest expense by approximately  20 million by 2018 end  which is likely to boost first quarter 2018 results  Overall  the company has a very low cost debt structure and ample availability to grow its businesses and make acquisitions On Mar 26  DENTSPLY announced a definitive agreement to acquire OraMetrix   a leading industry provider of innovative 3 D technology solutions The company also offers an advanced  CAD platform developed for dental professionals to deliver consistently predictable orthodontic outcomes  The transaction is expected to be completed by the second quarter of 2018 DENTSPLY s overall growth strategy rests on product innovation  The company s solid internal growth  amid challenging macroeconomic headwinds  is primarily driven by its innovative new products What Does our Model Predict Despite solid prospects  our quantitative model does not show a beat for DENTSPLY this earnings season This is because a stock needs to have a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat estimates Zacks ESP  The Earnings ESP for DENTSPLY is  2 73   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  DENTSPLY carries a Zacks Rank  5  Strong Sell   Notably  we caution against stocks with a Zacks Rank  4  Sell  or 5 going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks Worth a LookHere are a few medical stocks worth considering as they have the right combination of elements to post a beat this earnings season Becton  Dickinson and Company   NYSE BDX   has an Earnings ESP of  0 61  and a Zacks Rank  3  You can see  Cardinal Health Inc    NYSE CAH   has an Earnings ESP of  0 28  and a Zacks Rank  3 The Cooper Companies  Inc    NYSE COO   has an Earnings ESP of  0 26  and a Zacks Rank  3 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana      Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-05-01,Zacks Investment Research,https://www.investing.com/analysis/whats-in-store-for-dentsply-xray-this-earnings-season-200311776,200311776
122729,344244,BDX,Abbott To Strengthen Vascular Care Arm With Surmodics Deal,opinion,Abbott   NYSE ABT   has recently entered into an agreement with In Vitro Diagnostics technologies player  Surmodics  Inc    NASDAQ SRDX    Per the terms of the deal  the former will have exclusive worldwide commercialization rights over Surmodics  SurVeil drug coated balloon  The deal remains aligned with Abbott s focus to expand its broad line of vascular care products Notably  the SurVeil drug coated balloon by Surmodics is used to treat the superficial femoral artery and is under evaluation in a U S  pivotal clinical trial  Significantly  this new generation device is likely to complement and extend the company s vascular devices portfolio including stents and vessel closure devices for addressing peripheral artery disease  PAD  Per the American Heart Association  PAD is the narrowing of arteries causing reduced blood flow to the legs  stomach  arms and head  According to Abbott  this condition is often underdiagnosed leading to other serious vascular conditions  In this regard  drug coated balloons have emerged an important treatment option for the treatment of PAD Globally  over 200 million people are affected with PAD while 12 20  of Americans alone aged above 60 years are suffering from the disease  Undoubtedly  the market for the therapies related to this indication looks lucrative Per Abbott  the SurVeil drug coated balloon holds greater promises in capturing the market compared with traditional devices  This is because it includes a proprietary drug excipient formulation for a durable balloon coating and is manufactured using an innovative process to improve coating uniformity Pre clinical data for SurVeil has shown a three  to five times higher target tissue drug concentration  a more evenly distributed and durable drug effect  and lower incidence of downstream drug particles in comparison to the control drug coated balloon Accordingly  the Surmodics deal seems highly strategic from Abbott s point of view in monopolizing the huge and growing market for PAD regulating drug coated balloons Apart from SurVeil related pact  Abbott has choices to negotiate agreements for Surmodics  below the knee and arteriovenous fistula drug coated balloon products  currently in pre clinical development Per data by ReportsnReports  the global market for peripheral vascular interventions including lower extremity stents  percutaneous transluminal angioplasty  PTA  balloons  PTA drug eluting balloons  carotid stents and renal stents is estimated to rise from  2 1 billion in 2015 to  3 4 billion by 2022 at a CAGR of 6 8  Two major players in the drug coated balloons market are Medtronic  Inc    NYSE MDT   and Becton  Dickinson and Company   NYSE BDX   The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2018-02-28,Zacks Investment Research,https://www.investing.com/analysis/abbott-to-strengthen-vascular-care-arm-with-surmodics-deal-200295339,200295339
122752,344267,BDX,BD  BDX  Launches PAXgene In Europe For Advanced DNA Testing,opinion,"Becton  Dickinson and Company   NYSE BDX    popularly known as BD  has recently announced the commercial availability of the CE IVD marked PAXgene Blood circulating cell free DNA  ccfDNA  tube within the European Economic Area and Switzerland  Western Europe   The plastic tube  used for blood collection  was developed by PreAnalytiX GmbH  a joint venture between BD and Netherlands based provider of Sample to Insight solutions  QIAGEN N V    NYSE QGEN   
Since 2016  a research use only  RUO  version of the PAXgene Blood ccfDNA tube has been marketed by PreAnalytiX  The expanded access of the product in Europe will further consolidate BD s foothold in the molecular diagnostic testing space  
Per management  this launch will also heighten the growth prospects of the companies in Western Europe  who offer ccfDNA based tests Becton  Dickinson and Company Price and Consensus

   PAXgene at a Glance
The PAXgene Blood ccfDNA Tube provides a solution for clinical laboratories when the sample cannot be processed on the same day  It is used for the collection of whole blood samples and stabilization of ccfDNA  With PAXgene  samples can be stored in room temperature for up to 7 days  The stabilization is convenient for clinical laboratories as collection and processing occur days apart  unlike the standard EDTA  Ethylenediaminetetraacetic acid  tubes 
The tube includes a proprietary sample stabilization additive and the BD Vacutainer Hemogard technology to assure healthcare workers  safety  It ascertains accurate and consistent results in molecular diagnostic testing applications  using the ccfDNA  It can be used for treating cancer and also reduces the potential for errors in non invasive prenatal tests 
About PreAnalytiX
PreAnalytiX was jointly formed by Becton  Dickinson and QIAGEN with a view to develop  manufacture and sell integrated and standardized systems for sample collection  stabilization and purification of RNA and DNA from human blood or bone marrow  It offers a broad array of manual and automated products  in addition to serving healthcare institutions  academic researchers and clinical laboratories 
Gainful Market Prospects
Per a study by Markets and Markets  the global molecular diagnostics market is projected to reach  10 12 billion by 2021 from  6 54 billion in 2016  at a CAGR of 9 1  
High prevalence of infectious diseases and various types of cancer are some of the major factors driving this market 
Thus  BD s PAXgene has solid market prospects and we are optimistic of the launch to be perfectly strategic  The new development is also likely to secure a broader customer base in Europe 
Price Performance
Last year  Becton  Dickinson has outperformed the broader  in terms of price  The stock has returned 20 8  against the industry s rally of 11 6  

Zacks Rank   Key Picks
Becton  Dickinson carries a Zacks Rank  2  Buy  
Other top ranked stocks in the broader medical space are Centene Corp    NYSE CNC    and Haemonetics Corp    NYSE HAE    each sporting a Zacks Rank  1  Strong Buy   You can see 
Centene has a projected positive long term growth rate of 14 4   In the last six months  the stock has returned 16 3  
Haemonetics has an expected long term growth rate of 10 8   Last month  the stock has returned 4 9  
Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-02-21,Zacks Investment Research,https://www.investing.com/analysis/bd-bdx-launches-paxgene-in-europe-for-advanced-dna-testing-200292753,200292753
122860,344375,BDX,Should You Buy Becton  Dickinson  BDX  Ahead Of Earnings ,opinion,"Investors are always looking for stocks that are poised to beat at earnings season and Becton  Dickinson and Company   NYSE BDX   may be one such company  The firm has earnings coming up pretty soon  and events are shaping up quite nicely for their report That is because Becton  Dickinsonis seeing favorable earnings estimate revision activity as of late  which is generally a precursor to an earnings beat  After all  analysts raising estimates right before earnings   with the most up to date information possible   is a pretty good indicator of some favorable trends underneath the surface for BDX in this report In fact  the Most Accurate Estimate for the current quarter is currently at  2 41 per share for BDX  compared to a broader Zacks Consensus Estimate of  2 40 per share  This suggests that analysts have very recently bumped up their estimates for BDX  giving the stock a Zacks Earnings ESP of  0 31  heading into earnings season Becton  Dickinson and Company Price and EPS Surprise
   Why is this Important A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises  and outperforming the market  Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank  3  Hold  or better show a positive surprise nearly 70  of the time  and have returned over 28  on average in annual returns  see more   Given that BDX has a Zacks Rank  2  Buy  and an ESP in positive territory  investors might want to consider this stock ahead of earnings  You can see  Clearly  recent earnings estimate revisions suggest that good things are ahead for Becton  Dickinson  and that a beat might be in the cards for the upcoming report Breaking News  Cryptocurrencies Now Bigger than Visa The total market cap of all cryptos recently surpassed  700 billion   more than a 3 800  increase in the previous 12 months  They re now bigger than Morgan Stanley  NYSE MS   Goldman Sachs  NYSE GS  and even Visa  The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved Zacks has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market ",2018-02-01,Zacks Investment Research,https://www.investing.com/analysis/should-you-buy-becton-dickinson-bdx-ahead-of-earnings-200286416,200286416
122893,344408,BDX,Global In Vitro Diagnostic Market Booms  Stocks In Focus,opinion,The FDA approvals of Roche Holdings    OTC RHHBY   Hemlibra or Cobas Cdiff Nucleic acid test and Thermo Fisher Scientific s   NYSE TMO   slew of advancements in next generation sequencing  the latest one being the FDA approved Oncomine Dx Target Test  clearly point toward the rapid emergence of in vitro diagnostics  IVD  in the MedTech space The recent EvaluateMedTech World Preview indicates that while worldwide MedTech sales are expected to witness CAGR of 5 1  to  522 billion by 2022  steering ahead of cardiology  IVD will rake in annual sales of  69 6 billion at a CAGR of 5 9  The above data is just a small indicator of the vast scope for growth of the IVD market  For investors keen on MedTech  the most important fact is that IVD s benefits are not limited to any particular country or geographic territory  With the emergence of complex and transmittable diseases worldwide  this part of the MedTech space is currently in the spotlight IVD in a NutshellIf we go by FDA s definition  in vitro diagnostics are   tests that can detect diseases  conditions  or infections  Some tests are used in laboratory or other health professional settings and other tests are for consumers to use at home  Growth FactorsRapid occurrence of infectious diseases worldwide  increasing burden of killer bugs like cancer  cardiovascular diseases  stroke and other heart diseases  and diabetes in developing and developed nations as well as growing cognizance of early cancer screening  detection  and prevention have made IVD indispensable in the healthcare space Growing investment from both government and private players in the form of reimbursement coverage and speedy patent approvals are also driving demand  These apart  per a report by Research and Markets  increasing geriatric population  rising per capita GDP and per capita healthcare expenditure are acting as major growth catalysts  Per the report  owing to suitable demographical changes and rising disposable income coupled with improving basic infrastructure  developing regions are gradually becoming happy hunting grounds for this business Geographic Distribution So far  North America has the lead in the in vitro diagnostic market  Per Coherent Markets Insights  data  it is the highest contributing region with projected market share of 46 7  by 2024  at CAGR of 5 4  between 2016 and 2024   Favorable demography and regulatory policies along with increasing healthcare spending have aided growth of the IVD business in this geography  However  increasing instances of lifestyle oriented diseases  improving government funding and growing awareness of new technologies have fueled demand for IVD in emerging economies According to a recent report by Research and Market  China is the fastest growing among the top 10 IVD country markets  It is likely to expand more than threefold by 2022 from 2016 On the other hand  the revenue of the Indian IVD market has grown at a CAGR of 20  having increased from  0 64 billion in 2012 to  1 6 billion in 2017  data by Goldstein Research  Segmental Contribution Per a MedGadget report  apart from geographic distribution  the global in vitro diagnostic market has been segmented on the basis of application  type  end user and usability  Application wise  diabetes  infectious diseases  oncology  nephrology  autoimmune diseases and cardiology are generating huge revenues across the globe From the point of view of end user  hospitals  laboratory  point of care testing are the leading users   In terms of usability  disposable IVD devices and re usable IVD devices are widely used across the globe Key Players Roche remains the top player in the IVD market with expected sales of  12 8 billion in 2022  Key IVD developments at Roche include the Cobas range of tests  the latest one being Cobas Zika  the first commercially available test for the detection of the Zika virus RNA in samples of human plasma  On the other hand  Abbott s   NYSE ABT   recent acquisition of Alere should establish the company as the global leader in point of care testing  the fastest growing segment of in vitro diagnostics market  In this regard  the company noted that  point of care testing is a  7 billion segment of the in vitro diagnostics market and is growing rapidly Among the other bigwigs  Becton Dickinson   Company   NYSE BDX   deserves a mention  The company is striving to get approval for the commercialization of its innovative products in the fast growing infectious diseases testing market  Its BD Diagnostics provides products for the safe collection and transport of diagnostics specimens  as well as instruments and reagent systems to detect a broad range of infectious diseases  healthcare associated infections and cancer Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2017-11-21,Zacks Investment Research,https://www.investing.com/analysis/global-in-vitro-diagnostic-market-booms-stocks-in-focus-200267571,200267571
122894,344409,BDX,Becton  Dickinson Banks On Bard Buyout  Medical Unit Weak ,opinion,"On Dec 13  2017  we issued an updated research report on  Becton  Dickinson and Company   NYSE BDX    popularly known as BD  The stock carries a Zacks Rank  3  Hold   You can see The leading MedTech company is steadily progressing with the acquisition of C  R  Bard   NYSE BCR    Post completion  BD expects growth in adjusted earnings starting fiscal 2019  The acquisition will enable the company generate profits from complementary businesses and geographical expansion On Nov 16  BD announced that it will divest soft tissue core needle biopsy products for  100M to Merit Medical Systems Inc    NASDAQ MMSI    The products are currently sold under Bard s Aspira product line of tunneled home drainage catheters and accessories  The divestment is contingent on the completion of the BD s acquisition of Bard Year to date  BD has outperformed the  in terms of stock price  The company has returned 34 2   comparing favorably with the industry s rally of just 21 3   Notably  the current return is relatively higher than the S P 500 s increase of 21 9  Becton  Dickinson and Company Price and Consensus
     On the flip side  lackluster performance by BD s Medical Unit is a concern  Performance in the segment is affected by sluggishness in the Medication Management Solutions and Pharmaceutical Systems units in the United States Within the Diabetes Care unit  BD temporarily has paused shipments of insulin infusion sets  thanks to higher than anticipated rate of complaints associated with insertion during the pilot launch of the product  However  management conducted a clinical trial to gather insights and ensure that patients ultimately realize the full benefits of BD FlowSmart technology  BD continues to collaborate with Medtronic Plc   NYSE MDT   toward full commercialization of the productAdding to woes  the ongoing political conundrum pertaining to the repealing of Obamacare by the Republicans has given rise to uncertainties for dental stocks like BD and CONMED Corporation  Thus  lack of favorable developments in the regulatory front is a concern for these MedTech majors Zacks Editor in Chief Goes   All In   on This Stock Full disclosure  Kevin Matras now has more of his own money in one particular stock than in any other  He believes in its short term profit potential and also in its prospects to more than double by 2019  Today he reveals and explains his surprising move in a new Special Report ",2017-12-13,Zacks Investment Research,https://www.investing.com/analysis/becton-dickinson-banks-on-bard-buyout-medical-unit-weak-200273262,200273262
122895,344410,BDX,The Zacks Analyst Blog Highlights  Morris  EOG Resources  Becton  Dickinson  Sirius XM And ABB,opinion,For Immediate ReleaseChicago  IL   December 14  2017   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Morris   NYSE PM    EOG Resources   NYSE EOG    Becton  Dickinson   NYSE BDX    Sirius XM   NASDAQ SIRI   and ABB   NYSE ABB   Here are highlights from Wednesday s Analyst Blog  Top Research Reports for Phillip Morris  EOG Resources and Becton  DickinsonThe Zacks Research Daily presents the best research output of our analyst team  Today s Research Daily features new research reports on 16 major stocks  including Phillip Morris  PM   EOG Resources  EOG  and Becton  Dickinson  BDX   These research reports have been hand picked from the roughly 70 reports published by our analyst team today Phillip Morris s shares have underperformed the Zacks Tobacco industry over the last three months   8 1  vs   3    But the Zacks analyst likes Philip Morris  consistent efforts to improve the performance of its low risk products  In this category  the company s IQOS smokeless cigarette have been steadily expanding owing to consumer demand  Higher cigarette pricing has also been favoring the company  Though the company has been benefiting from enhanced volumes and revenues in the reduced risk products category  it has been suffering majorly due to consistent declines in cigarette volumes stemming from the shift of customer preference away from tobacco products Owing to such headwinds  Phillip Morris continued with its drab performance in third quarter 2017  wherein both earnings and revenues lagged the Zacks Consensus Estimate  These factors also compelled management to lower its 2017 view Shares of EOG Resources have gained around  12 7  over the last six months  outperforming the Zacks Oil   Gas E P Industry  which has gained  4  over the same period  EOG Resources holds premium acreages in the Permian  Bakken and Eagle Ford oil shale plays in the United States The Zacks analyst likes the firm s plan to complete 505 wells in the area  significantly higher than 443 recorded in 2016  The firm expects 80  and 90  of the wells to meet the standards of premium wells in 2017 and 2018  respectively  In the promising U S  shale plays  EOG Resources has identified 7 200 premium wells that can give access to almost 6 5 billion barrels of oil equivalent estimated potential reserves over a period of 10 years However  the company s lack of exposure to international resources is a drag  On top of that  increasing debt load is a cause of concern  Moreover  cash balances have been declining substantially over the first nine months  reflecting balance sheet weakness Becton  Dickinson s shares have outperformed the Zacks Dental Supplies industry over the last one year  gaining  30 5  vs   19 1   Becton  Dickinson and Company  popularly known as BD  is steadily progressing with its planned acquisition of medical technology player  C  R  Bard  Post completion  BD expects growth in adjusted earnings starting fiscal 2019  The Zacks analyst thinks the acquisition is a strategic one which will generate benefits from complementary businesses and geographical expansion Further  BD announced that it will divest its soft tissue core needle biopsy products for  100 million to Merit Medical  On the flipside  lackluster performance by the Medical segment is a concern Performance in the segment was affected by sluggishness in the Medication Management Solutions and Pharmaceutical Systems units in the United States  BD temporarily paused shipments of its insulin infusion sets  The voluntary recall of Barricor blood collection tubes in the recent past also adds to BD s woes Other noteworthy reports we are featuring today include Sirius XM  SIRI  and ABB  ABB  Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think Join us on Facebook  NASDAQ FB   Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates Media ContactZacks Investment Research800 767 3771 ext  9339Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit for information about the performance numbers displayed in this press release ,2017-12-13,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-morris-eog-resources-becton-dickinson-sirius-xm-and-abb-200273375,200273375
122896,344411,BDX,Becton  Dickinson  BDX  A Step Closer To Bard Acquisition,opinion,Shares of Becton  Dickinson and Company   NYSE BDX   fell 0 3  to  217 02 on Dec 26 following the Federal Trade Commission s  FTC  nod for the much talked about C  R  Bard   NYSE BCR   acquisition  C R  Bard was however up 0 6  and closed at  333 41 Becton  Dickinson and Company now awaits approval by the Ministry of Commerce of the People s Republic of China  MOFCOM  to complete the proposed acquisition  It also needs to fulfill certain customary closing conditionsDeal DetailsIn April 2017  Becton  Dickinson signed an agreement to acquire C R  Bard  Per management  Becton  Dickinson is on track to become one of the biggest medical technology devices company in the world with this buyout  The cash plus stock acquisition is valued at  24 billion  After the completion of the deal around  Becton  Dickinson and Company will create a third business segment   BD Interventional  Notably  C R  Bard will be integrated into this vertical  Further  Becton  Dickinson and Company announced that it will divest its soft tissue core needle biopsy products along with C  R  Bard s Aspira product line of tunneled home drainage catheters and accessories for  100 million to Merit Medical Systems  Inc    NASDAQ MMSI   in order to facilitate approval for the acquisition C  R  Bard had announced back in August that the majority of its shareholders approved its merger with Becton  Dickinson  Holders of approximately 99  of C R  Bard s shares that participated in the vote favored the merger Benefits for Becton  Dickinson and CompanyComing to the strategic advantages post the deal closure  Becton  Dickinson and Company will generate high single digit growth in adjusted earnings per share by fiscal 2019  The transaction will also lead to  300 million in pre tax annual savings in fiscal 2020 Becton  Dickinson and Company will be able to expand to new areas where C R  Bard currently operates   fast growing vascular access segments   PICCs  peripherally inserted central catheters   midlines and drug delivery ports  Moreover  the acquisition is expected to strengthen the combined entity s footprint in the home healthcare market in the United States  A research report by  Markets and Markets  reveals that the home healthcare market is expected to reach a total of  349 8 billion by 2020 at a CAGR of 9  ConclusionWe view the acquisition as a strategic fit as it will generate benefits from complementary businesses and geographical expansion  However  the combined entity is likely to face some challenges with regard to the integration of the new businesses and the costs associated with them  Apart from this  increased competition  delay in order renewal process and constricted federal spending are other concerns Share Price MovementBecton  Dickinson and Company has outperformed the broader  year to date  The stock has gained 31 1  compared with the broader industry s increase of 21 5  Zacks Rank   Key PicksBecton  Dickinson and Company carries a Zacks Rank  3  Hold  A better ranked medical stock is Bruker Corporation   NASDAQ BRKR    carrying a Zacks Rank  2  Buy   You can see Bruker has a long term expected earnings growth rate of 9 9   The stock has rallied roughly 60 8  in a year Wall Street s Next Amazon  NASDAQ AMZN Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time  It s a once in a generation opportunity to invest in pure genius ,2017-12-26,Zacks Investment Research,https://www.investing.com/analysis/becton-dickinson-bdx-a-step-closer-to-bard-acquisition-200276066,200276066
122935,344450,BDX,Boston Scientific  BSX  Tops Q2 Earnings   Sales  View Up,opinion,"Boston Scientific Corporation   NYSE BSX   posted adjusted earnings per share  EPS   after considering certain one time adjustments other than amortization expense  of 23 cents in the second quarter of 2017  up 21  from the year ago quarter 
Considering amortized expense adjustments  the quarter s adjusted EPS came in at 32 cents  up 18 5  from the year ago adjusted number  This figure although remained a penny ahead of the Zacks Consensus Estimate  it fell within the company s adjusted EPS guidance range of 30 32 cents 
Without these adjustments  the company reported earnings of 11 cents per share  in comparison to a loss of 15 cents per share in the year ago period Boston Scientific Corporation Price  Consensus and EPS Surprise

   Revenues in Detail
Revenues in the second quarter were up 6  year over year on reported basis and up 7  on operational basis  at constant exchange rate or CER  to  2 26 billion  The figure topped the company s guidance of  2 19  2 22 billion and also exceeded the Zacks Consensus Estimate of  2 21 billion 
Organic revenue growth in the second quarter  excluding the impact of changes in foreign currency exchange rates and sales from the acquisitions of EndoChoice Holdings and Symetis SA  was 6  year over year 
Geographically  in the second quarter  the company achieved operational growth of 9  in the U S   up 7  organically   4  in Europe  up 2    up 7  in the Asia  Middle East and Africa region  up 7   and up 12  in the emerging markets  up 14   
Segment Analysis
Boston Scientific currently has three global reportable segments  Cardiovascular  Rhythm Management and MedSurg 
The company generates maximum revenues from Cardiovascular  Sales from its subsegments   Interventional Cardiology and Peripheral Interventions   were  603 million  up 5  year over year at CER  and  273 million  up 7    respectively  during the second quarter 
The second largest contributor to Boston Scientific s top line was Rhythm Management  which includes Cardiac Rhythm Management  CRM  and Electrophysiology  CRM reflected a 2  year over year increase in sales to  480 million at CER in the reported quarter 
Worldwide  sales from pacemakers  within CRM  increased 4 9  to  151 million while defibrillators were down 1 2  to  329 million 
Electrophysiology sales went up 11 7  year over year at CER to  67 million 
Other segments like Endoscopy  Urology and Pelvic Health and Neuromodulation  under the MedSurg broader group  recorded sales of  400 million  up 12  at CER    280 million  up 10   and  154 million  up 14    respectively 
MarginsGross margin expanded 205 basis points  bps  year over year to 71 9  on 1 1  fall in cost of products sold  Adjusted operating margin also expanded 240 bps to 24 3  in the reported quarter  During the quarter  selling  general and administrative expenses went up 4 6  to  815 million  while research and development expenses increased 9 9  to  244 million  Royalty expenses reduced 15  to  17 million in the quarter 
Balance Sheet
Boston Scientific exited the second quarter with cash and cash equivalents of  195 million  up from  156 million at the end of the sequential last quarter  At the end of the second quarter  the company had a total long term debt of  5 84 billion  a marginal increase from  5 14 billion at the end of the first quarter 
Guidance
Boston Scientific has provided an update to its full year 2017 guidance 
The company raised its 2017 revenue guidance to the range of  8 89  8 99 billion  annualized growth of 6 7  on reported basis and growth of 6 8  on operational basis including contribution of approximately 120 bps from EndoChoice and Symetis  from the earlier band of  8 80  8 90 billion  annualized growth of 5 6  on reported basis and growth of 6 7  on operational basis   The current Zacks Consensus Estimate for revenues is  8 87 billion  below the guided range 
Adjusted EPS guidance range for 2017  has been slightly increased to  1 22  1 27 from the earlier range of 1 22  1 26  The Zacks Consensus Estimate of  1 24 is within this guided range 
The company also provided its third quarter 2017 financial guidance  Adjusted earnings are expected in the band of 29 31 cents per share on revenues of  2 18  2 21 billion  The Zacks Consensus Estimate for EPS stands at 31 cents while for revenues  it is  2 19 billion 
Our Take
Even amid challenging economic conditions  a competitive environment and severe currency headwinds  Boston Scientific posted a better than expected second quarter  with earnings missing the Zacks Consensus Estimate and revenues  ahead of the mark  While foreign exchange headwinds continue to pose challenges  we are concerned with the company s recent recall of one of its prime products  Lotus range of heart devices  Also the unimpressive defibrillator performance within the company s core CRM segment continues to remain a drag for the overall growth 
Nevertheless  Boston Scientific is leaving no stone unturned to strengthen its core businesses and invest in new technologies and global markets  which accounted for higher sales across all its geographies in the second quarter  We are also encouraged with the company gaining a number of approvals for its products  both in the domestic and overseas markets 
Among the recent developments  worth mentioning is the company s recent acquisition of Switzerland based Symetis SA  in a bid to fortify its structural heart business in Europe  This apart  the company received an FDA approval for the RESONATE family of implantable cardioverter defibrillator  ICD  and cardiac resynchronization therapy defibrillator  CRT D  systems  It also received CE Mark for the Vercise Gevia Deep Brain Stimulation  DBS  System and the first MR conditional directional DBS system for treatment of movement disorder symptoms in patients with Parkinson s disease  dystonia and essential tremor 
Zacks Rank   Other Key Picks
Currently  Boston Scientific carries a Zacks Rank  4  Sell  
Some other better ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Becton  Dickinson and Company   NYSE BDX   and Thermo Fisher Scientific Inc    NYSE TMO    Notably  PetMed sports a Zacks Rank  1  Strong Buy   while Becton  Dickinson and Company and Thermo Fisher Scientific carry a Zacks Rank  2  You can see 
PetMed has a long term expected earnings growth rate of 10 00   The stock has soared around 108 5  over the last three months 
Becton  Dickinson and Company has a long term expected earnings growth rate of 11 25   The stock has rallied around 14 4  over the last three months 
Thermo Fisher Scientific has a long term expected earnings growth rate of 12 25   The stock has gained around 8 4  over the last three months 
More Stock News  Tech Opportunity Worth  386 Billion in 2017
From driverless cars to artificial intelligence  we ve seen an unsurpassed growth of high tech products in recent months  Yesterday s science fiction is becoming today s reality  Despite all the innovation  there is a single component no tech company can survive without  Demand for this critical device will reach  387 billion this year alone  and it s likely to grow even faster in the future   
Zacks has released a brand new Special Report to help you take advantage of this exciting investment opportunity  Most importantly  it reveals 4 stocks with massive profit potential ",2017-07-27,Zacks Investment Research,"https://www.investing.com/analysis/boston-scientific-(bsx)-tops-q2-earnings---sales,-view-up-200204055",200204055
122936,344451,BDX,Zimmer  ZBH  Tops Q2 Earnings  Drops View On Dull Sales,opinion,"Zimmer Biomet Holdings  Inc    NYSE ZBH   reported second quarter 2017 adjusted earnings per share  EPS  of  2 08  up 2 9  year over year  Adjusted earnings were also ahead of the Zacks Consensus Estimate by 2 cents  Reportedly  net earnings came in at 90 cents per share  marking a massive increase from the year ago loss of 16 cents a share 
Revenue Details
Zimmer Biomet s second quarter net revenues came in at  1 95 billion  marking a 1 1  rise  up 2 1  at constant exchange rate or CER  year over year  The recently included LDR Holding contributed 240 basis points  bps  to the top line  Excluding the contribution from LDR Holding in the quarter  revenues declined 1 3  year over year  Revenues  however  remained in line with the Zacks Consensus Estimate 
Revenues generated in the Americas during the quarter  touched  1 21 billion  up 2 5  year over year at CER  while the same in EMEA  Europe  the Middle East and Africa  grossed  438 million  up 1 8    In the Asia Pacific  the figure was  307 million  up 6 8   Zimmer Biomet Holdings  Inc  Price  Consensus and EPS Surprise

   Segments
Revenues derived from Knees were down 1 3  year over year at CER to  680 million  Hips recorded sales of  470 million  down 0 2  from the prior year quarter  Revenues from S E T   Surgical  Sports Medicine  Foot and Ankle  Extremities and Trauma  were up 3 6  year over year to  423 million 
Among the other segments  Spine   CMF recorded an improvement of 33 5  to  194 million while Dental was down 5 7  to  110 million in the quarter  Other revenues dropped 7  to  77 million 
MarginsWith 17 6  reduction in cost of products sold to  527 7 million  Zimmer Biomet s gross margin expanded 610 bps to 72 9  in the second quarter  Selling  general and administrative expenses were up 2 2  at  748 million while research and development expenses increased 1 7  to  90 1 million  However  adjusted operating margin expanded 564 bps to 30 1  on 24 3  surge in operating profit to  588 6 million during the quarter 
Cash Position
Zimmer Biomet exited the second quarter with cash and cash equivalents of  450 million  down from  1 04 billion as of the first quarter end  Total long term debt was  10 7 billion compared with  11 5 billion at the end of the first quarter 
Year to date  operating cash flow was  715 9 million compared with  652 4 million in the year ago period  The company also paid  48 4 million in dividends during the second quarter 
2017 Outlook 
Based on a dull topline show  Zimmer Biomet has lowered its full year 2017 guidance  The company currently expects to register revenue growth at CER in the range of 1 8 2 7   earlier prediction was 3 2 4 2    This includes a contribution of approximately 120 bps from the LDR transaction  The current Zacks Consensus Estimate for revenues is pegged at  7 87 billion 
The adjusted EPS expectation has been forecast within the range of  8 20  8 30  lower than the earlier range of  8 50  8 60 for the year  The current Zacks Consensus Estimate for 2017 EPS is pegged at  8 51  much ahead of the current guidance 
Our Take
Zimmer Biomet ended the quarter on a mixed note  While earnings topped the Zacks Consensus Estimate  revenues remained in line with the same  We are disappointed by the company s declining sales performance within several of its core segments  The trimemd 2017 guidance also added to our concerns indicating little chances of recovery ahead  Nevertheless  improved gross and operating margin performance was encouraging 
We look forward to the expected synergy from the LDR Holding acquisition  which should broaden and complement the company s musculoskeletal offering  We are also impressed by the strong strategic and financial goals which the combined entity expects to reach  now that the deal has been closed 
Zacks Rank   Other Key Picks
Currently  Zimmer Biomet carries a Zacks Rank  3  Hold  
Some better ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Becton  Dickinson and Company   NYSE BDX   and Thermo Fisher Scientific Inc    NYSE TMO    Notably  PetMed sports a Zacks Rank  1  Strong Buy   while Becton  Dickinson and Company and Thermo Fisher Scientific carry a Zacks Rank  2  You can see 
PetMed has a long term expected earnings growth rate of 10 00   The stock has soared around 108 5  over the last three months 
Becton  Dickinson and Company has a long term expected earnings growth rate of 11 25   The stock has rallied around 14 4  over the last three months 
Thermo Fisher Scientific has a long term expected earnings growth rate of 12 25   The stock has gained around 8 4  over the last three months 
More Stock News  Tech Opportunity Worth  386 Billion in 2017
From driverless cars to artificial intelligence  we ve seen an unsurpassed growth of high tech products in recent months  Yesterday s science fiction is becoming today s reality  Despite all the innovation  there is a single component no tech company can survive without  Demand for this critical device will reach  387 billion this year alone  and it s likely to grow even faster in the future   
Zacks has released a brand new Special Report to help you take advantage of this exciting investment opportunity  Most importantly  it reveals 4 stocks with massive profit potential ",2017-07-27,Zacks Investment Research,"https://www.investing.com/analysis/zimmer-(zbh)-tops-q2-earnings,-drops-view-on-dull-sales-200204063",200204063
122937,344452,BDX,Align Technology  ALGN  Beats On Q2 Earnings And Revenues,opinion,Align Technology  Inc    NASDAQ ALGN   reported adjusted earnings per share  EPS  of 85 cents in the second quarter of 2017  up a substantial 37 1  year over year  Earnings were also higher than the company s guided range of 71 74 cents  The figure handily beat the Zacks Consensus Estimate of 73 cents RevenuesRevenues grew 32 3  year over year to  356 5 million in the quarter  surpassing the Zacks Consensus Estimate of  343 million Per management  strong top line was driven by robust Invisalign case shipments of 31  year over year to 41 3 thousand doctors shipped during the second quarter  The upside was backed by growth in North America and international regions and a 37 6  year over year increase in teenage cases across the board  thereby reaching a new benchmark of 1 million teen patients who adopted the Invisalign treatment Align Technology  Inc  Price  Consensus and EPS Surprise    Segments in DetailRevenues at the Clear Aligner segment  90 0  of total revenue  increased 31 9  year over year to  321 0 million in the reported quarter  primarily driven by continued strong Invisalign case volume growth across all customer channels and geographies In the second quarter  Invisalign case shipments amounted to 231 890  up 31 0  year over year  aided by growth across all regions  During the quarter  Align Technology added 41 265 Invisalign doctors worldwide  out of which 24 695 were from North America while 16 570 were from international regions Revenues from Scanner and Service  10 0   improved substantially by 36 7  to  35 4 million MarginsGross margin in the second quarter was down 20 basis points  bps  year over year to 75 9  on a 33 4  rise in cost of net revenue During the quarter  Align Technology witnessed a 34 2  year over year increase in selling  general and administrative expenses to  162 9 million and a 31 0  hike in research and development  R D  expenses to  24 4 million  The operating margin  however  contracted 80 bps to 23 4  due to higher operating expenses Financial DetailsAlign Technology exited the second quarter with cash and cash equivalents and short term marketable securities of  601 9 million  which marked a 10 3   rise from the preceding quarter In the reported quarter  Align Technology paid  50 million under an accelerated stock repurchase plan  ASR  in which the company received an initial delivery of roughly 0 3 million shares of common stock  Management has  250 million available for repurchase under the 2016 repurchase plan  which was announced last April GuidanceFor the third quarter of 2017  the company projects EPS of 78 81 cents on revenues of  355  360 million  The company also expects Invisalign case shipments in the band of 231 000 to 234 000  up 27  29  over the same period a year ago Our TakeAlign Technology ended the second quarter on a solid note  with both earnings and revenues beating the Zacks Consensus Estimate We are upbeat about the continued strong Invisalign volumes  which in turn drove the top line Additionally  in May  the company announced the receipt of two U S  patents for Align s SmartTrack aligner material that is exclusively used for Invisalign aligner treatment  Going forward  management anticipates consistent growth in the Asia Pacific region  In a bid to grow in this region  the company also opened new Invisalign Treatment Planning Facility in China  We are also upbeat about the multi million dollar marketing campaign initiated by the company for its Invisalign brand in order to gain through increased awareness We are also optimistic about the company expanding work flow options of its leading iTero scanners  In this context  Align Technology recently launched a software upgrade for its iTero Element intraoral scanners that is capable of comparing patient scans over time with the new TimeLapse technology Additionally  the company has a strong cash balance that enables it to carry out share repurchase programs and in turn provide solid returns to investors On the flip side  unfavorable foreign currency might affect the company s revenues in the to be reported quarter  Also  the company is exposed to seasonal demand fluctuations  higher operating expenses pertaining to increased head count along with higher investments targeted toward growth acceleration in geographical expansion and portfolio expansion Zacks Rank   Other Key PicksCurrently Align Technology sports a Zacks Rank  2  Buy  Other top ranked medical stocks are Mesa Laboratories  Inc    NASDAQ MLAB    INSYS Therapeutics  Inc    NASDAQ INSY   and Becton  Dickinson and Company   NYSE BDX    Notably  INSYS Therapeutics sports a Zacks Rank  1  Strong Buy   while Mesa Laboratories and Becton  Dickinson and Company carry a Zacks Rank  2  Buy   You can see INSYS Therapeutics has a long term expected earnings growth rate of 20   The stock has gained around 1 9  over the last three months Mesa Laboratories has a positive earnings surprise of 2 8  for the last four quarters  The stock has added roughly 2 6  over the last three months Becton  Dickinson and Company has a positive earnings surprise of 5 58  for the last four quarters  The stock has gained around 4 4  over the last month The Hottest Tech Mega Trend of All Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2017-07-27,Zacks Investment Research,https://www.investing.com/analysis/align-technology-(algn)-beats-on-q2-earnings-and-revenues-200204315,200204315
122938,344453,BDX,BD  BDX  Inks New Deal To Strengthen Foothold In STI Space,opinion,Becton  Dickinson and Company   NYSE BDX    commonly known as BD  recently announced an agreement with Italy based Euroclone for the development and global distribution of molecular assays  The molecular assays are exclusively formulated to detect sexually transmitted pathogens In fact  BD has been a leading player in providing solutions for women s health and sexually transmitted infections  STI  Notably  the company s latest development closely follows its recent launch of BD Ultra Fine micro pen needle 6mm x 32G for use with pen injection devices  The needles offer comfortable injection experience  enhancing customer satisfaction  The device is slated for distribution this month Coming back to the news  BD and Euroclone plan to launch these molecular assays outside of the United States from 2018 The molecular assays leverage on the company s flagship platform BD MAX System to detect infectious genital mycoplasmas  including Mycoplasma and Ureaplasma species  which are generally unidentifiable by the conventional methods  However  the assays are currently not available for sale in the United States Per management  the addition of these assays to the existing BD MAX portfolio along with the company s other assays like BD SurePath and the BD Onclarity HPV assay is likely fortify the company s foothold in clinical laboratories for testing STI Impressive Stock PerformanceShare prices of BD inched up 0 5  to close at  194 following the news release  Over the last year  the company has outperformed the broader industry  While the stock was up 6 9   the broader  gained just 5 9   Nonetheless  the current return is relatively lower than the S P 500 s addition of 14 5  over the same time frame Also  this Zacks Rank  3  Hold  company s focus on expanding into overseas markets  in particular  the emerging markets followed by new product launches and its acquisition driven strategy are its significant growth catalysts Our TakeBD has a diversified product portfolio  which reduces the risk of exposure to any one specific product  Additionally  a diverse revenue base and increased adoption of the company s new and existing products are expected to drive its top line growth Meanwhile  the latest development is likely to maintain the company s international footprint  Evidently  BD witnessed a 4 7  increase in revenues to  1 433 billion outside the United States on comparable currency neutral basis in the last quarter According to a report by Allied Market Research  the global sexually transmitted diseases testing market is anticipated to reach  167 4 billion by 2021  at a CAGR of 8 5   Markedly  after considering the huge potential of the market  we believe the latest development to be a strategic fit Stocks to Consider A few better ranked stocks in the broader medical sector include Edwards Lifesciences Corp    NYSE EW    IDEXX Laboratories  Inc    NASDAQ IDXX   and Cogentix Medical  Inc    NASDAQ CGNT   While Edwards Lifesciences sports a Zacks Rank  1  Strong Buy   IDEXX Laboratories and Cogentix Medical hold a Zacks Rank  2  Buy   You can see  Edwards Lifesciences delivered an average earnings beat of 10 8  over the last four quarters  The company has a long term expected earnings growth rate of 15 2  IDEXX Laboratories pulled off an average earnings beat of 9 3  over the trailing four quarters  It has a long term expected earnings growth rate of 19 8  Cogentix Medical came up with a positive earnings surprise of 200  in the last quarter  The stock represented a stellar return of 100 9  over the last year Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-09-21,Zacks Investment Research,https://www.investing.com/analysis/bd-bdx-inks-new-deal-to-strengthen-foothold-in-sti-space-200214672,200214672
122939,344454,BDX,EW Vs  BCR  Which Stock Is Poised For Better Q3 Earnings ,opinion,The Q3 earnings season had kick started last week with results from 87 S P 500 participants  24 7  of the total market cap  having been reported so far  We observed the S P 500 index to have made a pretty good opening with respect to both earnings and revenue growth  Per the latest   till Oct 20  2017  total earnings for these members went up 9 4  on 7 3  higher revenues With 180 S P 500 members lining up for releasing their quarterly results this week  we are decidedly bullish about the equity market scenario  gradually demonstrating an improvement from the sequentially last quarter A Look at MedTech Space Within Medical SectorWhile overall growth has been steadily accelerating from the preceding few quarters  performances  investors are concerned about the  sector  one of the 16 Zacks sectors  that has seen a lot of struggle during the past half year  thanks to the political power change and the ongoing policy restructuring related battle This lack of visibility befuddles the favorable trend this sector was maintaining over the past few quarters  For the third quarter  the expected earnings growth rate is standing at 2 2  on 4 8  revenue growth projection  In comparison  the reported earnings growth rate of second quarter 2017 was quite impressive at 7  on 4 4  revenue growth Needless to say  that the current crisis in the U S  MedTech industry  integral part of the broader Medical sector  shows no signs of abating  MedTech space was earlier hopeful about the change of power within the White House  However  it is currently fussing over the total failure of the Republicans  ObamaCare repeal and replacement  Considering the prevailing uncertainty over the implementation of the health policy  any respite from it in the near term seems unlikely Political turmoil and the health policy related battle apart  majority of the stocks  bottom line within this space is likely to be hurt in the third quarter on escalating costs induced by the consecutive hurricanes and Mexico earthquakes Given this gloomy backdrop  investors interested in the MedTech space will keenly await the earnings reports of key MedTech companies namely  Edwards Lifesciences Corporation   NYSE EW   and C  R  Bard  Inc    NYSE BCR   on Oct 24 Per our quantitative model  when stocks with a solid Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  are combined with a positive   then chances of beating estimates are always high  You can uncover the best stocks to buy or sell before they re reported with our  A Sneak Peek at Both StocksSimilar to the sequentially last quarter  Edwards Lifesciences seems to be gaining from its strong Transcatheter Heart Valve Therapy  THVT  segment  Banking on continued therapy adoption across all geographical regions with notable strength in the United States  the company is expected to maintain this bullish trend in the third quarter of 2017 as well Growth in THVT was driven by excellent clinical performance results from SAPIEN 3 as well as a continued strong therapy implementation across all regions in the last quarter  Also  with the receipt of an expanded FDA approval for SAPIEN 3 valve in early June  the top line at the THVT segment is expected to get a further boost this yet to be reported quarter   Read   The Zacks Consensus Estimate for THVT net sales of  496 million reflects an increase of 20 9  from the year ago quarter  The Zacks Consensus Estimate for transcatheter heart valves  THV  sales in the United States of  322 million shows an increase of 23 8  from the year ago quarter  Overall  third quarter revenues are projected at  833 89 million  Also  the Zacks Consensus Estimate for net sales in the United States of  467 million reflects an increase of 11 9  from the year ago quarter Notably  the company s earnings have outpaced the Zacks Consensus Estimate by an average of 10 8  in the trailing four quarters  While Edwards Lifesciences has an Earnings ESP of  2 32   it carries a Zacks Rank  3  You can see  Further  the stock has seen the Zacks Consensus Estimate for third quarter earnings of 87 cents per share being revised a penny downward over the last seven days  However  it has shown a rally of 26 4  from the year ago reported figure  The Zacks Consensus Estimate for the company s revenues is pegged at  834 million for the yet to be reported quarter  an 11 5  improvement from the year ago reported number of  748 million In this regard  we also anticipate the company s arch rival in transcatheter heart valves space  Boston Scientific Corporation   NYSE BSX    to fare well in the business this third quarter  Boston Scientific is slated to report third quarter 2017 numbers on Oct 26  before the market opens Edwards Lifesciences Corporation Price and EPS Surprise    Looking into C R  Bard s recent performance trend  we believe that the growing adoption of the company s flagship Lutonix drug coated balloon  DCB  will continue to be the key growth catalyst in the soon to be reported quarter  Within the Endovascular business  peripheral PTA line sales are solely driven by an accelerating demand for the Lutonix DCB in the United States  We expect this product to significantly contribute to the company s top line in this quarter   Read   Notably  the company s earnings have outpaced the Zacks Consensus Estimate by an average of 4 03  in the trailing four quarters  While C R  Bard has an Earnings ESP of  0 09   it carries a Zacks Rank of 3 The stock has seen the Zacks Consensus Estimate for third quarter earnings of  2 95 per share being revised a penny downward over the last 30 days  However  it has shown an improvement of 15 6  from the year ago reported figure  The Zacks Consensus Estimate for the company s revenues is pegged at  992 million for the yet to be reported quarter as compared to the year ago reported figure of  932 million  reflecting a 6 4  gain In this regard  we note that C R  Bard is slated to be acquired by Becton  Dickinson and Company   NYSE BDX   for  24 billion in the fourth quarter of 2017  This acquisition is expected to strengthen the company s footprint in the home healthcare market in the United States C R  Bard  Inc  Price and EPS Surprise    Comparative AnalysisAnalyzing all the revenue drivers and other fundamental factors for both Edwards Lifesciences and C R  Bard along with their respective Zacks Consensus Estimates  we may conclude that Edwards Lifesciences is expected to perform better than C R  Bard in the yet to be reported quarter Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-10-22,Zacks Investment Research,https://www.investing.com/analysis/ew-vs-bcr-which-stock-is-poised-for-better-q3-earnings-200220344,200220344
122972,344487,BDX,GNC Holdings  GNC  Q2 Earnings  Disappointment In The Cards ,opinion,GNC Holdings  Inc    NYSE GNC    a specialty retailer of health and nutrition related products  is scheduled to report second quarter 2017 results on Jul 27  before the opening bell Last quarter  the company posted a positive earnings surprise of 12 1   However  GNC Holdings  trailing four quarter earnings average lagged the Zacks Consensus Estimate by 20 5  Let s see how things are shaping up prior to this announcement Factors at PlayGNC Holdings  last reported first quarter 2017 adjusted earnings per share  EPS  reflected a massive 46 4  year over year deterioration  Revenues in the quarter dropped 3 6  year over year  The dismal performance was primarily due to lower sales at the U S    Canada international and manufacturing wholesale segments  Also  in the first quarter of 2017  gross margin and adjusted operating margin deteriorated  Hence  we expect a similar trend in the second quarter of 2017 as well GNC Holdings  Inc  Price and EPS Surprise   Moreover  GNC Holdings has a number of tough competitors in the market that include large international pharmacy chains  major international supermarket firms and large U S  based companies with global operations  Thus  we expect the company to slash product prices in the face of stiff competition  which  in turn  may hurt margins Also  currency headwinds continue to be a growing concern for GNC Holdings  Management also expects the failure to comply with FTC regulations and changing consumer preferences to hamper business However  on the bright side  the performance of One New GNC was quite encouraging during the first quarter of 2017  Banking on it  we expect the company to continue to gain in the yet to be reported quarter  Meanwhile  the launch of the PRO Access program has added members to the company s customer base  which is expected to drive growth Earnings WhispersOur proven model does not conclusively show an earnings beat for GNC Holdings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Zacks ESP   GNC Holdings has an Earnings ESP of 0 00   That is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at 39 cents  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  GNC Holdings has a Zacks Rank  4  Sell   Please note that we caution against stocks with a Zacks Rank  4 or 5  Strong Sell  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are a few companies you may want to consider as our proven model shows that they have the right combination of elements to post an earnings beat this quarter   Becton  Dickinson and Company   NYSE BDX   has an Earnings ESP of  0 41  and a Zacks Rank  2  You can see  Align Technology  Inc    NASDAQ ALGN   has an Earnings ESP of  1 37  and a Zacks Rank  2 Stryker Corporation   NYSE SYK   has an Earnings ESP of  0 66  and a Zacks Rank  2 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-07-18,Zacks Investment Research,https://www.investing.com/analysis/gnc-holdings-(gnc)-q2-earnings:-disappointment-in-the-cards-200202112,200202112
122973,344488,BDX,Align Technology  ALGN  Q2 Earnings  A Beat In The Cards ,opinion,We expect Align Technology  Inc    NASDAQ ALGN   to beat expectations when it reports second quarter 2017 earnings on Jul 27  after market close Last quarter  the company had posted a positive earnings surprise of 26 87   It is worth noting that Align Technology has outperformed the Zacks Consensus Estimate in three of the preceding four quarters  with an average positive earnings surprise of 19 89   Let s take a look at how things are shaping up prior to this announcement Why a Likely Positive Surprise Our proven model shows that Align Technology is likely to beat earnings because it has the perfect combination of two key ingredients Zacks ESP   Align Technology has an  of  1 37  as the Most Accurate estimate is at 74 cents while the Zacks Consensus Estimate is pegged lower at 73 cents  A favorable Zacks ESP serves as a meaningful and leading indicator of a likely positive earnings surprise  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Align Technology currently carries a Zacks Rank  2  Buy   Note that stocks with Zacks Rank  1  Strong Buy   2 or 3  Hold  have a significantly higher chance of beating earnings estimates Conversely  we caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions The combination of Align Technology s Zacks Rank  2 and  1 37  ESP makes us reasonably confident of an earnings beat What s Driving the Better Than Expected Earnings We are upbeat about Align Technology s execution of strategic initiatives like international expansion  thereby ensuring Invisalign treatment for a growing base of patients  In this context  the company strengthened its foothold internationally by acquiring the Invisalign distributors in the highly lucrative Europe  Middle East and Africa  EMEA  region as well as Brazil in Feb 2017  This is likely to drive the company s results in the to be reported quarter In May  the company announced the receipt of two U S  patents for Align s SmartTrack aligner material that is exclusively used for Invisalign aligner treatment  Moreover  in a bid to gain traction in the Invisalign platform  Align collaborated with Digital Smile Design in March  Post collaboration  Align s Invisalign clear aligner treatment can be used by dentists during tooth alignment procedures along with Smile Design protocols Align Technology  Inc  Price and EPS Surprise    Notably  to expand its Invisalign brand offerings  Align Technology introduced a patient friendly solution   Invisalign Teen with mandibular advancement   for teens in March  According to the company  this advancement will help it offer more options for teen treatment which might boost its top line in the yet to be reported quarter  Recently  the company expanded work flow options of its leading iTero scanners  In this context  Align collaborated with exocad GmbH in March  whereby the integrated portfolio will result in high tech workflow solution for efficient scanning  design and manufacturing of in house dental prosthesis  In February  the company had announced the addition of digital workflow for Nobel Biocare implants to its iTero intraoral scanner portfolio Moreover  the company saw increased adoption of iTero scanners for Invisalign case submissions instead of PVS impressions especially in North America  thereby driving Invisalign utilization  Management expects this bullish trend to likely continue in the yet to be reported quarter Notably  for second quarter 2017  the company projects earnings per share of 71 74 cents on revenues of  340  345 million  The company also expects Invisalign case shipments in the band of 221 000 to 224 000  up 25 27  from a year ago On the flip side  unfavorable foreign currency might affect the company s revenues in the to be reported quarter  Also  the company is exposed to seasonal demand fluctuations  higher operating expenses pertaining to increased head count along with higher investments targeted toward growth acceleration in geographical expansion and portfolio expansionOther Stocks to ConsiderHere are some other companies you may consider as our model shows that they also have the right combination of elements to post an earnings beat in the upcoming quarter Becton  Dickinson and Company   NYSE BDX   has an Earnings ESP of  0 41  and a Zacks Rank  2  You can see  Thermo Fisher Scientific Inc   NYSE TMO   has an Earnings ESP of  0 44  and a Zacks Rank  2 Stryker Corporation   NYSE SYK   has an Earnings ESP of  0 66  and a Zacks Rank  2 3 Top Picks to Ride the Hottest Tech TrendZacks just released a Special Report to guide you through a space that has already begun to transform our entire economy   Last year  it was generating  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for those who make the right trades early ,2017-07-19,Zacks Investment Research,https://www.investing.com/analysis/align-technology-(algn)-q2-earnings:-a-beat-in-the-cards-200202338,200202338
122974,344489,BDX,What s In Store For Express Scripts  ESRX  In Q2 Earnings ,opinion,"Pharmacy benefit manager  Express Scripts Holding Company   NASDAQ ESRX    is scheduled to report second quarter 2017 results on Jul 25  after market close  This St  Louis  MO based company is the largest pharmacy benefit manager  PBM  in North America Meanwhile  the company s earnings exceeded the Zacks Consensus Estimate by almost 0 8  in the last reported quarter  The stock has delivered positive earnings surprises in the past four quarters at an average of 0 3  Express Scripts  stock has underperformed the Zacks classified  industry in the last six months  Specifically  the stock lost 12 1  during this period compared to the industry s gain of 3 7   Moreover  the current rate is way lower than the S P 500 s 8 8  over the same time frame  This indicates looming concerns ahead 
Express Scripts Holding Company Price and EPS Surprise
    Let s take a look at how things are shaping up prior to the second quarter earnings announcement Factors at PlaySecond Quarter Outlook  For the second quarter of 2017  Express Scripts expects total adjusted claims in the range of  343 million to  353 million  Adjusted earnings per diluted share for the second quarter are estimated in the band of  1 70 to  1 74  representing growth of 8  to 11  on a year over year basis  Furthermore  the company anticipates compounded annual EBITDA growth in the band of 2  to 4  from 2017 through 2020 for the core PBM business Favorable Macroeconomic Scenario  We expect Express Scripts to continue to benefit from increased generic utilization  shift toward mail orders  strong specialty growth and an aging population in the U S  Branded drugs are becoming increasingly expensive due to double digit brand inflation  Thus  continued rise in the price of specialty drugs and increased regulatory burden has been driving demand for generics  a key catalyst for the company Cutthroat Competition in Niche Space  On the flipside  Express Scripts faces intense competition in the PBM industry  The company faces competition from independent PBMs like MedImpact and Navitus Health Solutions  Moreover  the niche space is dominated by players like CVS  Aetna  NYSE AET  and Cigna  NYSE CI   among others  We expect intensifying competition to mar second quarter revenues Estimate Revision Trend  Express Scripts  estimate revision trend lacks luster at the moment  For the current quarter  one analyst moved south  compared to no upward revision in the last two months  In fact  over the last three months  the current quarter estimates declined almost 1 2  to  1 71 per share Probable Loss of Biggest Customer  Although it is too early to gauge the losses  Express Scripts is on the verge of losing its biggest customer   leading health insurer Anthem Inc   ANTM   Following a series of legal conundrum  Anthem is no longer expected to extend its pharmacy benefits management agreement withExpress Scripts  which is slated for expiration by 2019 end  Per management  Express Scripts might lose almost 50  of its revenues related to the Anthem contract by the second quarter itself Earnings WhispersBuoyed by the above factors  our proven model does not conclusively show that Express Scripts is likely to beat earnings this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat estimates  This is not the case here  as you will see below Zacks ESP The Earnings ESP for Express Scripts is  0 59  as the Most Accurate estimate is pegged at  1 70  while and the Zacks Consensus Estimate stands at  1 71  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Express Scripts currently carries a Zacks Rank  3  Though a favorable Zacks Rank increases the predictive power of ESP  the company s negative ESP makes surprise prediction difficult Meanwhile  we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks that Warrant a LookHere are a few companies you may want to consider as our proven model shows that they have the right combination of elements to post an earnings beat this quarter Becton  Dickinson and Company   NYSE BDX   has an Earnings ESP of  0 41  and a Zacks Rank  2  You can see  Align Technology  Inc    NASDAQ ALGN   has an Earnings ESP of  1 37  and a Zacks Rank  2 Stryker Corporation   NYSE SYK   has an Earnings ESP of  0 66  and a Zacks Rank  2 3 Top Picks to Ride the Hottest Tech Trend Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy   Last year  it was generating  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for those who make the right trades early ",2017-07-19,Zacks Investment Research,https://www.investing.com/analysis/what's-in-store-for-express-scripts-(esrx)-in-q2-earnings-200202442,200202442
122975,344490,BDX,Is A Surprise In Store For CR Bard  BCR  In Q2 Earnings ,opinion,"Murray Hill  NJ based CR Bard Inc    NYSE BCR   is scheduled to report second quarter 2017 earnings  after market close on Jul 25 Last quarter  the company reported adjusted earnings of  2 87  exceeding the Zacks Consensus Estimate by 22 cents  Also  the company s earnings topped the Zacks Consensus Estimate in all the last four quarters with an average beat of 4 34  Delving deeper into the fundamentals of the stock  let s see how things are shaping up prior to this release Factors at PlayWe believe that the growing adoption of the company s flagship Lutonix drug coated balloon  DCB  will continue to be the key growth catalyst in the to be reported quarter  In this regard  Lutonix DCB is used to treat patients suffering from peripheral arterial disease  PAD   Within the Endovascular business  peripheral PTA line sales are solely driven by accelerating demand for the Lutonix DCB in the U S  We expect to see this product to significantly contribute to the company s top line in this quarter Furthermore  the company s investments in emerging markets have strengthened its position internationally  We are also upbeat on the solid contribution from the company s vascular product line  The urology and oncology segments are likely to drive second quarter sales On the flip side  a challenging Med tech environment  especially in the hernia fixation and peripheral stent businesses raises concerns  The company continues to witness significant pricing pressure as well  Also  unfavorable foreign currency will continue to hurt top  and bottom line growth Furthermore  uncertainties associated with the possibilities of a repeal of the Affordable Care Act under President Trump add to the company s concerns Earnings WhispersOur quantitative model doesn t point to an earnings beat either this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here as you will see below Zacks ESP  The Earnings ESP for CR Bard is 0 00   This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at  2 84  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  CR Bard carries a Zacks Rank  3  which increases the predictive power of ESP  However  the company s ESP of 0 00  makes surprise prediction difficult We caution against stocks with a Zacks Ranks  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revisions C R  Bard  Inc  Price and EPS Surprise
    Stocks to Consider
 Here are a few companies you may want to consider as our proven model shows that they have the right combination of elements to post an earnings beat this quarter   Becton  Dickinson and Company   NYSE BDX   has an Earnings ESP of  0 41  and carries a Zacks Rank  2  You can see  Align Technology  Inc    NASDAQ ALGN   has an Earnings ESP of  1 37  and holds a Zacks Rank  2 Stryker Corporation   NYSE SYK   has an Earnings ESP of  0 66  and carries a Zacks Rank  2 3 Top Picks to Ride the Hottest Tech Trend   Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy   Last year  it was generating  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for those who make the right trades early ",2017-07-20,Zacks Investment Research,https://www.investing.com/analysis/is-a-surprise-in-store-for-cr-bard-(bcr)-in-q2-earnings-200202378,200202378
122976,344491,BDX,Is A Surprise In Store For ResMed  RMD  In Q4 Earnings ,opinion,"ResMed Inc    NYSE RMD   is slated to report fourth quarter fiscal 2017 results  after markets close on Aug 1 Last quarter  the company delivered a positive earnings surprise of 1 4   The four quarter average earnings beat is 1 0   Let s see how things are shaping up for this announcement Factors at PlayManagement expects SG A expenses margin in the band of 26  27  in the yet to be reported quarter  while it was 26 8  in third quarter 2017  Also  R D expenses margin is projected at 7  for fourth quarter 2017 as compared to 6 8  of the preceding quarter   Hence  we expect the bottom line drag to continue in the yet to be reported quarter ResMed Inc  Price and EPS Surprise 
   Meanwhile  the company generates a significant portion of its revenues from international markets  Notably  in the last reported quarter  currency impacted ResMed s combined EMEA and Asia Pacific revenues by 3   This is likely to dent results in the fourth quarter as well Moreover  overall macroeconomic uncertainty is a major obstacle when it comes to the company s international operations Also  the market for sleep disordered breathing  SDB  products is highly competitive with respect to product price  features and reliability  Other challenges like competitive bidding and reimbursement pressure continue to hurt the stock On the brighter side  an expanding chronic obstructive pulmonary disease  COPD  market is a huge opportunity for ResMed  In line with this  the company released positive data pertaining to a clinical trial related to its Home Oxygen Therapy   Home Mechanical Ventilation  HOT HMV   The results demonstrated that COPD patients who received non invasive ventilation  NIV  at home with oxygen therapy had a 51  decreased risk of re hospitalization or death  and stayed out of the hospital more than three times longer  compared to those who received oxygen alone  The company s current endeavors to gain traction in the COPD market are expected to boost revenues Further  as a major breakthrough in the treatment of sleep apnea  ResMed introduced AirTouch F20 full face mask with UltraSoft memory foam  which keeps patients on CPAP therapy comfortable throughout the night  AirTouch F20 is available in the U S  and Canada now which is expected to drive the company s top line in the yet to be reported quarter ResMed s efforts to expand its business internationally are encouraging The company s revenue performance across all segments in the reported third quarter of 2017 was impressive  We expect the company to maintain a similar trend in this quarter ResMed s estimate revision trend is also encouraging  For the current year  the company saw one estimate move north with no movement in the opposite direction over the last one month  This has taken the current year estimate from  2 79 to  2 80 over the same period Earnings WhispersOur proven model does not conclusively show an earnings beat for ResMed this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Zacks ESP   ResMed has an Earnings ESP of 0 00   That is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at 75 cents  You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  ResMed has a Zacks Rank  2  which increases the predictive power of ESP  However  the company s 0 00  ESP makes surprise prediction difficult Meanwhile  we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are some companies you may consider as our model shows that they have the right combination of elements to post an earnings beat in the upcoming quarter Becton  Dickinson and Company   NYSE BDX   has an Earnings ESP of  0 41  and a Zacks Rank  2 Thermo Fisher Scientific Inc   NYSE TMO   has an Earnings ESP of  0 44  and a Zacks Rank  2  You can see  Stryker Corporation   NYSE SYK   has an Earnings ESP of  0 66  and a Zacks Rank  2 Will You Make a Fortune on the Shift to Electric Cars  Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ",2017-07-20,Zacks Investment Research,https://www.investing.com/analysis/is-a-surprise-in-store-for-resmed-(rmd)-in-q4-earnings-200202661,200202661
122977,344492,BDX,Quest Diagnostics  DGX  Tops Q2 Earnings  Raises  17 View,opinion,"Quest Diagnostics Inc    NYSE DGX   second quarter 2017 adjusted earnings per share  EPS  of  1 55 beat the Zacks Consensus Estimate by 9 93  and the year ago number by 15 7  Adjusted EPS in the reported quarter excluded charges related to restructuring and integration  retirement of debt as well as amortization expenses  The reported EPS came in at  1 37  in line with the year ago figure Reported revenues in the second quarter inched up 1 9  year over year to  1 94 billion  However  it lagged the Zacks Consensus Estimate of  1 95 billion  According to the company  the year over year improvement came on the back of extended tie ups with hospital health systems and strength in several of the company s advanced diagnostic offerings 
Quest Diagnostics Incorporated Price  Consensus and EPS Surprise
    Volume  measured by the number of requisitions  increased 1 8  year over year in the second quarter  Also  revenue per requisition increased 0 7   Diagnostic information services revenues in the quarter rose 2 5  on a year over year basis to  1 86 billion Cost of services during the reported quarter was  1 17 billion  up 1 3  year over year  Gross margin came in at 39 8   reflecting a rise of 40 basis points  bps  year over year Among the operating expenses  selling  general and administrative expenses increased 1 6  to  437 million in the reported quarter  Adjusted operating margin showed an improvement of 50 bps to 17 3  Quest Diagnostics exited the second quarter with cash and cash equivalents of  314 million  which marked a 14 4  fall from the preceding quarter  Year to date net cash provided by operating activities was  490 million  compared with  464 million in the year ago period In the second quarter  the company repurchased 1 4 million shares for  150 million  As of Jun 30  2017  Quest Diagnostics was left with  1 1 billion of authorization under the previous share repurchase plan OutlookQuest Diagnostics raised its full year 2017 revenue guidance  The company now expects full year revenues in the range of  7 69 billion to  7 74 billion  annualized growth of 2 6 3 4   from the earlier stated range of  7 64 billion to  7 72 billion  annualized growth of 2 3    The current Zacks Consensus Estimate for revenues is pegged at  7 69 billion  on par with the lower end of the company s updated guided range In addition  the company s 2017 adjusted EPS range has been raised to  5 62  5 72 from the earlier forecast of  5 45  5 60  The Zacks Consensus Estimate of  5 56 is below this range Operating cash flow for 2017 is expected at around  1 2 billion  above the previous guidance of  1 1 billion  The current estimates for capital expenditure are pegged at  250  300 million  unchanged  Our TakeQuest Diagnostics  second quarter earnings exceeded the Zacks Consensus Estimate  while revenues lagged the same  On a positive note  the company is currently refocusing on its core diagnostic information services business and working on disciplined capital deployment  Also  the raised guidance for adjusted earnings  revenues and net cash from operating activities buoy optimism about the company s performance We are also highly optimistic about the company s focus on its new two point strategy  According to Quest Diagnostics  its planned divestiture of the Focus Diagnostics products business is part of its strategy to refocus on diagnostic information services   In addition  several new collaborations with hospitals and integrated delivery networks were major growth drivers  In this regard  we are looking forward to the company s deal with Walmart  NYSE WMT   Particularly  the company is positive about its recent agreement with PeaceHealth in the Pacific Northwest  which is expected to bolster growth in 2017  Also  management is upbeat about its latest acquisitions of Med Fusion and ClearPoint to advance in the diagnostics space However  over the past several quarters  the overall soft industry trends  leading to a low volume environment  acted as a dampener for the company Zacks Rank   Key PicksCurrently  Quest Diagnostics carries a Zacks Rank  3  Hold  A few better ranked stocks in the broader medical sector are PetMed Express  Inc    NASDAQ PETS    Becton  Dickinson and Company   NYSE BDX   and Thermo Fisher Scientific Inc    NYSE TMO    Notably  PetMed sports a Zacks Rank  1  Strong Buy   while Becton  Dickinson and Company and Thermo Fisher Scientific carry a Zacks Rank  2  You can see PetMed has a long term expected earnings growth rate of 10 00   The stock has gained around 108 5  over the last three months Becton  Dickinson and Company has a long term expected earnings growth rate of 11 25   The stock has gained around 14 4  over the last three months Thermo Fisher Scientific has a long term expected earnings growth rate of 12 25   The stock has gained around 8 4  over the last three months More Stock News  Tech Opportunity Worth  386 Billion in 2017From driverless cars to artifical intelligence  we ve seen an unsurpassed growth of high tech products in recent months  Yesterday s science fiction is becoming today s reality  Despite all the innovation  there is a single component no tech company can survive without  Demand for this critical device will reach  387 billion this year alone  and it s likely to grow even faster in the future    Zacks has released a brand new Special Report to help you take advantage of this exciting investment opportunity  Most importantly  it reveals 4 stocks with massive profit potential ",2017-07-24,Zacks Investment Research,"https://www.investing.com/analysis/quest-diagnostics-(dgx)-tops-q2-earnings,-raises-'17-view-200203301",200203301
122978,344493,BDX,Thermo Fisher  TMO  Tops Q2 Earnings   Revenues  View Up ,opinion,"Thermo Fisher Scientific Inc    NYSE TMO   reported better than expected performance in second quarter 2017  Adjusted EPS came in at  2 30  beating the Zacks Consensus Estimate by 1 8  and the year ago quarter figure by 13 0  On a reported basis  second quarter EPS of  1 56 marked a 20  year over year rise Revenues in the quarter came in at  4 99 billion  up 10  year over year  Sales also exceeded the Zacks Consensus Estimate of  4 91 billion by 1 6  Quarter in DetailOrganic revenues in the second quarter grew 4  year over year and up 8  on the back of acquisitions  Total revenue grew 1   offset by currency translation Thermo Fisher currently operates under four business segments  Life Sciences Solutions  Analytical Instruments  Specialty Diagnostics and Laboratory Products and Services Revenues at the Life Sciences Solutions segment improved 3  year over year to  1 40 billion while Analytical Instruments Segment sales grew 47  to  1 17 billion  reflecting the acquisition of FEI Company  Revenues at the Laboratory Products and Services segment grew 4  to  1 79 billion  while the Specialty Diagnostics segment recorded a 1  increase to  862 million 
Thermo Fisher Scientific Inc Price  Consensus and EPS Surprise
    Gross margin of 48 3  during the second quarter was up 10 basis points  bps  year over year on a 10 3  rise in gross profits  Adjusted operating margin expanded approximately 80 bps to 23 1  despite a 4 3  rise in selling  general and administrative expenses and 21 5  increase in research and development expenses The company exited the second quarter with cash and cash equivalents of  611 0 million  compared with  713 3 million at the end of the previous quarter  Year to date net cash provided by operating activities was  1 21 billion  compared with  1 25 billion in the year ago period Guidance RaisedBacked by a solid second quarter performance and a less adverse foreign exchange environment forecast  Thermo Fisher raised its full year 2017 financial guidance  The revenue guidance has been raised to a range of  19 71  19 89 billion  growth of 8  to 9  from the previous year  from the earlier band of  19 51  19 71 billion  The current Zacks Consensus Estimate of  19 65 billion is close to the low end of the guided range The company has also raised its adjusted EPS guidance to a range of  9 15 to  9 28  reflecting growth of 11  to 12  from the previous year  earlier prediction was  9 12 to  9 28   The Zacks Consensus Estimate of  9 23 per share is also near the low end of the band Patheon Acquisition DealIn a parallel announcement  the company informed about entering into a definitive agreement to acquire Patheon N V  and thereby paving its way into the contract development and manufacturing organization  CDMO  market   The total transaction value is estimated to be roughly  7 2 billion  which includes the assumption of approximately  2 0 billion of net debt  Apart from strengthening the biopharmaceutical offerings per management  this deal is also expected to be immediately and considerably accretive to Thermo Fisher s adjusted EPS by  0 30 in the first full year after close  Bottom LineThermo Fisher ended the second quarter on a promising note with both adjusted earnings and revenues beating the Zacks Consensus Estimate We are encouraged by the company s series of product launches along with major progress in precision medicine initiatives  Thermo Fisher s acquisition of FEI Company has already started to boost its analytical instruments portfolio  The company also opened Center of Excellence for electron microscopy in Saudi Arabia  Management is upbeat about the company gaining entry into the CDMO market through the agreement to acquire Patheon for  7 2 billion  The raised guidance is all the more encouraging indicating the fact that this overall bullish trend will continue through 2017 Zacks Rank   Other Key PicksCurrently  Thermo Fisher carries a Zacks Rank  2  Buy  Some other top ranked stocks worth considering in the broader medical sector are PetMed Express  Inc   NASDAQ PETS    Becton  Dickinson and Company   NYSE BDX   and Quest Diagnostics Inc    NYSE DGX    Notably  PetMed sports a Zacks Rank  1  Strong Buy   while Becton  Dickinson and Company and Quest Diagnostics carry a Zacks Rank  2  You can see PetMed has a long term expected earnings growth rate of 10 00   The stock has gained around 21 1  over the last month Becton  Dickinson and Company has a long term expected earnings growth rate of 11 25   The stock has gained around 4 8  over the last month Quest Diagnostics has a long term expected earnings growth rate of 8 39   The stock has gained around 16 7  over the last six months The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2017-07-25,Zacks Investment Research,"https://www.investing.com/analysis/thermo-fisher-(tmo)-tops-q2-earnings---revenues,-view-up-200203648",200203648
123009,344524,BDX,Becton  Dickinson  BDX  Q2 Earnings Beat  Increase Y Y ,opinion,"Becton  Dickinson and Company   NYSE BDX    popularly known as BD  reported second quarter fiscal 2017 earnings of  2 30 per share  which beat the Zacks Consensus Estimate of  2 23 and increased 5 5  on a year over year basis Interestingly  BD has posted positive earnings surprises in the past four quarters  at an average of 6 9   Furthermore  the stock currently has a Zacks Rank  2  Buy   signifying probabilities of outperformance in the near term Getting back to the quarter  BD registered revenues of  2 969 billion  beating the Zacks Consensus Estimate of  2 921 billion  Revenues fell 3 2  on a year over year basis  However  on a comparable  currency neutral basis  revenues increased 5 2  in the second quarter Becton  Dickinson and Company Price  Consensus and EPS Surprise
    Segment DetailsBD Medical segment  Revenues at the segment decreased 6 8  year over year to  1 987 billion owing to the divestiture of the Respiratory Solutions business in Oct 2016 However  the segment witnessed strong performance by the Pharmaceutical Systems and Medication Management Solutions units  Results were partially affected by the timing of customer orders and capital placement Of the major highlights at the BD Medical segment  the company is expected to make notable changes in its U S  dispensing business model within the Medication Management Solutions unit BD Life Sciences segment  Revenues at the segment increased 4 9  from the year ago quarter to  982 million  This marked an increase of 5 8  on a currency neutral basis  The upside came from improvement in Diagnostic Systems and Preanalytical Systems units However  BD Life Sciences segment witnessed a decrease in revenues at the Biosciences unit Geographically  on a reported basis  U S  revenues decreased 5 4  to roughly  1 627 billion  while International revenues were flat at  1 342 billion  On a comparable basis  adjusted U S  revenues increased 4   International revenues rose 6 5  on a currency neutral basis in the reported quarter GuidanceThe company maintained its fiscal 2017 revenue and adjusted earnings guidance For fiscal 2017  on a comparable and currency neutral basis  revenues are anticipated to increase approximately 4 5  to 5 0   Notably  this excludes Respiratory Solutions and other divestitures that closed in fiscal 2016 Meanwhile  adjusted earnings  on a currency neutral basis  are expected in the range of  9 70 to  9 80  reflecting year over year growth of 13 0  to 14 0  However  after including the estimated unfavorable impact from foreign currency  the company expects adjusted diluted earnings per share between  9 35 and  9 45  representing growth of approximately 9  to 10  Other Key PicksOther top ranked stocks in the broader medical sector include Neovasc Inc    NASDAQ NVCN    Hologic  Inc    NASDAQ HOLX   and Sunshine Heart Inc   NASDAQ SSH    Notably  all the stocks sport a Zacks Rank  1  Strong Buy   You can see  Hologic has a long term expected earnings growth rate of 11 33   The stock has a solid one year return of roughly 32 8  Sunshine Heart posted a positive earnings surprise of 58 24  in the last reported quarter  The stock recorded a stellar EPS growth rate  last 3 5 years of actual earnings  of almost 22  Neovasc saw a stellar gain of 14  over the last three months  The stock has a projected sales growth of 102 88  for the current year 5 Trades Could Profit   Big League   from Trump Policies If the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ",2017-05-01,Zacks Investment Research,"https://www.investing.com/analysis/becton,-dickinson-(bdx)-q2-earnings-beat,-increase-y-y-200186595",200186595
123010,344525,BDX,Becton  BDX  Announces  4 5B Follow On Share Offerings,opinion,Leading global medical technology company  Becton  Dickinson and Company   NYSE BDX    popularly known as BD  recently announced a follow on offering of  4 5 billion for its shares  Of these  2 25 billion consists of common stock while the remaining  2 25 billion are depositary shares Stock PerformanceYear to date  Becton shares have increased roughly 8 61  comparing unfavorably with the Zacks categorized   sub industry s addition of 11 41   The current level is also lower than the S P 500 s return of 8 87  in the same time frame More About the OfferingComing back to the news  Becton s common stock intended for the offering is valued at par of  1 00 per share  Of the depositary shares  each represents 0 05  interest in its mandatory convertible preferred stock with a par value  1 00 per share The company intends to use the proceeds from the offerings to finance a portion of the cash consideration payable in connection with its planned acquisition of C  R  Bard Inc    NYSE BCR    The acquisition is expected to close in the fall of 2017  We believe the combined company will have a larger presence in medication management and infection prevention space and bolster its foothold in the global medical devices market  which is expected to reach a worth of  543 9 billion by 2020 Based in Franklin Lakes  NJ  Becton  Dickinson is a medical technology company engaged principally in the development  manufacture and sale of medical devices  instrument systems and reagents Going forward  BD s focus on product launches is a significant catalyst in our view  Additionally  its expansion plans  especially in the emerging overseas markets and the acquisition driven strategy hold considerable promise On the flipside  lower demand for healthcare products  intensifying competition  significant exposure to foreign exchange volatility and higher debt levels pose major headwinds Zacks Rank   Stocks to ConsiderBecton has a Zacks Rank  3  Hold  Better ranked medical stocks include  Baxter International Inc    NYSE BAX   and Bio Rad Laboratories  Inc    NYSE BIO    Baxter International sports a Zacks Rank 1  Strong Buy  while Bio Rad Laboratories carries a Zacks Rank  2  Buy   You can see   Baxter International rose around 21 0  in the last one year  in comparison to the S P 500 s 16 1   It has a four quarter average earnings surprise of 17 14  Bio Rad Laboratories gained 57 2  in the past one year  better than the S P 500 mark  It has a four quarter average earnings surprise of 13 10   The Best   Worst of ZacksToday you are invited to download the full  up to the minute list of 220 Zacks Rank  1  Strong Buys  free of charge  From 1988 through 2015 this list has averaged a stellar gain of  25  per year  Plus  you may download 220 Zacks Rank  5  Strong Sells   Even though this list holds many stocks that seem to be solid  it has historically performed 6X worse than the market ,2017-05-11,Zacks Investment Research,https://www.investing.com/analysis/becton-(bdx)-announces-$4.5b-follow-on-share-offerings-200188580,200188580
123011,344526,BDX,What Drove Becton  Dickinson  BDX  To A New 52 Week High ,opinion,Share price of Becton  Dickinson and Company   NYSE BDX    based in Franklin Lakes  NJ  Becton  scaled a new 52 week high of  196 01 on Jun 27 and closed at  194 99  The company has gained 17 36  in the last six months  ahead of the S P 500 s 10 67  gain  The stock has a market cap of  44 27 billion Comparison with Broader IndustryAlmost throughout 2016  the company s share price consistently outperformed the Zacks categorized  sub industry  The stock has rallied 18 84  over this period  outshining the sub industry s gain of 15 52   The company s five year historical growth rate is favorable at 10 10  as compared with 2 80  of the S P 500 index Estimate Revision TrendThis Zacks Rank  3  Hold  company s estimate revision trend for the current year stands favorable  In the last 60 days  five estimates have moved up with one moving at the opposite direction  The magnitude of estimate revision over the same time period increased around 0 1  to  9 43 per share Catalysts   The market is upbeat about the strategic acquisitions and collaborations made by the company  In this regard  we note that Becton  Dickinson announced collaboration for its IMPRESS instrument management system with cloud based solution provider  UniteOR s surgical tray tracking and vendor management solution  The system provides greater visibility of surgical tray management to health care workers in the operating room and sterile processing department  This integration with UniteOR allows Becton  Dickinson to offer a truly integrated approach for complex challenges that hospitals and health systems face with regard to surgical tracking Becton  Dickinson has inked an agreement to acquire C R  Bard Inc    NYSE BCR    This deal will enhance Becton  Dickinson s portfolio and offerings in high growth areas  Per management  the company is on its way to become one of the biggest medical technology devices companies in the world with this buyout Also  the company recently completed the buyout of Israeli based  global infusion pump systems manufacturer  Caesarea Medical Electronics Apart from the acquisitions and mergers  other catalysts include the company s receipt of 510 k  clearance from the FDA for a flow cytometer system with a leucocount reagent assay  which is used in residual white blood cell enumeration Becton  Dickinson also announced the global distribution of a complete line of products for mass spectrometry that provides high speed and high confidence identification of pathogens in clinical laboratories  This is a critical first step in the fight against antimicrobial resistance  The company s mass spectrometry solutions suite includes MBT Biotargets and MBT Sepsityper as well as standard reagents and other products Further  Becton  Dickinson s focus on geographical expansion in overseas markets like India  China  Brazil and Turkey is boosting market s sentiments for the share Key PicksA few better ranked stocks in the broader medical sector are Inogen Inc    NASDAQ INGN   and Luminex Corporation   NASDAQ LMNX    Notably  Inogen and Luminex both sport a Zacks Rank  1  Strong Buy   You can see  Inogen has a long term expected earnings growth rate of 17 50   Notably  the stock represents an impressive one year return of 99 5  Luminex has a long term expected earnings growth rate of 16 25   Additionally  the stock represents an impressive one year return of 20 3  Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ,2017-06-28,Zacks Investment Research,"https://www.investing.com/analysis/what-drove-becton,-dickinson-(bdx)-to-a-new-52-week-high-200198047",200198047
123012,344527,BDX,Becton  Dickinson  BDX  Poised On C R  Bard Acquisition,opinion,On Jul 7  we issued an updated research report on Franklin Lakes  NJ based Becton  Dickinson and Company   NYSE BDX    The company is a medical technology firm engaged principally in the development  manufacture and sale of medical devices  instrument systems and reagents Over the past one month  Becton  Dickinson has traded above the Zacks categorized  sub industry  The stock has gained 3 55  in this period  higher than the broader industry s 3 16  improvement  The company s five year historical growth rate is also favorable at 10 10   as compared with 2 80  of the S P 500 index This Zacks Rank  3  Hold  company s estimate revision trend for the current year looks favorable  In the last 60 days  five estimates have moved up  while one moved in the opposite direction  The estimate revision over the same time period increased around 0 1  to  9 43 per share The market is upbeat about the company s strategic acquisitions and collaborations  Becton  Dickinson recently signed an agreement to acquire C R  Bard Inc    NYSE BCR    Per management  Becton  Dickinson is on its way to become one of the biggest medical technology devices company in the world with this buyout  The cash plus stock acquisition is valued at  24 billion  After the completion of the deal in the fourth quarter of fiscal 2017  the company plans to create a third business segment  BD Interventional  Notably  C R  Bard will be integrated into this vertical Coming to the strategic advantages post the closure of the deal  Becton  Dickinson will generate high single digit growth in adjusted earnings per share by fiscal 2019  The transaction will lead to a pre tax annual savings worth  300 million in fiscal 2020  BD will be able to expand to new areas where C R  Bard currently operates  These include fast growing vascular access segments like PICCs  peripherally inserted central catheters   midlines and drug delivery ports In this regard  we note that Becton  Dickinson announced collaboration for its IMPRESS instrument management system with cloud based solution provider  UniteOR s surgical tray tracking and vendor management solution  The system provides greater visibility of surgical tray management to health care workers in the operating room and sterile processing department  This integration with UniteOR allows Becton  Dickinson to offer a truly integrated approach for complex challenges that hospitals and health systems face with regard to surgical tracking Also  the company completed the buyout of Israeli based  Caesarea Medical Electronics  a global infusion pump systems manufacturer Apart from the acquisitions and mergers  other catalysts include the company s receipt of 510 k  clearance from the FDA for a flow cytometer system with a leucocount reagent assay  which is used in residual white blood cell enumeration Becton  Dickinson also announced the global distribution of a complete line of products for mass spectrometry that provides high speed and high confidence identification of pathogens in clinical laboratories  This is a critical first step in the fight against antimicrobial resistance  The company s mass spectrometry solutions suite includes MBT Biotargets and MBT Sepsityper as well as standard reagents and other products Further  Becton  Dickinson s focus on geographical expansion in overseas markets like India  China  Brazil and Turkey is boosting market sentiments for the share Key PicksA few better ranked stocks in the broader medical sector are Mesa Laboratories  Inc    NASDAQ MLAB   and Edap Tms S a    NASDAQ EDAP    Notably  both the stocks sport a Zacks Rank  1  Strong Buy   You can see  Mesa Laboratories has a positive earnings surprise of 2 84  for the last four quarters  Notably  the stock represents an impressive one year return of 15 3  Edap Tms has a positive return of 26  for the last three months  The company posted a solid earnings surprise of 533 3  in the last reported quarter Will You Make a Fortune on the Shift to Electric Cars Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2017-07-09,Zacks Investment Research,"https://www.investing.com/analysis/becton,-dickinson-(bdx)-poised-on-c.r.-bard-acquisition-200200050",200200050
123013,344528,BDX,Can Quest Diagnostics  DGX  Pull A Surprise In Q2 Earnings ,opinion,Quest Diagnostics Inc    NYSE DGX   is scheduled to report second quarter 2017 earnings results before the opening bell on Jul 25 Last quarter  the company beat the Zacks Consensus Estimate by 16 cents  delivering a positive earnings surprise of 13 68   It is worth noting that Quest Diagnostics outperformed the Zacks Consensus Estimate in each of the preceding four quarters at an average of 5 15   Let s take a look at how things are shaping up prior to this announcement Factors at PlayPosing a threat to Quest Diagnostics  revenue per requisition performance  the last reported first quarter 2017 saw a 20 basis points  bps  decrease in the same  Moreover  we remain apprehensive  as the company s two Professional Lab Services  PLS  engagement  WJ Barnabas Health and HealthONE System of HCA Holdings  Inc   HCA  carry lower revenue per requisition due to the nature of work This apart  unit price headwinds had  less than 100 bps in the first quarter  While unit price headwinds stayed in moderate ranges  at approximately 1   over the last few years  the company continues to expect the same for 2017 too Quest Diagnostics Incorporated Price and EPS Surprise    Also  over the last two years  Quest Diagnostics faced several reimbursement issues that affected its revenues  The company is concerned about the CMS  Centers for Medicare   Medicaid Services  proposal related to Protecting Access to Medicare Act  PAMA   However  while reimbursement pressure has likely acted as an overhang on performance in the to be reported quarter  the company expects to beat the pressure through test and business mix On a positive note  as observed in the reported first quarter of fiscal 2017  Quest Diagnostics seems to be determined to stimulate performance by adhering to its two point growth strategy   Accelerate growth and Drive operational Excellence We are also optimistic about the successful execution of the company s strategy to grow its esoteric testing business and drive profitable growth Also  in the recent past  Quest Diagnostics witnessed significant growth through infectious disease testing  prescription drug monitoring and industry leading wellness business  We expect these growth drivers to remain active through the second quarter as well  driving the same metrics as in the preceding quarter We believe all these recent developments will significantly contribute to the company s top line in the second quarter The company currently expects full year 2017 revenues within the range of  7 64 billion to  7 72 billion  annualized growth of 2 3    The current Zacks Consensus Estimate for revenues is pegged at  7 69 billion  close to the low end of the company s guided range  In addition  the company s 2017 adjusted earnings per share have been forecasted between  5 45 and  5 60  The Zacks Consensus Estimate of  5 56 is within this range Earnings WhispersOur proven model does not conclusively show that Quest Diagnostics is likely to beat earnings this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here as you will see below Zacks ESP  Quest Diagnostics has an Earnings ESP of 0 00   That is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at  1 41 You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Quest Diagnostics has a Zacks Rank  3  which increases the predictive power of ESP  However  an ESP of 0 00  makes surprise prediction difficult Meanwhile  we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are a few companies you may want to consider as our proven model shows that they have the right combination of elements to post an earnings beat this quarter   Becton  Dickinson and Company   NYSE BDX   has an Earnings ESP of  0 41  and a Zacks Rank  2  You can see  Align Technology  Inc    NASDAQ ALGN   has an Earnings ESP of  4 11  and a Zacks Rank  2 Stryker Corporation   NYSE SYK   has an Earnings ESP of  0 66  and a Zacks Rank  2 5 Trades Could Profit  Big League  from Trump PoliciesIf the stocks above spark your interest  wait until you look into companies primed to make substantial gains from Washington s changing course Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals  tariffs  lower taxes  higher interest rates  and spending surges in defense and infrastructure ,2017-07-17,Zacks Investment Research,https://www.investing.com/analysis/can-quest-diagnostics-(dgx)-pull-a-surprise-in-q2-earnings-200201850,200201850
123014,344529,BDX,Edwards Lifesciences  EW  Q2 Earnings  A Surprise In Store ,opinion,"Edwards Lifesciences Corporation   NYSE EW   is scheduled to report second quarter 2017 earnings on Jul 26  after market close Last quarter  the company had posted a positive earnings surprise of 14 63   It is worth noting that Edwards Lifesciences has outperformed the Zacks Consensus Estimate in three of the preceding four quarters  with an average positive earnings surprise of 7 21   Let s take a look at how things are shaping up prior to this announcement Factors at PlayEdwards Lifesciences posted strong global sales in the last reported quarter  primarily buoyed by strength in Transcatheter Heart Valve TAVR   Banking on continued therapy adoption across all geographies with notable strength in the U S   the company is expected to maintain this bullish trend in the second quarter of 2017 as well In the TAVR space  Edwards Lifesciences reported highly encouraging European post approval clinical trial results for its SAPIEN 3 transcatheter heart valve in May 2017  The company also demonstrated successful results pertaining to its CENTERA valve for transcatheter aortic valve replacement procedures in the much awaited EuroPCR 2017 held in May 
Edwards Lifesciences Corporation Price and EPS Surprise
    We are also upbeat about the company s initiative of strategic investment in research and development and receipt of regulatory approvals for those products  Moving on  the latest breakthrough achieved in its TAVR segment is the FDA approval for its SAPIEN 3 valve in early Jun 2017 Bullish on the company s ongoing performance  management raised growth expectations to the high end of the projected full year 2017 guidance for each segment Moreover  we note that the company projected total sales between  810 million and  850 million and adjusted earnings per share of 82 cents to 92 cents for the second quarter Apart from this  management completed the acquisition of Israel based Valtech Cardio  a developer of Cardioband System for transcatheter repair of the mitral and tricuspid valves  toward the end of 2016  All these are expected to boost the top line in the quarter to be reported On the flip side  tough competition in the cardiac devices market and reimbursement issues continues to challenge the company  We also believe that unfavorable foreign currency will affect the company s gross margin in to be reported quarter Earnings WhispersOur proven model does not conclusively show an earnings beat for Edwards Lifesciences this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here as you will see below Zacks ESP  Edwards Lifesciences has an Earnings ESP of 0 00   That is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at  1 41 You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Edwards Lifesciences has a Zacks Rank  2  which increases the predictive power of ESP  However  an ESP of 0 00  makes surprise prediction difficult Meanwhile  we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are a few companies you may want to consider as our proven model shows that they have the right combination of elements to post an earnings beat this quarter   Becton  Dickinson and Company   NYSE BDX   has an Earnings ESP of  0 41  and a Zacks Rank  2  You can see  Align Technology  Inc    NASDAQ ALGN   has an Earnings ESP of  1 37  and a Zacks Rank  2 Stryker Corporation   NYSE SYK   has an Earnings ESP of  0 66  and a Zacks Rank  2 Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-07-18,Zacks Investment Research,https://www.investing.com/analysis/edwards-lifesciences-(ew)-q2-earnings:-a-surprise-in-store-200202056,200202056
123044,344559,BDX,Dental Stocks  Earnings Roster For Nov 3  BDX  VWR  ACET,opinion,"The current week is set to see a plethora of earnings releases as many bigwigs are lined up to report their quarterly numbers  Notably  the third quarter earnings season is projected to be the first quarter to see positive earnings growth after five consecutive quarters of decline  courtesy of improving growth trends  a string of positive surprises and stability in current quarter estimates A glimpse at the earnings scorecard reveals that 332 S P 500 members have already reported their quarterly figures  which accounted for 74 1  of the index s total market capitalization as of Nov 1  As per the latest   reported earnings increased 1 9  year over year on a 1 3  surge in revenues  with the beat ratio being 72 9  for earnings and 55 4  for revenues Coming to the Medical universe  medical is one of the major broader sectors among the 16 Zacks sectors in the S P 500 cohort that is expected to report earnings growth in the third quarter  The sector is likely to report earnings growth of 6  on revenue improvement of 7 3   Dental is an important component of this sector and is expected follow the same earnings growth trajectory in the quarter  Here  we take a sneak peek into three Dental stocks set to report their quarterly figures on Nov 3 Based in Franklin Lakes  NJ  Becton  Dickinson and Company   NYSE BDX    commonly known as BD  is a medical technology company engaged principally in the development  manufacture and sale of medical devices  instrument systems and reagents BD is set to report fourth quarter fiscal 2016 earnings  Last quarter  the company reported earnings of  2 35 per share  which beat the Zacks Consensus Estimate of  2 19  Notably  BD s results compared favorably with the Zacks Consensus Estimate in the last four quarters  resulting in an average beat of 6 25  BECTON DICKINSO Price and EPS Surprise
    An unfavorable foreign exchange rate is anticipated to remain a headwind for the coming quarters for BD  Additionally  tough year over year comparisons in the fiscal fourth quarter also pose as concerns  However  on the brighter note  BD s innovative product line  number of regulatory approvals both in the U S  and international markets and strategic partnerships are likely to boost BD s trajectory  read more    As per our model  a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to beat earnings Thus  the company is not likely to beat earnings  given the combination of an earnings ESP of 0 00  and a Zacks Rank  3  You can see  Headquartered in Radnor  PA  VWR Corporation   NASDAQ VWR    also known as VWR  is an independent worldwide provider of products  services and solutions to laboratory and production facilities VWR is scheduled to release its third quarter 2016 financial results before the market opens  In the last quarter  the company reported adjusted earnings per share of 42 cents  reflecting a 23 5  rise from the year ago quarter  in line with the Zacks Consensus Estimate VWR CORP Price and EPS Surprise
    Based on a series of initiatives adopted of late  VWR has showed balanced growth in the Americas and EMEA APAC organically  Additionally  VWR has successfully maintained a diverse and stable customer base  which is a key positive in our view  However  headwinds like margin pressure  strengthening of domestic currency and competitive landscape are major downsides Nevertheless  our proven model does not conclusively show that the company is likely to beat earnings  given the combination of a Zacks Rank  3 and earnings ESP of 0 00   Please check our  that enables you to find stocks that are expected to come out with earnings surprises Headquartered in Port Washington  New York  ACETO Corporation   NASDAQ ACET   is an international company engaged in the development  marketing  sales and distribution of Human Health products  Pharmaceutical Ingredients and Performance Chemicals ACETO CORP Price and EPS Surprise
    ACETO is scheduled to report first quarter fiscal 2017 financial results after the closing bell  Last quarter  the company posted adjusted earnings of 35 cents per share  missing the estimate mark by 2 cents  We are upbeat about the new launches of Fluocinolone Acetonide Body Oil and Fluocinolone Acetonide Scalp Oil by ACETO s subsidiary Rising Pharmaceuticals in the quarter However  our proven model does not conclusively show that the company is likely to beat earnings  given the combination of a Zacks Rank  5  Strong Sell  and earnings ESP of 0 00   This is because we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revisions  Looking for Ideas with Even Greater Upside Today s investment ideas are short term  directly based on our proven 1 to 3 month indicator  In addition  I invite you to consider our long term opportunities  These rare trades look to start fast with strong Zacks Ranks  but carry through with double and triple digit profit potential  Starting now  you can look inside our home run  value  and stocks under  10 portfolios  plus more ",2016-11-01,Zacks Investment Research,"https://www.investing.com/analysis/dental-stocks'-earnings-roster-for-nov-3:-bdx,-vwr,-acet-200162244",200162244
123045,344560,BDX,Becton  Dickinson  BDX  Beats Q4 Earnings   Revenues,opinion,"Based in New Jersey  Becton  Dickinson and Company   NYSE BDX   is a medical technology company engaged principally in the development  manufacture and sale of medical devices  instrument systems and reagents  These products are used by healthcare institutions  life science researchers  clinical laboratories  the pharmaceutical industry and the general public Currently  Becton  Dickinson has a Zacks Rank  3  Hold  but that could change following its fourth quarter fiscal 2016 earnings report which has just released  We have highlighted some of the key details from the just released announcement below  BECTON DICKINSO Price and EPS Surprise
    Earnings  Becton  Dickinson s adjusted earnings of  2 12 per share beat the Zacks Consensus Estimate by 3 cents and increased from  1 94 posted in the year ago quarter on a currency neutral basis  Revenues  Adjusted revenues amounted to  3 23 billion  up 5 6  from the year ago quarter on a comparable currency neutral basis  Revenues beat the Zacks Consensus Estimate of  3 22 billion Key Stats  BD Medical generated revenues of  2 24 billion  up 7 3  on a year over year basis  BD Lifesciences generated revenues of  996 million  up 2 1  from the year ago quarter  On a comparable basis  adjusted U S  revenues increased 7 2   International revenues increased 5 2  on a currency neutral basis in the reported quarter Major Factors  BD Medical s year over year growth reflects strong performance in the Medication Management Solutions  Pharmaceutical Systems and Diabetes Care units Revenue growth in the BD Lifesciences segment reflects strong performance in the Preanalytical Systems and Biosciences units Check back later for our full write up on this Becton  Dickinson and Company earnings report later Confidential from ZacksBeyond this Tale of the Tape  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-11-03,Zacks Investment Research,"https://www.investing.com/analysis/becton,-dickinson-(bdx)-beats-q4-earnings---revenues-200162481",200162481
123047,344562,BDX,6 Dividend Growth Stocks To Trump Rising Yield,opinion,"Dividend stocks lost some of their shine due to rising yields after Republican Donald Trump was elected as the new president  Yet  investors are still adding some of these to their portfolio  In particular  stocks with a strong history of dividend hike year over year are enjoying a solid run Why Growth Focused DividendsStocks that have a strong history of dividend growth as opposed to those that pays high yields form a healthy portfolio with more scope for capital appreciation irrespective of the stock market direction  This is because these stocks generally act as a hedge against economic uncertainty while simultaneously offer downside protection with their consistent increase in payouts Additionally  these stocks have superior fundamentals that make dividend growth a quality and promising investment for the long term  These include a sustainable business model  a long track of profitability  rising cash flows  good liquidity  strong balance sheet and some value characteristics  Further  a history of strong dividend growth indicates that a future hike is likely  which makes the portfolio safer Although these stocks do not necessarily have the highest yields  they have outperformed for a longer period than the broad stock market or any other dividend paying stock Here are the screening parameters that could result in a winning dividend growth portfolio 5 Year Historical Dividend Growth greater than zero  This selects stocks with a solid dividend growth history 5 Year Historical Sales Growth greater than zero  This represents stocks with a strong record of growing revenue 5 Year Historical EPS Growth greater than zero  This represents stocks with a solid earnings growth history Next 3 5 Year EPS Growth Rate greater than zero  This represents the rate at which a company s earnings are expected to grow  Improving earnings should help companies to sustain dividend payments Price Cash Flow less than M Industry  A ratio less than M industry indicates that the stock is undervalued in that industry and that an investor needs to pay less for a better cash flow generated by the company 52 Week Price Change greater than S P 500  Median   This ensures that the stock appreciated more than the S P 500 over the past one year Zacks Rank Less than 3  Stocks having a Zacks Rank  1  Strong Buy  and 2  Buy  generally outperform than their peers in all types of market environment VGM Style Score of B or better  This is simply a weighted combination of Value  Growth and Momentum  This when combined with a Zacks Rank  1 or  2 offers the best upside potential Market Capitalization greater than  2 billion  We have eliminated small caps stocks to ensure better flexibility and tradability Here are six of the 12 stocks that fit the bill EnerSys   NYSE ENS    This Pennsylvania based company is a global leader in stored energy solutions for industrial applications  It saw solid earnings estimate revision of 19 cents over the past three months  with an expected earnings growth of 16 54   It has a Zacks Rank  1 and a VGM Style Score of A  You can see  Dick s Sporting Goods Inc    NYSE DKS    This Pennsylvania based company is a leading full line sporting goods retailer in the United States  The stock saw positive earnings estimate revision of 21 cents over the past 90 days for this fiscal year and delivered earnings surprises in two of the past four quarters  with an average beat of 4 68   The stock has a Zacks Rank  2 and a VGM Style Score of A Becton  Dickinson and Company   NYSE BDX    This New Jersey based company is engaged in the development  manufacturing  and selling of medical devices  instrument systems  and reagents worldwide  The stock saw solid earnings estimate revision of nickel over the past 90 days for this fiscal year with an expected earnings growth rate of 10 78   It has a Zacks Rank  2 and a VGM Style Score of B Everest Re Group Ltd    NYSE RE    This Bermuda based company is a world leader in property and casualty reinsurance and insurance  offering innovative products  responsive service and unsurpassed financial strength  The stock saw whopping earnings estimate revision of  1 15 over the past 90 days for this year and delivered earnings surprises in three of the past four quarters  with an average beat of 25 64   It has a Zacks Rank  2 and a VGM Style Score of B Southwest Gas Corporation   NYSE SWX    This Nevada based company is engaged in the business of purchasing  transporting and distributing natural gas in portions of Arizona  Nevada and California  It saw positive earnings estimate revision of a couple of cents for this year over the past 30 days  with an expected growth rate of 7 88   Southwest Gas has a Zacks Rank  2 and a VGM Style Score of B Discover Financial Services   NYSE DFS    This Illinois based company is an operator of a direct banking and payment services company in the United States  It delivered an average positive earnings surprise of 0 12  over the past four quarters and saw earnings estimate revision of seven for this year over the past 90 days  The stock has a Zacks Rank  2 and a VGM Style Score of B You can get the rest of the stocks on this list by signing up now for your 2 week free trial to the Research Wizard and start using this screen in your own trading  Further  you can also create your own strategies and test them first before taking the investment plunge The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out 
 
Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material 
Disclosure  Performance information for Zacks  portfolios and strategies are available at   
Zacks Restaurant Recommendations  In addition to dining at these special places  you can feast on their stock shares  A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector ",2016-11-13,Zacks Investment Research,https://www.investing.com/analysis/6-dividend-growth-stocks-to-trump-rising-yield-200164503,200164503
123048,344563,BDX, Becton  BDX  Gets FDA 510 k  For New Flow Cytometer System ,opinion,Leading global medical technology company  Becton  Dickinson and Company   NYSE BDX    popularly known as BD  recently announced that it has received 510 k  clearance from the U S  Food and Drug Administration  FDA   The FDA clearance was for a new flow cytometer system with a leucocount reagent assay used in residual white blood cell enumeration Stock PerformanceIn the last three months  the price performance of BD was encouraging  The stock added 8 60   comparing favorably with the Zacks classified  sub industry s gain of 5 69   Also  the stock s performance compares favorably with the S P 500 s return of 3 87  over the same time frame  Added to this  a long term expected earnings growth rate of 9 94  instills confidence in investors Despite the bullish price trend  estimate revision for the stock has been quite disappointing  The full year has seen 10 estimates move south over the last two months  compared with no movement in the opposite direction  As a result  the stock dropped a nominal 1  to  9 42 over the same time frame  These mixed sentiments justify the stock s Zacks Rank  3  Hold   More About the ApprovalComing back to the news  the new flow cytometer system provides a simple solution for identifying and counting rWBCs in leucoreduced blood products  This is also compatible with the company s Leucocount kit and Trucount tubes  We feel the combination of products will appeal to the niche market of blood banks and clinical laboratories for an easy to use cell analysis solution to help determine and quantify the presence of residual white blood cells  Also  the fully automated system improves overall lab efficiency and simplifies workflow  Finally  the system offers the performance of a full function clinical flow cytometer but in a compact design that easily fits on a benchtop or within a hood Based in Franklin Lakes  NJ  Becton  Dickinson is a medical technology company engaged principally in the development  manufacture and sale of medical devices  instrument systems and reagents Going forward  BD s focus on product launches is a significant catalyst in our view  Additionally  its expansion plans  especially in the emerging overseas markets and the acquisition driven strategy hold considerable promise On the flipside  lower demand for healthcare products  intensifying competition  significant exposure to foreign exchange volatility and higher debt levels pose major headwinds Key PicksSome better ranked stocks in the broader medical sector are Inogen Inc    NASDAQ INGN    IDEXX Laboratories  Inc    NASDAQ IDXX   and Fluidigm Corporation   NASDAQ FLDM    Notably  Inogen and IDEXX Laboratories sport a Zacks Rank  1  Strong Buy  while Fluidigm carries a Zacks Rank  2  Buy   You can see  Inogen has a long term expected earnings growth rate of 17 50   Notably  the stock registered an impressive one year return of 70 6  IDEXX Laboratories has a long term expected earnings growth rate of 15 04   Additionally  the stock returned an impressive 97 5  in the last one year Fluidigm has a long term expected earnings growth rate of 25   The stock delivered a positive earnings surprise of 1 6  last quarter Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public  Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ,2017-04-06,Zacks Investment Research,https://www.investing.com/analysis/becton-(bdx)-gets-fda-510(k)-for-new-flow-cytometer-system-200181777,200181777
123049,344564,BDX,Will Zimmer Biomet  ZBH  Beat Earnings Estimates In Q1 ,opinion,"Orthopedic reconstructive products manufacturer  Zimmer Biomet Holdings  Inc    NYSE ZBH   is expected to beat earnings when it reports its first quarter 2017 financial numbers on Apr 27  before the opening bell  Last quarter  the company s earnings exceeded the Zacks Consensus Estimate by 1 42   Also  it reported an average beat of 2 03  for the trailing four quarters  Let s see how things are shaping up prior to this announcement Why a Likely Positive Surprise Our proven model shows that Zimmer Biomet is likely to beat earnings because it has the perfect combination of two key ingredients Zacks ESP   Zimmer Biomet has an  of  1 42  as the Most Accurate estimate is  2 14 while the Zacks Consensus Estimate is pegged at  2 11  A favorable Zacks ESP serves as a meaningful and leading indicator of a likely positive earnings surprise   You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Zimmer Biomet currently carries a Zacks Rank  3  Hold   Note that stocks with Zacks Rank  1  Strong Buy   2  Buy  or 3 have a significantly higher chance of beating earnings estimates Conversely  we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revisions The combination of Zimmer Biomet s Zacks Rank  3 and a positive ESP make us reasonably confident of an earnings beat What is Driving the Better than Expected Earnings Zimmer Biomet Holdings  Inc  Price and EPS Surprise
    Zimmer Biomet is successfully executing its goal of strategic investments to further broaden and diversify its musculoskeletal portfolio  Lately  the company introduced more than 50 new clinical technology solutions and services Within its spine business  the company introduced differentiated technologies such as the Mobi C cervical disc prosthesis  We are betting on G7 Acetabular System in its hip business  Recently  the company made expanded introduction of the G7 Dual Mobility Construct  the Taperloc Complete Hip Stem and the Arcos Femoral Revision System  These apart  the OsseoTi Porous Metal Technology and Vitamin E infused advanced bearing materials are also expected to contribute significantly to the company s operating performance  All these commercial introductions should start generating top line accretion from the first quarter itself Within S E T   Surgical  Sports Medicine  Foot and Ankle  Extremities and Trauma   we are extremely hopeful about the company s recent addition of Cayenne Medical  which should strengthen Zimmer Biomet s position in the growing market of sport medicine  This will also help the company address the  18 billion S E T  market We should also keep an eye on the company s craniomaxillofacial and thoracic portfolio as it previously stated that  in 2017 it plans to introduce differentiated expansions within this space  Considering clinically relevant innovation and commercial excellence as key drivers of its growth  Zimmer Biomet also has plans to release Zimmer Biomet Signature Solutions this year  It is an integrated offering is the first suite of end to end services to enhance patient outcomes in musculoskeletal procedures while capturing pre operative efficiencies and care episode cost savings Further  we are optimistic about the synergies from the  13 35 billion acquisition of Biomet  The buyout bolsters the company s presence in the  10 billion global spine market by expanding its portfolio of innovative solutions and strengthening its hold in the fast growing cervical disc replacement market Regarding Zimmer Biomet s net EBIT synergies  the company expects to realize cumulative target of  350 million by mid 2018 with approximately  310 million of cumulative net benefit achieved by year end 2017  This reflects  85 million of incremental synergies in the year  This should start getting reflected from the first quarter The market assumption for 2017 also looks quite promising  The musculoskeletal markets are expected to grow approximately 3   similar to 2016 with global market conditions remaining relatively stable However  factors like macroeconomic uncertainties  pricing pressure and unfavorable currency fluctuations adversely impacted Zimmer Biomet s sales during the quarter  With regard to price  the company forecasted a decline of approximately 2   consistent with the range experienced over the last several years Other Stocks to ConsiderHere are some other companies you may consider as our model shows that they have the right combination of elements to post an earnings beat in the upcoming quarter Becton  Dickinson and Company   NYSE BDX   has an Earnings ESP of  0 45  and a Zacks Rank  2  You can see Humana Inc    NYSE HUM   has an Earnings ESP of  2 06  and a Zacks Rank  2 Hill Rom Holdings  Inc    NYSE HRC   has an Earnings ESP of  1 27  and a Zacks Rank  2 Zacks  2017 IPO Watch List Before looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth ",2017-04-19,Zacks Investment Research,https://www.investing.com/analysis/will-zimmer-biomet-(zbh)-beat-earnings-estimates-in-q1-200184015,200184015
123050,344565,BDX,Will Thermo Fisher  TMO  Pull A Surprise In Q1 Earnings ,opinion,"MA based medical instruments manufacturer  Thermo Fisher Scientific  Inc    NYSE TMO   is scheduled to report first quarter 2017 results before the opening bell on Apr 26  Last quarter  the company reported a positive earnings surprise of 1 69   In the trailing four quarters  it posted an average beat of 2 42   Let s see how things are shaping up prior to this announcement Factors at PlayWe remain encouraged by the company s focus to boost growth through the implementation of strategies and strengthening of its product offerings  These initiatives are likely to help it post solid results in the first quarter The company already spent  750 million in research and development in 2016  Some of its recently introduced products worth mentioning include Q Exactive instruments for BioPharma and applied markets  which extended the capabilities of Orbitrap Mass Spec platform  Integrion HPIC system in Chromatography  TSX high performance refrigerators and freezers in installed base of lab equipment  It also introduced new targeted assays for cancer research that run on Ion Torrent Next Generation Sequencing instruments  new tests for autoimmune disease and drugs of abuse  and new Clariom Pico assays for more effective biomarker discovery  We expect all these innovations to significantly contribute to the company s top line in the first quarter The company s focus on expanding capabilities in the fast growing Asia Pacific and emerging markets should also lead to encouraging results  In 2016  standout contributors were China  India and South Korea  With strategic investments to support key customer applications  Thermo Fisher expects to maintain this bullish momentum in 2017 Thermo Fisher Scientific Inc Price and EPS Surprise
    The growth is likely to be in applied markets such as environmental and food safeties as well as life science  This apart  the company is currently betting on some key focus areas with enormous opportunities  These are advancing precision medicine from mass spectrometry to targeted gene sequencing and structural biology  The recent acquisition of FEI is the highlight of the to be reported quarter  Thermo Fisher also expects to realize total synergies of approximately  80 million by the end of the three years following the deal closure  with about  55 million of cost synergies and roughly  25 million of adjusted operating income benefits from revenue related synergies  This should get reflected from the first quarter itself However  we are apprehensive about Thermo Fisher citing foreign exchange to the tune of  300 million on 2017 revenues  an impact of 1 5   and 20 cents on adjusted EPS  around 2 5    Given one less selling day in the first quarter  Thermo Fisher expects slightly lower than average growth This apart  unfavorable macroeconomic condition continues to weigh heavily on Thermo Fisher s stock  Also competitive headwind continues to pose a threat on the stock s value Earnings WhispersOur proven model does not conclusively show that Thermo Fisher is likely to beat earnings this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here as you will see below 
Zacks ESP  Thermo Fisher s Earnings ESP is  0 49   since the Most Accurate estimate of  2 02 is below the Zacks Consensus Estimate of  2 03  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Thermo Fisher has a Zacks Rank  3 which increases the predictive power of ESP  However  a negative ESP makes surprise prediction difficult Note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are some companies you may consider as our model shows that they have the right combination of elements to post an earnings beat in the upcoming quarter Becton  Dickinson and Company   NYSE BDX   has an Earnings ESP of  0 45  and a Zacks Rank  2  You can see Humana Inc    NYSE HUM   has an Earnings ESP of  2 06  and a Zacks Rank  2 Hill Rom Holdings  Inc    NYSE HRC   has an Earnings ESP of  1 27  and a Zacks Rank  2 Zacks  2017 IPO Watch List Before looking into the stocks mentioned above  you may want to get a head start on potential tech IPOs that are popping up on Zacks  radar  Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential  This Special Report gives you the current scoop on 5 that may go public at any time One has driven from 0 to a  68 billion valuation in 8 years  Four others are a little less obvious but already show jaw dropping growth ",2017-04-19,Zacks Investment Research,https://www.investing.com/analysis/will-thermo-fisher-(tmo)-pull-a-surprise-in-q1-earnings-200184002,200184002
123074,344589,BDX,Becton  Dickinson  BDX  Q3 Earnings  What s In The Cards ,opinion,Becton  Dickinson and Company   NYSE BDX   is set to report third quarter fiscal 2016 earnings results on Aug 4  Last quarter  Becton  Dickinson beat the Zacks Consensus Estimate by almost 8 5   17 cents  We note that on average  the company delivered a positive earnings surprise of 5 04  through the last four quarters Let s see how things are shaping up prior to this announcement Factors at PlayBecton  Dickinson s innovative product pipeline is a key catalyst in our view  A plethora of regulatory approvals both in the U S  and International markets is aiding the company to rapidly expand its product portfolio  BECTON DICKINSO Price and EPS Surprise   Management at Becton  Dickinson expects strong demand for its Pyxis ES platform and infusion pumps to be the primary growth drivers in the third quarter Additionally  partnerships and collaborations are also providing the company a competitive edge  Moreover  the CareFusion merger has unlocked considerable growth and cost saving opportunities for Becton  Dickinson However  unfavorable foreign exchange rate is anticipated to remain a headwind for the rest of year  Tough year over year comparisons in the third quarter also remain a concern Earnings WhispersOur proven model does not conclusively show that Becton  Dickinson is likely to beat on earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank of  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here as you will see below Zacks ESP  Becton  Dickinson currently has an Earnings ESP of 0 00   This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at  2 20 Zacks Rank  Becton  Dickinson has a Zacks Rank  3 which increases the predictive power of ESP  However  a 0 00  ESP makes surprise prediction difficult We caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are some companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter   Nektar Therapeutics   NASDAQ NKTR   with an Earnings ESP of  50 00  and Zacks Rank  1 GlycoMimetics Inc    NASDAQ GLYC   with an Earnings ESP of  13 64  and Zacks Rank  1 ANI Pharmaceuticals Inc    NASDAQ ANIP   with an Earnings ESP of  2 63  and a Zacks Rank  1 ,2016-07-28,Zacks Investment Research,"https://www.investing.com/analysis/becton,-dickinson-(bdx)-q3-earnings:-what's-in-the-cards-200145029",200145029
123076,344591,BDX,Becton  Dickinson  BDX  Beats Q3 Earnings   Revenues,opinion,Based in New Jersey  Becton  Dickinson and Company   NYSE BDX   is a medical technology company engaged principally in the development  manufacture and sale of medical devices  instrument systems and reagents  These products are used by healthcare institutions  life science researchers  clinical laboratories  the pharmaceutical industry and the general public  Currently  Becton  Dickinson has a Zacks Rank  3  Hold  but that could change following its third quarter fiscal 2016 earnings report which has just released  We have highlighted some of the key details from the just released announcement below  Earnings  Becton  Dickinson s adjusted earnings of  2 35 per share beat the Zacks Consensus Estimate by 16 cents and increased 19 5  year over year on a currency neutral basis  Revenues  Adjusted revenues amounted to  3 20 billion  up 3 9  from the year ago quarter on a comparable currency neutral basis  Revenues beat the Zacks Consensus Estimate of  3 19 billion Key Stats  BD Medical generated revenues of  2 24 billion  up 3  on a year over year basis  BD Lifesciences generated revenues of  963 million  up 6  from the year ago quarter  On a comparable basis  adjusted U S  revenues increased 3 4   International revenues increased 4 6  on a currency neutral basis in the reported quarter  BECTON DICKINSO Price and EPS Surprise   Major Factors  BD Medical s year over year growth reflects strong performance in the Medication Management Solutions and Diabetes Care units  and solid growth in the Medication and Procedural Solutions unit  Revenue growth in the BD Lifesciences segment reflects strong performance in the Diagnostic Systems and Preanalytical Systems units  and modest growth in the Biosciences unit  Stock Price  Following the earnings release  share prices did not show any movement in the pre market trading session  Check back later for our full write up on this Becton  Dickinson and Company earnings report later ,2016-08-04,Zacks Investment Research,"https://www.investing.com/analysis/becton,-dickinson-(bdx)-beats-q3-earnings---revenues-200146027",200146027
123077,344592,BDX,Becton  Dickinson  BDX  Gets USFDA Clearance For BD MAX,opinion,Leading global medical technology company  Becton  Dickinson and Company   NYSE BDX   recently announced that it got the clearance for its proprietary BD MAX CT GC TV assay from the U S  Food and Drug Administration  FDA   The BD MAX CT GC TV assay provides health care providers the ability to detect for Chlamydia trachomatis  CT   Neisseria gonorrhoeae  GC  and Trichomonas Vaginalis  TV  from a single specimen through just one test  Notably  CT  GC and TV are among the most prevalent sexually transmitted infections  STIs   Per the U S  Centers for Disease Control and Prevention  CDC  estimate  about 2 86 million new chlamydial infections and 820 000 gonorrheal infections occur each year BD MAX system is a fully integrated  automated molecular platform  which can run both In Vitro Diagnostics  IVD  and open system assays in a flexible and efficient manner  Specimen collection options are also flexible  It can use urine specimens  self collected vaginal swabs and clinician collected endocervical swabs  Once samples are loaded onto the BD MAX System  results will be ready in less than three hours  Lastly  all the reagents are ready to use and can be stored at room temperature BD s innovative product pipeline is a key growth driver  A vast array of regulatory approvals both in the U S  and international markets are helping the company to rapidly expand its product portfolio  Moreover  the collaboration with Check Points will drive demand for BD MAX assays that detect carbapenem resistant organisms  CRO  in international markets  Both companies also plan to develop and commercialize a next generation CRO assay for launch outside the U S  in 2017 and later in the U S  BECTON DICKINSO Price   Further  the partnership with Central Admixture Pharmacy Services   CAPS   will allow BD Intelliport Medication Management System customers to buy a portfolio of frequently used CAPS  pre filled anesthesia syringes We believe that these partnerships and collaborations will lend BD a competitive edge  which will eventually boost its overall results  Although the Zacks Consensus Estimate for full year 2016 has remained steady at  8 56 over the last seven days  it reflects year over year growth of almost 19 6  Zacks Rank   Key Picks Currently  BD carries a Zacks Rank  3  Hold   Some better ranked stocks in the broader medical sector are Almost Family Inc    NASDAQ AFAM    RadNet  Inc    NASDAQ RDNT   and US Physical Therapy Inc    NYSE USPH    Notably  all the three stocks sport a Zacks Rank  1  Strong Buy   You can see  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-09-14,Zacks Investment Research,"https://www.investing.com/analysis/becton,-dickinson-(bdx)-gets-usfda-clearance-for-bd-max-200153690",200153690
123080,344595,BDX,Becton  BDX  To Expand Syringe Capacity At Holdrege Facility ,opinion,Leading global medical technology company Becton  Dickinson and Company   NYSE BDX   announced that it is expanding capacity at its Holdrege  NE facility  The capacity expansion would cost  100 million and be directed toward insulin syringe manufacturing operations  The company already produces more than two billion insulin syringes annually  This averages to production of more than 250 000 syringes per hour   BD began operations in Holdrege in 1966 in a 12 000 square foot building with 66 associates  Gradually  the facility has grown to 350 000 square feet with more than 650 associates manufacturing 20 different products Based in Franklin Lakes  NJ  Becton  Dickinson  popularly known as BD  is a medical technology company engaged principally in the development  manufacture and sale of medical devices  instrument systems and reagents An innovative product pipeline is the key growth driver at BD  A huge number of regulatory approvals both in the U S  and international markets are facilitating expansion of the company s product portfolio  The company also has a partnership with Central Admixture Pharmacy Services  CAPS  under which BD Intelliport Medication Management System customers will be allowed to buy a portfolio of the frequently used CAPS pre filled anesthesia syringes  BECTON DICKINSO Price   We believe that such partnerships and collaborations will lend BD a competitive edge and eventually boost its overall results  Although the Zacks Consensus Estimate for the full year has remained unchanged at  8 56 over the last seven days  it reflects year over year growth of almost 19 6  Zacks Rank   Key PicksCurrently  BD carries a Zacks Rank  3  Hold   Better ranked stocks in the medical sector include GW Pharmaceuticals plc   NASDAQ GWPH    NuVasive  Inc    NASDAQ NUVA   and Baxter International Inc    NYSE BAX    each sporting a Zacks Rank  1  Strong Buy  GW Pharmaceuticals consistently surpassed expectations in the last four quarters  with an average positive surprise of 41 67   This represents an impressive year to date return of approximately 58 1   better than the S P 500 s 6 5  over the same period NuVasive also has a steady record in beating earnings expectations over the last four quarters  with an average positive surprise of 18 98   This represents an impressive year to date return of approximately 25 78   better than the S P 500 s 6 5  over the same period Finally  Baxter International also surpassed expectations in each of the last four quarters  with an average positive surprise of 30 55   This represents an impressive year to date return of approximately 26 34   better than the S P 500 s 6 5  over the same period  You can see  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-09-22,Zacks Investment Research,https://www.investing.com/analysis/becton-(bdx)-to-expand-syringe-capacity-at-holdrege-facility-200155211,200155211
123081,344596,BDX,Becton Unveils New Instrument For Faster Bacteria Detection,opinion,"Leading global medical technology company Becton  Dickinson and Company   NYSE BDX   introduced a new diagnostic instrument BD Phoenix M50 ID AST  The new instrument helps in rapid identification of bacteria and detection of antimicrobial resistance  The system requires no preventative maintenance  In addition to this  the system offers multiple languages  facilitating broader adoption in laboratories around the world The BD Phoenix M50 system also offers integration with multiple other analyzers  including the BD BACTEC and BD Bruker MALDI Biotyper systems  This is done through BD EpiCenter middleware connectivity that enables data traceability and security   Based in Franklin Lakes  NJ  Becton  Dickinson  popularly known as BD  is a medical technology company engaged principally in the development  manufacture and sale of medical devices  instrument systems and reagents An innovative product pipeline is the key growth driver at BD  A huge number of regulatory approvals both in the U S  and international markets are facilitating expansion of the company s product portfolio  The company also has a partnership with Central Admixture Pharmacy Services  CAPS  under which BD Intelliport Medication Management System customers will be allowed to buy a portfolio of the frequently used CAPS pre filled anesthesia syringes  We believe that such partnerships and collaborations will lend BD a competitive edge and eventually boost its overall results  Although the Zacks Consensus Estimate for the full year has remained unchanged at  8 56 over the last seven days  it reflects year over year growth of almost 19 6   BECTON DICKINSO Price
    Zacks Rank   Key PicksCurrently  BD carries a Zacks Rank  3  Hold   Some better ranked stocks in the broader medical sector are CryoLife Inc    NYSE CRY    IDEXX Laboratories Inc    NASDAQ IDXX   and Masimo Corporation   NASDAQ MASI    All these stocks sport a Zacks Rank  1  Strong Buy   You can see  CryoLife has recorded a year to date return of 63 0   better than the S P 500 s 6 1  over the same time frame  In fact  the company posted positive earnings surprises in the last four quarters  the average being 502 50  IDEXX has a strong year to date return of 54 6   The company also surpassed estimates in the last four quarters at an average rate of 12 7  Masimo has an impressive long term expected earnings growth rate of 15  and a solid year to date return of 43 3  Confidential from Zacks Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-02,Zacks Investment Research,https://www.investing.com/analysis/becton-unveils-new-instrument-for-faster-bacteria-detection-200156811,200156811
123082,344597,BDX,Becton Sells 50 1  Stake In Respiratory Business To Apax,opinion,"Leading global medical technology company  Becton  Dickinson and Co    NYSE BDX   or BD  announced the launch of a JV with Apax Partners  christened Vyaire Medical  The JV would be a standalone  global respiratory solutions company and will have an estimated annual revenue of over  800 million  Becton also sold a 50 1  stake in its Respiratory Solutions business to funds advised by Apax Partners  a private equity firm  The company plans to use net proceeds for share repurchases  BD will retain a 49 9  minority interest in the new company The new JV  Vyaire Medical includes all business lines within BD s Respiratory Solutions business  This consists of Ventilation  Respiratory Diagnostics  Vital Signs and AirLife  BD said its Respiratory Solutions facilities will be transferred to the new company  including locations in California  Minnesota  Mexico  Brazil  Germany and China  The new company will employ more than 5 000 associates around the world Based in Franklin Lakes  NJ  Becton  Dickinson  popularly known as BD  is a medical technology company engaged principally in the development  manufacture and sale of medical devices  instrument systems and reagents  BECTON DICKINSO Price
    An innovative product pipeline is the key growth driver at BD  A huge number of regulatory approvals both in the U S  and international markets are facilitating expansion of the company s product portfolio The company also has a partnership with Central Admixture Pharmacy Services  CAPS   Under this collaboratyion  BD Intelliport Medication Management System customers will be allowed to buy a portfolio of the frequently used CAPS pre filled anesthesia syringes We believe that such partnerships and collaborations will lend BD a competitive edge and eventually boost its overall results  Although the Zacks Consensus Estimate for the full year remained unchanged at  8 56 over the last seven days  it reflects year over year growth of almost 19 6  Key PicksA few notable stocks in the medical product sector are Quidel Corp    NASDAQ QDEL    NuVasive  Inc    NASDAQ NUVA   and GW Pharmaceuticals plc   NASDAQ GWPH   Quidel is expected to record earnings growth of 20   higher than the industry average of 14 8  over the next five years  It has a four quarter average earning surprise of 59 39  NuVasive has a trailing four quarter average earning surprise of 18 98   For the past five years  the stock saw a 16 6  earnings growth compared to the industry average of 5  GW Pharmaceuticals has a four quarter average earning surprise of 41 67    Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-09,Zacks Investment Research,https://www.investing.com/analysis/becton-sells-50.1-stake-in-respiratory-business-to-apax-200158008,200158008
123084,344599,BDX,Becton  Dickinson  BDX  Q4 Earnings  What s In The Cards ,opinion,"Becton  Dickinson and Company   NYSE BDX   is set to report fourth quarter fiscal 2016 earnings results on Nov 3  Last quarter  the company reported earnings of  2 35 per share  which beat the Zacks Consensus Estimate of  2 19 Notably  Becton  Dickinson s results compared favorably with the Zacks Consensus Estimate in the last four quarters  resulting in an average beat of 6 25  Let s see how things are shaping up prior to this announcement Factors at PlayBecton  Dickinson s innovative product pipeline is a key catalyst in our view  A plethora of regulatory approvals both in the U S  and International markets are helping the company to rapidly expand its product portfolio Management at Becton  Dickinson expects strong demand for its Pyxis ES platform and infusion pumps to be the primary growth drivers in the fiscal fourth quarter Additionally  partnerships and collaborations are also providing the company a competitive edge  Moreover  the CareFusion merger has unlocked considerable growth and cost saving opportunities for Becton  Dickinson However  an unfavorable foreign exchange rate is anticipated to remain a headwind for the rest of year  Tough year over year comparisons in the fiscal fourth quarter also pose as concerns  BECTON DICKINSO Price and EPS Surprise   Earnings WhispersOur proven model does not conclusively show that Becton  Dickinson is likely to beat on earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank of  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here as you will see below Zacks ESP  Becton  Dickinson currently has an Earnings ESP of  1 44   This is because the Most Accurate estimate stands at  2 06 and the Zacks Consensus Estimate is pegged at  2 09  Please check our  that enables you find stocks that are expected to come out with earnings surprises Zacks Rank  Becton  Dickinson has a Zacks Rank  3 which increases the predictive power of ESP  However  a negative ESP makes surprise prediction difficult We caution against stocks with a Zacks Rank  4 or 5  Sell rated  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are some companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter   Glaukos Corporation   NYSE GKOS   has an Earnings ESP of  100  and a Zacks Rank  1  You can see 
Penumbra  Inc    NYSE PEN   has an Earnings ESP of  45 46  and a Zacks Rank  3 Invuity  Inc    NASDAQ IVTY   has an Earnings ESP of  1 61  and a Zacks Rank  2 Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-31,Zacks Investment Research,"https://www.investing.com/analysis/becton,-dickinson-(bdx)-q4-earnings:-what's-in-the-cards-200161976",200161976
123107,344622,BDX,DENTSPLY  XRAY   What s In Store This Earnings Season ,opinion,"DENTSPLY SIRONA Inc    NASDAQ XRAY   is expected to report first quarter 2016 results on May 6  Last quarter  the company reported earnings of 65 cents per share  which were in line with the Zacks Consensus Estimate Notably  the company s results compared favorably with the Zacks Consensus Estimate in the last four quarters  with an average beat of 3 46  
Let s see how things are shaping up for this quarter Factors at PlayWe believe DENTSPLY s results will be benefited by its expanding product portfolio  Moreover  the combined entity    Dentsply and Sirona    will benefit from revenue and cost synergies in 2016 Meanwhile  a gradual recovery of the U S  market should boost results at DENTSPLY  Also  the emerging markets provide significant opportunities for the company as these areas are vastly untapped with low dental products penetration However  integration will be a risk in the near term  Moreover  unfavorable foreign exchange rate volatility will continue to hurt DENTSPLY s results in the immediate future  Additionally  higher capital expenditure on product development coupled with persistent decline in sales is expected to put margins under pressure Earnings WhispersOur proven model does not conclusively show that DENTSPLY is likely to beat earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here as you will see below Zacks ESP  The Earnings ESP for DENTSPLY is  1 59   This is because the Most Accurate estimate stands at 64 cents  while the Zacks Consensus Estimate is pegged at 63 cents Zacks Rank  DENTSPLY carries a Zacks Rank  4  Note that we caution against stocks with a Zacks Rank  4 and  5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are a few stocks worth considering that  per our model  have the right combination of elements to post an earnings beat this quarter Quality Systems   NASDAQ QSII    with an Earnings ESP of  6 25  and a Zacks Rank  2 The Cooper Companies   NYSE COO    with an Earnings ESP of   52  and a Zacks Rank  2 Becton  Dickinson and Co    NYSE BDX    with an Earnings ESP of  1 99  and a Zacks Rank  3 ",2016-05-03,Zacks Investment Research,https://www.investing.com/analysis/dentsply-(xray):-what's-in-store-this-earnings-season-200127703,200127703
123108,344623,BDX,2 Dental Stocks Reporting Earnings This Week  BDX  XRAY,opinion,The week has been flooded with earnings releases as most of the bigwigs have either reported or are lined up to release their quarterly numbers this week  By the end of this week  more than 88  of S P 500 members will complete their quarterly reporting The releases so far have not been much of a disappointment  contrary to the anticipations at the onset of the earnings season  thanks to the lower estimates  As per the latest   overall first quarter earnings for S P 500 companies are expected to be down 7 3  from the year ago quarter  slightly better than the earlier estimated decline of 9 7  Notably  earnings growth is expected to be positive for 7 of the 16 Zacks sectors in the quarter ended Mar 2016  Medical is one of the few sectors that are expected to record earnings growth in the first quarter  As per our scorecard  60 4  of the Medical sector companies have already released their results with earnings growth of 6 3  and revenue improvement of 11 8  Dental is an important component of the medical sector and is expected follow the same earnings growth trajectory in the quarter  Notably  most of the large market caps have already reported and so far  the results have been quite encouraging EPS and Sales Surprise from top 5 Large Caps in the sector We now take a sneak peek into two major dental providers lined up to report earnings late this week Becton  Dickinson and Company   NYSE BDX    popularly known as BD  is scheduled to report second quarter fiscal 2016 results on May 5  BD s innovative product pipeline  expansion into overseas markets and synergies from the CareFusion  NYSE CFN  merger are the key growth catalysts We note that BD has posted a positive earnings surprise of 4 07  on an average over the last four quarters   Read More   DENTSPLY SIRONA Inc    NASDAQ XRAY   is set to report first quarter 2016 results on May 6  The company s results will be benefited by its expanding product portfolio and increasing penetration into the emerging markets Notably  the company s results compared favorably with the Zacks Consensus Estimate in the last four quarters  with an average beat of 3 46    Read More   Check later on our full write up on earnings releases of these stocks ,2016-05-03,Zacks Investment Research,"https://www.investing.com/analysis/2-dental-stocks-reporting-earnings-this-week:-bdx,-xray-200127961",200127961
123109,344624,BDX,3 Medical Devices Stocks Set To Beat This Earnings Season,opinion,"As of the end of last week  310 S P 500 members have reported their Q1 results  representing 85 3  of the sector s total market capitalization on the index  While to our great disappointment  we have seen that total earnings for these index members are down  7 2  year over year on  2 4  lower revenues  here is some real good news for investors keen on the Medical sector 
So far  more than 60  of the Medical sector index members have released their first quarter financial numbers  out of which 78 1  have reported better than expected earnings performance on revenue beat of 68 8   Accordingly  earnings were up 6 3  year over year on an 11 8  revenue growth rate 
While the global economic hullabaloo has been seen to hit the economy hard  leaving the conventional heavyweights like Finance  Tech  aerospace or oil energy in a position to pull the industry wide average expectation down  this stupendous first quarter performance by the Medical sector is something investors definitely need to muse on Beaming Medical Device Space
In fact  if we eliminate major drug and biotech stocks from Medical  which are currently entwined in pricing and prescription drug affordability related issues  this space confined mostly by medical device stocks indeed lends a lot of optimism  A recent EvaluateMedTech World Preview claims that the medical device space is positioned for impressive growth in the near term  At a glance  worldwide  medical device sales are expected to grow at a CAGR of 4 1  to  477 5 billion by 2020 
Needless to say that the factors like the recent exemption of the Medical Device Excise tax for the next two years came in as a much needed breather for these Medical device stocks  This dreadful tax  which was commonly referred to as  fund of the Affordable Care Act  ACA    simply took a toll on the entire medical device industry  since its enactment in 2013 
Data published in a report in FierceMedical Device stated that in 2014  Johnson   Johnson  NYSE JNJ  made a payment of  180 million in medical device tax payments  while Medtronic  NYSE MDT   legacy Covidien and Smith   Nephew  LON SN   SNN  paid  112 million   60 million and  25 million  respectively 
We believe this exemption  albeit temporary  has boosted the positive sentiment in the medical device investment world  as most analysts believe it to be adequate for companies to address pressing issues such as a lack of opportunity for research and development  innovation  pipeline development  and to make investments needed to accelerate patient and provider access to innovative health care products 
Apart from that  the strong product cycle and consistent innovation across different markets have continued to remain the major growth drivers in the medical device subsector Making the Right Choice
With a wide number of stocks in the medical device sector that almost always muddle up one s stock picking prowess  the Zacks methodology could offer some relief  One can narrow down choices by focusing on stocks that sport the desirable combination of a positive  and a favorable Zacks Rank   Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  
Earnings ESP is our proprietary methodology for identifying stocks that have high chances of surprising with their next earnings announcement  It shows the percentage difference between the Most Accurate estimate and the Zacks Consensus Estimate 
Our research shows that for stocks with this combination  the chance of a positive earnings surprise is as high as 70  
Going by this criterion  we hereby present three medical device stocks that are poised to beat estimates this quarter Becton  Dickinson and Company    NYSE BDX   
Popularly known as BD  this global medical technology company has an innovative product pipeline  which is a key catalyst in our view  A set of FDA approvals in the last quarter has added products like TotalysMultiProcessor and TotalysSlidePrep instruments  FACSPresto system and FACSPresto CD4 Hb Cartridge and Vacutainer UltraTouch Push Button Blood Collection Set to the company s ever expanding product portfolio 
Meanwhile  BD s expansion into overseas markets  particularly the emerging markets  is a major positive  Moreover  the CareFusion  NYSE CFN  merger has opened up significant growth opportunities for the company  Further  the combined manufacturing footprint and operations  along with lower overhead expenses should result in significant cost savings 
BD will report its second quarter fiscal 2016 results on May 5  The stock boasts an Earnings ESP of  1 99   coupled with a Zacks Rank  2 Cardica Inc     NASDAQ CRDC   
Cardica develops proprietary stapling and anastomotic devices for cardiac and minimally invasive surgical procedures  The company s product portfolio facilitates minimally invasive and robot assisted surgeries  Cardica s MicroCutter XCHANGE 30 has been manufactured and cleared for use in the U S  for transection and resection in multiple open or minimally invasive urologic  thoracic and pediatric surgical procedures  as well as application for transection  resection and or creation of anastomoses in the small and large intestine  and the transection of the appendix 
Cardica will report third quarter fiscal 2016 results on May 5 after the market closes  We believe the company is poised to beat the Zacks Consensus Estimate given its Zacks Rank  2 and an Earnings ESP of  4 26  Quality Systems Inc     NASDAQ QSII   
Headquartered in Irvine  CA  Quality Systems Inc is a developer and marketer of healthcare information systems  The company continues to focus on growing its presence in the RCM  population health and interoperability solutions markets  Continuing investments in research   development will help Quality Systems to penetrate these markets  going forward  The latest acquisition of HealthFusion will enable the company to enter the small physician segment  It will also boost the company s share in the ambulatory market 
Quality Systems is expected to report its fourth quarter fiscal 2016 numbers on May 19  We expect the company to beat our fourth quarter earnings estimates as it has a favorable combination of a Zacks Rank  2 and an Earnings ESP of  6 25  
Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-05-04,Zacks Investment Research,https://www.investing.com/analysis/3-medical-devices-stocks-set-to-beat-this-earnings-season-200128014,200128014
123110,344625,BDX,Becton  Dickinson  BDX  Beats Q2 Earnings   Sales,opinion,Based in New Jersey  Becton  Dickinson and Company   NYSE BDX   is a medical technology company engaged principally in the development  manufacture and sale of medical devices  instrument systems and reagents  These products are used by healthcare institutions  life science researchers  clinical laboratories  the pharmaceutical industry and the general public  Currently  Becton  Dickinson has a Zacks Rank  3  Hold  but that could change following its second quarter fiscal 2016 earnings report which has just released  We have highlighted some of the key details from the just released announcement below  Earnings  Becton  Dickinson s adjusted earnings of  2 18 per share beat the Zacks Consensus Estimate by 17 cents and increased 44 7  year over year on a currency neutral basis  Revenues  Adjusted revenues amounted to  3 07 billion  up 55 2  from the year ago quarter on a currency neutral basis  Revenues beat the Zacks Consensus Estimate of  3 06 billion Key Stats  BD Medical generated revenues of  2 14 billion  up 99 5  on a year over year basis  BD Lifesciences generated revenues of  936 million  up 3 4  from the year ago quarter Major Factors  On a comparable basis  adjusted U S  revenues increased 5 7   International revenues increased 4 8  on a currency neutral basis in the reported quarter  Stock Price  Following the earnings release  share prices did not show any movement in the pre market trading session  Check back later for our full write up on this Becton  Dickinson and Company earnings report later ,2016-05-05,Zacks Investment Research,"https://www.investing.com/analysis/becton,-dickinson-(bdx)-beats-q2-earnings---sales-200128141",200128141
123111,344626,BDX,Becton  Dickinson  BDX  Inks Partnership Deal With CAPS,opinion,Becton  Dickinson and Company   NYSE BDX    popularly known as BD  recently announced a partnership with Central Admixture Pharmacy Services  CAPS   The agreement will allow BD Intelliport Medication Management System customers to buy a portfolio of frequently used CAPS  pre filled anesthesia syringes According to BD   CAPS  pre filled anesthesia syringes are designed to prevent common compounding and labeling errors that occur in the operating room  These syringes are prepared in a controlled environment and undergo continuous testing for sterility  potency and endotoxin to meet strict new FDA quality control requirements  BD s Intelliport System can automatically identify and utilize these syringes  The system is capable of providing real time medication identification  dose measurement and patient drug allergy alerts at the point of injection  It is also capable of updating patient s electronic medical record  EMR  following medication administration   The new collaboration reflects BD s growing focus on patient safety and improving workflow  The earlier announced collaborations with Medtronic   NYSE MDT      for the infusion set and Parker Institute for Cancer Immunotherapy    in relation to the new Cell Sorter program are key growth drivers in our view Apart from partnerships  BD s endeavor to develop innovative products is noteworthy  A plethora of FDA approvals in recent times has added products like Totalys MultiProcessor and Totalys SlidePrep instruments  FACSPresto system and FACSPresto CD4 Hb Cartridge and Vacutainer UltraTouch Push Button Blood Collection Set to the company s portfolio Recently  BD announced the receipt of CE marking for its BD MAX Vaginal Panel    a new in vitro diagnostic  IVD  assay  The product expands BD s reproductive and sexually transmitted Infections Portfolio Most recently  BD introduced its newest cell sorter    the BD FACSMelody system    which follows the launch of the company s flow cytometers like BD Accuri C6 Plus and BD FACSCelesta systems Zacks Rank   Key PicksBD carries a Zacks Rank  3  Hold  Better ranked stocks in the same space include Halyard Health   NYSE HYH   and C R  Bard   NYSE BCR    While Halyard Health sports a Zacks Rank  1  Strong Buy   C R  Bard has a Zacks Rank  2  Buy  ,2016-06-13,Zacks Investment Research,"https://www.investing.com/analysis/becton,-dickinson-(bdx)-inks-partnership-deal-with-caps-200135555",200135555
123112,344627,BDX,5 Stocks We Like,opinion,"A small measure of stability has returned to markets early this week after a ferocious bout of volatility that wiped  3 trillion from the world s balance sheets in the worst two day sell off of all time 
Many investors are understandably nervous about what s next 
I m here to tell you  Don t be 
Chances are  the Brexit is probably not the first financial temper tantrum you ve lived through  nor will it be the last  Getting all worked up about it just isn t worth the aggravation 
Today we re going to talk about why  and what you need to do to build up a profit positioning reflex that the world s most successful investors regard as second nature 
It s deceptively simple  elegant  and easy to execute  What s more  once you ve built up the reflex I m going to talk about today  you ll know how to immediately position yourself for profits the next time markets pitch a fit 
And  you ll have a huge advantage over other investors 
 Euro Shrink  Will Bring Tremendous Profits
I ve been intimately involved with the markets now for 35 years as a trader  a consultant  and an analyst  and stuff like the Brexit comes and goes more often than any of us would care to admit  The Internet and 24 hour news cycle we live with today just makes it seem worse 
For example  I vividly recall Black Monday in 1987   my first major crash  It  too  was unprecedented  and in the pre Internet days the news headlines were going bananas  Cell phones were in their infancy and smartphones were just a pipe dream  People were forced to wait for the breaking headlines  which meant they actually had time to think 
That was followed shortly by the U S  Savings   Loan Crisis in 1989  the Asian currency contagion in 1998  the dot bomb crash of 2000  the terrorist attacks of 2001  and ultimately  the Lehman Brothers blowout of 2008 
There is no doubt in my mind that we re going to see more  exits    every one of which will be held up in the media as a sensational event  unlike anything we ve ever seen before  
Somewhat tongue in cheek  here s what I think we re dealing with 
There will be more  a Frexit  France leaving   a Spexit  Spain leaving   a Nexit  the Netherlands leaving  
Other headline worthy possibilities include a Departugal  Italeave  Fruckoff  Czechout  Oustria  Finish  Slovlong  Latervia  Byegium  It s Spainreal 
At the end of the day  the European Union  EU  could shrink all the way to  Ditchland  
I am not trying to ruin your day here 
What I want you to come to terms with is the flawed notion that a crisis like the Brexit is a  one and done  event  That s na ve at best  and wishful thinking at worst 
Since we ve been investing together  I ve helped you identify fabulous opportunities that have led to spectacular performance and thrashed the markets  Examples include Becton Dickinson and Company  NYSE BDX   American Water Works  NYSE AWK  and Altria Group  NYSE MO   These  must have  investments have beaten the markets over time by as much as 44 to 1 
I ve also helped you aggressively hunt down the weakest companies  like Shake Shack  NYSE SHAK   Twitter  NYSE TWTR  and GoPro  NASDAQ GPRO   often at times when Wall Street was enamored with them  They ve produced double digit profits for everybody who s following along  as I hope you are 
To be clear  I am not telling you this to brag  I make my share of mistakes  too 
What I want you to understand is that there s always opportunity   and the Total Wealth Principles  Tactics  and approach will help you find them when other investors cannot and the headlines make doing so seem impossible 
Capturing profits during challenging times doesn t start with analysis or even data  It starts with the person who looks back at you in the mirror every morning 
Just like riding a bike or learning to cook a five star meal  you have to build up the reflexes needed to handle an event like the Brexit profitably 
Let me explain 
Five Terrific Companies to Buy Right Now
The overwhelming majority of investors run for the hills when the markets go haywire  which is why their portfolios are a fraction of what they could be  and why they repeatedly miss out on the enormous gains they so desperately want 
But the best investors and the most consistently profitable players have a very different take  Many run straight into the fire knowing full well that they ve got the advantage   not to mention plenty of profit potential 
They re net buyers  and I want you to be one of  em 
You don t have to bet the farm or even make a major purchase  Even a single share of something will do 
My goal is to help you build up the reflex needed to capitalize on chaos  and the mental strength that will allow you to view every major market event as an opportunity  not an excuse to bury your head in the sand 
And that comes from doing  just like riding a bike 
A single of share of Alphabet  NASDAQ GOOGL   for example  would have set you back  663 on Monday if you swooped in when it hit rock bottom  It s trading at  687 as I write this 
Facebook  NASDAQ FB  dropped all the way to  108 23  It s at  114 at the moment  and climbing 
If that kind of volatility isn t your thing  consider some of the more defensive plays we ve talked about this year   names like Raytheon Company  NYSE RTN   Altria Group  and American Water Works Co 
They didn t drop all that much because they re attracting capital  so there s implied stability and profit potential to boot 
Now  I ve talked to tens of thousands of investors over the years  and many think that they re going to outsmart the markets by waiting for a pullback  when the recovery starts  
That s wishful thinking 
The pullbacks they re longing for no longer exist  Approximately 70  of today s trading volume is driven by computers  which means price movement is more like a dogpile  If you re not in when it starts  you miss 80  of the move  perhaps more 
Case in point  March 2009 
Lots of investors sold out in a panic as the S P 500 and the Dow collapsed  They felt great because they  got out of the way  or  didn t try to catch a falling knife    comments I heard repeatedly during presentations around the world  and that were echoed in a blizzard of email 
That didn t last very long though 
The markets reversed  the bulls went on a rampage  and the vast majority of those very same people were left on the sidelines and completely missed out on the 211 19  run in the S P 500 into July 2015  the 302 68  run in the Nasdaq  and the 172 92  run in the Dow over the same time frame 
Here s the thing 
Many investors fantasize about really big returns  but very few actually have the reflexes needed to achieve that   which is why we re having this discussion today 
They like to think it s the headlines  or the economy  or China  or any of half a dozen other scary things that s caused them to lose out 
But that s not the case 
They re simply missing the reflex they need to overcome their fears 
To be clear  I am not saying that you need to buy indiscriminately every time the markets falter  There are going to be times when the stuff simply hits the proverbial fan  But even that doesn t change the reflexive behavior we re talking about today 
Learn to overcome your fears for a darn good reason 
 because doing so can help you be far more profitable ",2016-07-01,Keith Fitz-Gerald,https://www.investing.com/analysis/the-best-stocks-in-the-world-are-on-sale-now--we-like-these-five-200139490,200139490
123135,344650,BDX,Where We ll Find the Biggest Potential Profits Of 2016,opinion,"In my 2015 forecast  I predicted that defense  natural resources  and medical device companies would be the big stories of the year  despite volatility that was going to give most investors fits 
Sure enough  Raytheon Company  N RTN  has taken off as the war against ISIS intensifies  Returns are now 214 66  and counting  American Water Works  N AWK  has logged an impressive 112 66   and Becton Dickinson and Company  N BDX  is rocking 124 62  to date  Bear in mind  these gains come despite the Dow and S P 500 being modestly down for the year 
I also urged you to avoid or short companies that didn t have the quality we know leads to bigger profits and more stable income  like Twitter  N TWTR  and GoPro Inc  O GPRO   Those shorts have produced returns of 36  and 71  to date 
As exciting as those numbers are  2016 could be even better 
The Bull Market Lives On  for Us
The Fed continues to fly by the seat of its pants using badly flawed economic models with no bearing on reality  Europe s already challenging fiscal situation is being compounded by an unprecedented migration from the Middle East  China s slowing down  and Japan fell into its fourth recession in five years  only to have the numbers revised away a month later  Nationalism is on the rise worldwide  as is protectionism 
So the investing backdrop is challenging  to say the least 
But some of our favorite companies continue to pull ahead  We saw a 30  performance gap between the best and worst segments of the S P 500 in 2015  and I see that becoming even more graphic this year  If projections hold   growth may average 8  in 2016 
The run could last another three years  although not all in a straight line  Since 1926  economic recoveries have lasted an average of 58 months  so you could argue that the current expansion is past its prime at 78 months  However  three recoveries since 1981 have gone on for an average of 95 months  according to Kiplinger  Central bank meddling  wrong though it is  has that positive side 
Investors remain more interested in buying than selling  During the run up following last August s flash crash  for example  volume was 5 1 in favor of buying several days running  According to InvestTech CEO James Stack  stocks tend to rise an average of 24  over the following 12 months when we see that happen 
Further  we d still have to go another 36 months to match the nine year bull market that started in October 1990 and produced returns of 546  
Smart Risks and Good Companies Will Beat Beat Bad Markets
Overweighting U S  based large cap stocks that provide products and services with the pricing power will be necessary to overcome more central bank meddling and increasingly challenging global protectionism 
Fuel for growth  technology enabled opportunities  and allocation will be key   they re all in industries where revenue is rising and  are stable or increasing 
The synchronized recovery central bankers and politicians have tried to engineer will  unfortunately  remain a fantasy  Recovery  reform  and resurrection will be worldwide buzzwords 
Despite runaway debt and resulting stagnant growth  America s still the global economic leader  The BRICS are B U S T E D but  at a 50  discount to U S  stocks  chances are we ll be doing some shopping there in the next 12 months 
Prepare to Capitalize on Volatility

Bonds remain relevant  for now  Yellen has already begun one of the slowest rate hike cycles in history  This leaves the cost of capital low  the dollar strong  and energy cheap  Tax advantaged munis and government paper will benefit in 2016 
Gold prices will remain trapped in a tightly defined range of  900 to  1 100 for much of the year depending on how the Fed handles additional rate hikes  That s good because it will give investors an entry point to hedge their bond portfolios before the real run starts 
Other themes we ll follow closely in 2016 include 
Digital protection  Thieves have stolen more than 200 million charge accounts and personal information in the past 24 months  They will steal more 
The  War on Success  continues unabated  Taxes will rise  as will the real cost of everything  Our politicians  as usual  will be clueless to the consequences 
Startups will have to prove it or lose it  FOMO   the fear of missing out   will be replaced by NLYA   not losing your asteroids   on the next round of  
Productivity growth remains slower than expected  Pessimists will call for more stimulus  not knowing that makes matters worse  Still  they ll probably get it since no politician wants to fail on his or her watch 
China will not collapse  but the slowdown will change global business in two ways  First  companies that overextended in China will collapse  and there will be a sharp rise in defaults  Second  there will be a fresh round of investment into China by Western companies doubling down 
Nowcasting  The practice of combining current data with forecasting will come into its own  speeding up corporate decision making and profit taking 
Human augmentation  We re less than five years away from the earliest human machine interfaces  and we re tracking emerging human augmentation companies more closely than ever 
Protracted low prices are wreaking havoc on overleveraged energy companies  leading the strongest to make exciting new investments  in each other  That will translate to strong growth when prices stabilize  and sooner than most expect 
In closing  never forget that there s always a bull market somewhere  My job is to help you find it  together 
Best regards for great investing and a fabulously profitable 2016 ",2015-12-29,Keith Fitz-Gerald,https://www.investing.com/analysis/where-we-39;ll-find-the-biggest-potential-profits-of-2016-377751,377751
123136,344651,BDX,BDX  Excellent Candidate For Long Term Dividend Growth,opinion,"Becton  Dickinson and Company  N BDX  is a world leader in medication management and patient safety solutions  The company has been in operation for more than 115 years and has increased its dividend for 44 consecutive years 
With a diverse portfolio of medical products  meaningful exposure to emerging markets and a large acquisition under its belt  BDX appears to be an excellent candidate for long term dividend growth investors to consider 
Business OverviewBDX was founded in 1897 and manufactures a wide range of medical supplies  devices  lab equipment  and diagnostics products  Some of its key products include syringes  needles  dispensing systems  and catheters  but its portfolio is well diversified  Many products help hospitals deliver medicines to patients  Customers include hospitals  clinics  physicians  offices  pharmacies  labs  blood banks  and others 
By geography  the majority of BDX s sales are from outside of the U S   and the company generates around 25  of its total sales from emerging markets 
Business AnalysisBDX acquired CareFusion  N CFN  for  12 2 billion in March 2015  Analyzing this deal  which was 20 times larger than any acquisition BDX had ever made  will highlight some of the strengths of BDX s business model 
CareFusion is a provider of medical devices and diagnostic products to hospitals and physicians  This deal essentially doubled the addressable market opportunity that BDX s medical segment had from  8 billion to  16 billion 
BDX s extensive distribution channels  which reach all over the world  were a major driver behind the acquisition  CareFusion s complementary products can be plugged into BDX s existing channels to reach international markets it had never been in before  60  of BDX s sales are abroad  but 75  of CareFusion s business is in the U S   
As seen below  BDX will now be able to offer integrated medication management solutions and smart devices   from drug preparation and pharmacy to dispensing on the hospital floor  administration to the patient  and subsequent monitoring 
Source  BDX Investor Presentation
As hospitals increasingly look to cut costs and improve quality  we believe medical device suppliers will likely continue consolidating  With CareFusion under its belt  BDX should be able to better help hospitals manage their drug use and cut down on their waste for several reasons 
First  many of their products are complementary and will allow hospitals to save money by only purchasing from one supplier instead of several  For example  CareFusion manufactures equipment that pumps drugs into the catheters that are currently sold by BDX and put drugs into patients 
Additionally  CareFusion provides BDX with software that helps hospitals track drug usage and the machines they use to store medicines and fill orders  These offerings will become increasingly important as hospitals focus on becoming more efficient 
Other competitors lack the breadth and depth of BDX s portfolio and seem increasingly likely to get squeezed out by the larger players  BDX s brand recognition  distribution reach  and economies of scale serve as additional advantages in its markets 
Beyond its comprehensive product portfolio and distribution channels  BDX spends over  600 million on R D and has built up an arsenal of patents  The healthcare industry also operates under numerous regulations in every country  further raising barriers to entry Key RisksSimilar to our analysis of dividend aristocrat Medtronic  N MDT   BDX must comply with a variety of healthcare regulations  which could result in pricing pressure  lower reimbursement rates for some of its products  and other unexpected headwinds  For example  part of the Affordable Care Act  which was enacted in March 2010  enacted a 2 3  excise tax on U S  sales of certain medical devices 
On the flipside  at least in the U S   healthcare reform is helping more Americans gain health insurance coverage  increasing the number of needles  syringes  and other medical supplies consumed 
Outside if regulatory risk and currency headwinds  the company will have its hands full integrating CareFusion and extracting its expected synergies over the next few years  Given the size of this deal  especially compared to BDX s historical acquisitions  execution needs to be strong 
All things considered  BDX s diversified portfolio  recession resistant products  strong business model  long operating history  and disciplined management team increase the company s durability Dividend AnalysisWe analyze 25  years of dividend data and 10  years of fundamental data to understand the safety and growth prospects of a dividend  Dividend Safety ScoreOur Safety Score answers the question   Is the current dividend payment safe   We look at factors such as current and historical EPS and FCF payout ratios  debt levels  free cash flow generation  industry cyclicality  ROIC trends  and more  Scores of 50 are average  75 or higher is very good  and 25 or lower is considered weak 
BDX s dividend Safety Score of 88 is excellent  Over the last four quarters  BDX s dividend has consumed 45  of the company s free cash flow  providing plenty of cushion and room for future growth 
Looking longer term  we can see that BDX s payout ratios have largely remained between 25  and 40   the 2015 spike in its EPS payout ratio is due to noisy accounting charges and isn t significant   Such a stable ratio shows that BDX has done a great job of consistently growing its earnings to fuel its dividend growth and has been consistently profitable Source  Simply Safe Dividends
Source  Simply Safe Dividends
Evaluating BDX s performance during the recession can help us understand how resilience of its business  Many healthcare related products tend to be more recession resistant because sick and injured people still need to be taken care of regardless of economic conditions  As seen below  BDX s sales actually grew each year  and its stock outperformed the S P 500 by 20  in 2008 Source  Simply Safe Dividends
The company has also generated a return on invested capital in the mid teens over the last decade  indicating that the company has an economic moat and has a stable business model Source  Simply Safe Dividends
Free cash flow generation is also very important to evaluate when it comes to evaluating the safety of a company s dividend  Businesses that fail to generate free cash flow must rely on debt and equity markets to keep paying their dividend and are often of lower quality 
BDX has generated positive and growing free cash flow in each of its last 10 years of business Source  Simply Safe Dividends
Finally  analyzing the balance sheet is important because companies with high amounts of debt could find themselves in a crunch if business trends deteriorate and they must make interest and debt payments  They will always pay credit holders before issuing a dividend 
BDX s balance sheet was stretched to finance the company s acquisition of CareFusion  but management is focused on paying down debt over the next several years  Given the company s consistent free cash flow generation  we aren t concerned by the temporarily higher debt load  Importantly  there is plenty of cash flow to comfortably cover a larger interest expense and the dividend  Source  Simply Safe Dividends
All things considered  BDX s dividend is extremely safe  With a long operating history  a diversified portfolio of recession resistant products  and strong brand recognition  BDX is a high quality blue chip dividend stock Dividend Growth ScoreOur Growth Score answers the question   How fast is the dividend likely to grow   It considers many of the same fundamental factors as the Safety Score but places more weight on growth centric metrics like sales and earnings growth and payout ratios  Scores of 50 are average  75 or higher is very good  and 25 or lower is considered weak 
BDX achieved an excellent dividend Growth Score of 79  which means that it has some of the strongest dividend growth potential in the market  The company s favorable rating is driven by its low payout ratios  strong earnings growth  and consistent cash flow generation 
BDX has increased its dividend for 44 consecutive years  firmly securing its spot on the list of dividend aristocrats  The company has consistently increased its dividend at a 10  annual rate over the last decade and most recently raised its dividend by 10  earlier this month 
Assuming BDX meets expectations for continued 10   earnings growth  we expect the dividend to continue growing at a similar rate Source  Simply Safe DividendsValuationBDX trades at 17 6x forward earnings and offers a dividend yield of 1 8   which is lower than its five year average dividend yield of 2 0  
BDX s management team expects the company s sales and earnings to grow 4 5  and 10   per year  respectively  In other words  the stock appears to offer double digit total return potential if all goes as planned 
BDX appears to be an excellent business trading at a reasonable price  However  its low dividend yield makes it more appealing for very long term dividend growth investors ConclusionBDX is an excellent medical technology company  Its acquisition of CareFusion appears to offer numerous long term growth opportunities as the healthcare landscape continues evolving and international markets spend more on healthcare 
The company s dividend is extremely safe with excellent growth prospects as well  If the company can deliver on management s double digit earnings growth goal  the stock looks attractively priced at less than 18x forward earnings estimates 
While the stock is not currently in our Top 20 Dividend Stocks portfolio  it s one that long term dividend growth investors should certainly keep an eye on ",2016-01-05,Brian Bollinger,https://www.investing.com/analysis/a-double-digit-dividend-growth-stock-378774,378774
123137,344652,BDX,Swing Trading Watch List  MNST  CDW  VSH  BDX  RIG,opinion,"Here s today s swing trading watch list 
Short  Monster Beverage  O MNST 

Short  CDW Corp  O CDW 

Short  Vishay Intertech  N VSH 

Long  Becton Dickinson  N BDX 

Long  Transocean  N RIG ",2016-02-08,Ryan Mallory,https://www.investing.com/analysis/swing-trading-watch-list:-$mnst-$cdw-$vsh-$bdx-$rig-383602,383602
123138,344653,BDX,Swing Trades  MNST CDW VSH BDX RIG,opinion,"Here s Today s Swing Trading Watch List 
Short Monster Beverage  O MNST 

Short Cdw Corp   O CDW 

Short Vishay Intertechnology  N VSH 

Long Becton Dickinson and Company  N BDX 

Long Transocean  N RIG ",2016-02-08,Ryan Mallory,https://www.investing.com/analysis/swing-trades:-mnst-cdw-vsh-bdx-rig-383721,383721
123142,344657,BDX,Baxter  BAX  Q1 Earnings  A Surprise in Store for the Stock ,opinion,Baxter International Inc    NYSE BAX   is set to report first quarter 2016 earnings on Apr 26  Last quarter  Baxter reported earnings of 43 cents per share  which beat the Zacks Consensus Estimate by 38 7   12 cents   Notably  the company s earnings have topped the Zacks Consensus Estimate in the last four quarters  by an average of 25  Let s see how things are shaping up for this quarter Factors at PlayFor the first quarter of 2016  Baxter expects sales growth in the range of 3  to 4   at constant currency  Including the impact of foreign exchange rate volatility  Baxter estimates sales decline of 2  on a year over year basis  Adjusted earnings are forecasted in the range of 28 cents to 30 cents per share We believe Baxter s expanding product pipeline is a key growth catalyst  Newly launched products like SIGMA SPECTRUM infusion pump and AMIA APD cycler with SHARESOURCE two way connectivity are expected to drive top line growth in the quarter  We expect continuing robust performance from the IV solutions in the quarter Moreover  the ongoing restructuring program will help in reducing operating expenses  However  continuing foreign exchange rate volatility and lower U S  cyclophosphamide sales  expected to decline by  90 million year over year in full year 2016  are major headwinds Earnings WhispersOur proven model does not conclusively show that Baxter is likely to beat earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here as you will see below Zacks ESP  Baxter has a 0 00  ESP  This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at 29 cents Zacks Rank  Baxter carries a Zacks Rank  3  Hold   which increases the predictive power of ESP  but when combined with a 0 00  ESP  it makes surprise prediction difficult We caution against stocks with a Zacks Rank  4 and 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revision momentum Stocks to ConsiderHere are a few stocks worth considering that  per our model  have the right combination of elements to post an earnings beat this quarter PAREXEL International Corporation   NASDAQ PRXL   with earnings ESP of  2 25  and a Zacks Rank  1 Align Technology Inc    NASDAQ ALGN   with earnings ESP of  12 82  and a Zacks Rank  2 Becton  Dickinson and Company   NYSE BDX   with earnings ESP of  2 49  and a Zacks Rank  2 Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days  Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-04-22,Zacks Investment Research,https://www.investing.com/analysis/baxter-(bax)-q1-earnings:-a-surprise-in-store-for-the-stock-200126198,200126198
123144,344659,BDX,Will Thermo Fisher  TMO  Exceed Q1 Earnings Expectations ,opinion,"We expect Massachusetts based medical instruments manufacturer  Thermo Fisher Scientific  Inc    NYSE TMO   to beat expectations when it reports first quarter 2016 results before the opening bell on Apr 28  Last quarter  the company had reported a positive earnings surprise of 47   Also  the four quarter trailing average beat is pegged at 1 41   Let s see how things are shaping up for this announcement 

 
Why a Likely Positive Surprise 
Our proven model shows that Thermo Fisher is likely to beat earnings because it has the right combination of two key ingredients 
Zacks ESP  Thermo Fisher s  is  0 58   since the Most Accurate estimate stands at  1 75 while the Zacks Consensus Estimate is pegged lower at  1 74  A favorable Zacks ESP serves as a meaningful and leading indicator of a likely positive earnings surprise  
Zacks Rank  Thermo Fisher currently has a Zacks Rank  3  Hold   Note that stocks with a Zacks Rank  1  2 or 3 have a significantly higher chance of beating earnings estimates  Conversely  Sell rated stocks   4 or 5  should never be considered going into an earnings announcement 
The combination of Thermo Fisher s Zacks Rank  3 and  0 58  ESP makes us reasonably confident of a positive earnings beat 
What is Driving the Better than Expected Earnings 
After a solid 2015  Thermo Fisher is looking forward to continue this momentum even in 2016  It is encouraging to note that with about 4  expected organic growth for full year 2016  the company anticipates reporting 7  growth in the first quarter 
As in 2015  even in the first quarter of 2016  the company expects to see strong growth in the bioproduction and biosciences businesses  Strong productivity and incremental cost synergies are expected to further improve operational efficiencies down the line 
With respect to Life Technologies synergy  per the company  it is perfectly on track to deliver revenue and cost synergy targets  By the end of 2015  the company realized  130 million of incremental cost synergies  in line with its full year target  Revenue synergies at 2015 end were  90 million  much faster than anticipated  This puts Thermo Fisher in a comfortable position to achieve its full year 2016 targeted synergy to deliver  150 million in revenue  The company is also confident of its overall three year synergy target which has been raised from  300 million to  350 million 
Apart from the Life Technologies integration  we are also focusing on the company s emerging market growth strategies  The company expects to garner 25  of total revenue from the high growth Asia Pacific and emerging markets by 2016 from 19  in 2011  10  in 2006   Thermo Fisher s expanding presence in emerging markets will continue to be an important growth driver for the first quarter 
In this context  we need to mention the company s recent decision to buy Affymetrix Inc   AFFX  for  1 3 billion  Affymetrix  which works on multiplex and simultaneous analysis of biological systems at the cell  protein  and gene level  facilitating the transition of research tools into clinical and applied markets  is expected to boost Thermo Fisher s offering in the fast growing flow cytometry market through an advanced antibody portfolio  Although this impending acquisition  to close in second quarter 2016  will not have any impact on the company s first quarter performance  investor sentiment is picking up based on this news 
Other Stocks to Consider
Here are some other companies you may want to consider as our model shows they too have the right combination of elements to post an earnings beat this quarter  
Align Technology Inc    NASDAQ ALGN   has an Earnings ESP of  12 82  and a Zacks Rank  2  Buy  
Becton  Dickinson and Co    NYSE BDX   has an Earnings ESP of  2 49  and a Zacks Rank  2 
Gilead Sciences Inc    NASDAQ GILD   has an Earnings ESP of  1 65  and a Zacks Rank  2 
Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days  Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-04-22,Zacks Investment Research,https://www.investing.com/analysis/will-thermo-fisher-(tmo)-exceed-q1-earnings-expectations-200126176,200126176
123145,344660,BDX,What s In The Cards For HCA Holdings  HCA  In Q1 Earnings ,opinion,HCA Holdings Inc    NYSE HCA   is expected to report first quarter 2016 results on May 3  Last quarter  the company reported earnings of  1 69 per share  which beat the Zacks Consensus Estimate by 30 cents Notably  the company s results compared favorably with the Zacks Consensus Estimate in the last four quarters  with an average beat of 5 53  Let s see how things are shaping up for this quarter Factors at PlayHCA Holdings is expected to benefit from the growing admission rate and improving payor mix based on the continuing implementation of the Affordable Care Act  Obamacare   The company is also poised to benefit from robust same store growth and stringent cost management   Earnings WhispersOur proven model does not conclusively show that HCA Holdings is likely to beat earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here as you will see below Zacks ESP  The Earnings ESP for HCA Holdings is  1 34   This is because the Most Accurate estimate stands at  1 47  while the Zacks Consensus Estimate is pegged at  1 49 Zacks Rank  HCA Holdings carries a Zacks Rank  2  which when combined with  1 34  ESP makes surprise prediction difficult Meanwhile  we caution against stocks with a Zacks Ranks  4 and  5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are a few stocks worth considering that  per our model  have the right combination of elements to post an earnings beat this quarter Quality Systems   NASDAQ QSII    with an Earnings ESP of  6 25  and a Zacks Rank  2 Becton  Dickinson and Company   NYSE BDX    with an Earnings ESP of  1 99  and a Zacks Rank  2 The Cooper Companies   NYSE COO    with an Earnings ESP of   52  and a Zacks Rank  2 ,2016-05-02,Zacks Investment Research,https://www.investing.com/analysis/what's-in-the-cards-for-hca-holdings-(hca)-in-q1-earnings-200127078,200127078
123151,344666,BDX,What s In Store For Cerner  CERN  This Earnings Season ,opinion,"Cerner Corporation   NASDAQ CERN   is expected to report first quarter 2016 results on May 5  Last quarter  the company reported earnings of 58 cents per share  which beat the Zacks Consensus Estimate by a nickel Notably  the company s results compared favorably with the Zacks Consensus Estimate in the last four quarters  with an average beat of 1 87  
Let s see how things are shaping up for this quarter Factors at PlayFor the first quarter of 2016  Cerner forecasts revenues between  1 15 billion and  1 2 billion  The mid point of the guided range reflects 18  year over year growth  The company also projects new business bookings between  1 15 billion and  1 25 billion Adjusted earnings  before share based compensation expense and acquisition related adjustments  are expected in the range of 52 cents to 54 cents  At mid point  this reflects 18  growth on a year over year basis We believe that Cerner s strong product portfolio will help it boost its customer base  The frequent contract wins reflect growing traction  Moreover  the company has strong growth opportunities in the revenue cycle management  RCM  and ambulatory market However  the HCIT market is highly competitive which exerts considerable pressure on both pricing and margins  Moreover  a growing proportion of low margin services and technology resale may affect margins  Meanwhile  stringent hospital budgets continue to exert pressure on pricing  which is an added concern Earnings WhispersOur proven model does not conclusively show that Cerner is likely to beat earnings this quarter  That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here as you will see below Zacks ESP  Cerner has an  of 0 00   This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at 49 cents Zacks Rank  Cerner carries a Zacks Rank  4  Note that we caution against stocks with a Zacks Ranks  4 and  5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderHere are a few stocks worth considering that  per our model  have the right combination of elements to post an earnings beat this quarter Quality Systems   NASDAQ QSII    with an Earnings ESP of  6 25  and a Zacks Rank  2 Becton  Dickinson and Company   NYSE BDX    with an Earnings ESP of  1 99  and a Zacks Rank  2 The Cooper Companies   NYSE COO    with an Earnings ESP of   52  and a Zacks Rank  2 ",2016-05-02,Zacks Investment Research,https://www.investing.com/analysis/what's-in-store-for-cerner-(cern)-this-earnings-season-200127366,200127366
123155,344670,BDX,Humana  HUM  Q1 Earnings May Disappoint  Stock To Suffer ,opinion,Humana Inc    NYSE HUM   is set to report first quarter 2016 results on May 4  before the market opens  Last quarter  the company posted a negative earnings surprise of 0 68   Let s see how things are shaping up for this announcement Factors to be Considered this Quarter    Humana has likely witnessed an increase in operating expenses owing to higher benefit expenses as well as depreciation and amortization expenses Moreover  the company is expected to have experienced weakness in Group Medicare Advantage business in the first quarter  This is likely to adversely impact earnings and result in a fall in net membership However  Humana s Medicare Part D Prescription Drug Plan  PDP    part of its Medicare business   has likely displayed net membership growth in the to be reported quarter Notably  Humana is set to be acquired by Aetna Inc    NYSE AET   to form a combined company by the second half of 2016 With respect to the surprise trend  the company delivered positive surprises in two of the last four quarters  with a negative beat of 0 11  Earnings WhispersOur proven model does not conclusively show that Humana is likely to beat on earnings this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here as you will see below Zacks ESP  Humana has an Earnings ESP of  0 55   This is because the Most Accurate estimate is pegged at  1 82  while the Zacks Consensus Estimate stands at  1 81 Zacks Rank  Humana carries a Zacks Rank  4  Sell  We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Currently  the stock is trading at  177 07  We expect the release to lead to stock movement Stocks to ConsiderHere are some companies from the medical sector that you may want to consider as these have the right combination of elements to post an earnings beat this quarter Aceto Corp    NASDAQ ACET   has an Earnings ESP of  5 26  and a Zacks Rank  3  The company is set to report first quarter earnings on May 5 Becton  Dickinson and Company   NYSE BDX   has an Earnings ESP of  1 99  and a Zacks Rank  2  The company is slated to report first quarter earnings on May 5 ,2016-05-02,Zacks Investment Research,https://www.investing.com/analysis/humana-(hum)-q1-earnings-may-disappoint:-stock-to-suffer-200127284,200127284
123176,344691,BDX,5 Stocks To Watch Today  BX  HBI  BEAV  BDX  CREE,opinion,"Here s tomorrow s swing trading watch list 

Long The Blackstone Group LP  NYSE BX 



Long Hanesbrands Inc  NYSE HBI 



Long B E Aerospace Inc  NASDAQ BEAV 



Short Becton Dickinson and Company  NYSE BDX 



Short Cree Inc  NASDAQ CREE ",2015-04-08,Ryan Mallory,"https://www.investing.com/analysis/swing-trading-watch-list:-bx,-hbi,-beav,-bdx,-cree-247637",247637
123177,344692,BDX,Swing Trades  BX  HBI  BEAV  BDX  CREE,opinion,"Here s today s swing trading watch list
Long Blackstone Group  NYSE BX 

Long HanesBrands  NYSE HBI 

Long BE Aerospace  NASDAQ BEAV 

Short Becton Dickinson  NYSE BDX 

Short Cree  Inc  NASDAQ CREE ",2015-04-08,Ryan Mallory,"https://www.investing.com/analysis/swing-trading-watch-list:-bx,-hbi,-beav,-bdx,-cree-247750",247750
123178,344693,BDX,Lackluster Earnings Reports Put Eager Bulls Back Into Waiting ,opinion,"Even with many of the global issues pushed off the front page  eager bulls found yet another reason to keep the troops in the barracks  The only newsworthy items are related to corporate earnings reports  which have been mixed at best  interspersed with the occasional spectacular report    primarily from mega caps like Google  NASDAQ GOOGL   Facebook  NASDAQ FB   or Amazon  NASDAQ AMZN   Some of the bulls have taken their chips off the table until after Labor Day  while others have merely scaled back to scalping some trades  Either way  stocks appear destined to thrash about for the rest of the summer 
In this weekly update  I give my view of the current market environment  offer a technical analysis of the S P 500 chart  review our weekly fundamentals based SectorCast rankings of the ten U S  business sectors  and then offer up some actionable trading ideas  including a sector rotation strategy using ETFs and an enhanced version using top ranked stocks from the top ranked sectors 

Market overview 

Earnings season is off and running  and yes  some of the reports have been startlingly strong  Beyond the blowout numbers from mega caps like Google  Facebook  and Amazon  we have heard the occasional terrific report from firms like Sabrient favorite Valeant Pharmaceuticals  NYSE VRX   On the flip side  IBM  NYSE IBM   United Technologies  NYSE UTX  and Verizon  NYSE VZ  have disappointed  In any case  leadership has been narrowing  and market breadth is about the worst in the past 15 years 

Healthcare has been by far the best performing sector again this year  but Financials are starting to perk up  And looking forward  there is optimism that banks will do well in an environment of rising rates and a steepening yield curve 

Of course  given the strength of the US dollar  commodities across the board are in glut mode  with much weeping and gnashing of teeth in the Energy and Basic Materials sectors  Nevertheless  refiners of petroleum products are doing quite well  thank you  and enjoying strong operating margins  The  crack spread   i e   the difference between the cost paid for crude oil versus the price received for refined product has been very attractive  Sabrient favorites in the space include Tesoro  NYSE TSO   Valero Energy  NYSE VLO   and Marathon Petroleum  NYSE MPC  

Other than earnings  the other big news story is China s stock market  which took a big  8  hit on Monday  its worst selloff in eight years  which led regulators to announce they will begin buying shares as a way to stabilize the market 

Of course  the Fed s plan for making their first move with the fed funds rate is still a matter of interest  but it is certainly unclear as to when that might occur  despite the Fed s desire to not surprise the markets with such actions   I myself have long thought it might not occur until next year  but recently I gave more credence to the possibility of a move this fall  The Fed seems to be signaling September  and most economists seem to think that s the highest likelihood  But according to ConvergEx  the CME Fed Funds futures is indicating lower than 50  likelihood until December  and in fact  inflation and GDP growth are both indicative of a fragile economy that the Fed is unlikely to want to burden 

Bill Gross recently said that the Fed needs to just go ahead and raise the fed funds rate essentially to prove that the economy doesn t really rely upon low rates to function  Hmmm  We shall see  And for his own part  Jeffrey Gundlach has predicted that a move won t occur this year  and moreover  he thinks that the 10 year Treasury yield will soon fall again toward the 2  level  Note that the 10 year yield closed Friday at 2 27   while the 30 year yield was at 2 97  

The CBOE Market Volatility Index  VIX   a k a  fear gauge  closed last Friday at 13 74  but then on Monday it spiked above 16  which is back above the 15 fear threshold  but still well below the 20 panic threshold that has held as resistance through the summer  In fact  S P recently reported that with the exception of gold and oil  volatility is generally down across asset classes  and implied volatility in every equity market is below its 200 day simple moving average 

SPY chart review 

The SPDR S P 500 Trust  ARCA SPY  closed last week at 208  but then fell on Monday to close at 206 79  where it is again probing historically solid support at the important 200 day simple moving average  As I suspected it would  the long standing uptrend line was easily recaptured  after a brief hesitation   but recent news events once again brought the bears out in enough force to push price down once again  In effect  SPY succumbed to a triple top formation as shown  and in fact the Russell 2000 small cap index actually displays a more ominous head and shoulders pattern   Oscillators RSI  MACD  and Slow Stochastic are all pointed downward with more room to run to the downside  Major support is right here at current levels corresponding to the critical 200 day SMA  which is still rising bullishly  by the way   followed by earlier in year support at 205  then round number support at the 200 price level 



Latest sector rankings  

Relative sector rankings are based on our proprietary SectorCast model  which builds a composite profile of each equity ETF based on bottom up aggregate scoring of the constituent stocks  The Outlook Score employs a forward looking  fundamentals based multifactor algorithm considering forward valuation  historical and projected earnings growth  the dynamics of Wall Street analysts  consensus earnings estimates and recent revisions  up or down   quality and sustainability of reported earnings  forensic accounting   and various return ratios  It helps us predict relative performance over the next 1 3 months 

In addition  SectorCast computes a Bull Score and Bear Score for each ETF based on recent price behavior of the constituent stocks on particularly strong and weak market days  High Bull score indicates that stocks within the ETF recently have tended toward relative outperformance when the market is strong  while a high Bear score indicates that stocks within the ETF have tended to hold up relatively well  i e   safe havens  when the market is weak 

Outlook score is forward looking  while Bull and Bear are backward looking  As a group  these three scores can be helpful for positioning a portfolio for a given set of anticipated market conditions  Of course  each ETF holds a unique portfolio of stocks and position weights  so the sectors represented will score differently depending upon which set of ETFs is used  We use the iShares that represent the ten major U S  business sectors  Financial  NYSE IYF   Technology  NYSE IYW   Industrial  NYSE IYJ   Healthcare  NYSE IYH   Consumer Goods  NYSE IYK   Consumer Services  NYSE IYC   Energy  NYSE IYE   Basic Materials  NYSE IYM   Telecommunications  NYSE IYZ   and Utilities  NYSE IDU   Whereas the Select Sector SPDRs only contain stocks from the S P 500  I prefer the iShares for their larger universe and broader diversity  Fidelity also offers a group of sector ETFs with an even larger number of constituents in each 


Here are some of my observations on this week s scores 

1  Healthcare has returned to the top spot with an Outlook score of 82  primarily due to favorable sentiment among Wall Street analysts  net upward revisions to earnings estimates  and a market topping forward long term growth rate  However  its forward P E remains pricey  Financial takes second with a score of 78  primarily due to its low forward P E  Utilities falls to third place with a score of 72  followed by Technology and Consumer Goods  Staples Noncyclical   All five score above 60  and then there is a gap down to Industrial at 36 and Consumer Services  Discretionary Cyclical  at 35  Thus  we have a two tier ranking 

2  Energy remains at the bottom with an Outlook score of 5  while Telecom again takes the second spot in the bottom two with a 17  Both sectors score poorly in most factors of the GARP model across the board  although Telecom has enjoyed recent upgrades to earnings estimates 

3  Looking at the Bull scores  Healthcare  Financial  and Technology all share the top score of 59  Energy has the lowest Bull score of 48 and is the only one below 50  The top bottom spread has narrowed to only 11 points  reflecting high sector correlations on particularly strong market days  i e   broad risk on buying   It is generally desirable in a healthy market to see low correlations reflected in a top bottom spread of at least 20 points  which indicates that investors have clear preferences in the stocks they want to hold 

4  Looking at the Bear scores  Utilities displays the top score of 55  followed by Consumer Goods  Staples Noncyclical   which means that stocks within these sectors have been the preferred safe havens  relatively speaking  on weak market days  Basic Materials scores the lowest at 39  The top bottom spread is 16 points  which reflects moderate sector correlations on particularly weak market days  Ideally  certain sectors will hold up relatively well while others are selling off  so it is generally desirable in a healthy market to see low correlations reflected in a top bottom spread of at least 20 points 

5  Healthcare displays the best all around combination of Outlook Bull Bear scores  followed by Financial  while Energy is clearly the worst  Looking at just the Bull Bear combination  Consumer Goods  Staples Noncyclical  is the best  followed by Healthcare and Utilities  indicating superior relative performance  on average  in extreme market conditions  whether bullish or bearish   while Energy and Materials are the worst 

6  Overall  this week s fundamentals based Outlook rankings continue to look mostly neutral  with Utilities and Consumer Goods  Staples Noncyclical  in the top five  well ahead of Consumer Services  Discretionary Cyclical   Industrial  and Basic Materials  Keep in mind  the Outlook Rank does not include timing or momentum factors  but rather is a reflection of the fundamental expectations of individual stocks aggregated by sector 

Stock and ETF Ideas 

Our Sector Rotation model  which appropriately weights Outlook  Bull  and Bear scores in accordance with the overall market s prevailing trend  bullish  neutral  or defensive   now reflects a neutral bias and suggests holding Healthcare  Financial  and Utilities in that order   Note  In this model  we consider the bias to be neutral from a rules based trend following standpoint when SPY is below its 50 day but still above its 200 day simple moving average  

Other highly ranked ETFs in SectorCast from the Healthcare  Financial  and Utilities sectors include iShares Global Healthcare ETF  NYSE IXJ   PowerShares KBW Bank Portfolio  NYSE KBWB   and Guggenheim Invest S P 500 Equal Weight Utilities ETF  NYSE RYU  

For an enhanced sector portfolio that enlists some top ranked stocks  instead of ETFs  from within the top ranked sectors  some long ideas from Healthcare  Financial  and Utilities sectors include Becton  Dickinson   Co  NYSE BDX   Valeant Pharmaceuticals  NYSE VRX   The Travelers Companies  NYSE TRV   SunTrust  NYSE STI   The AES Corp  NYSE AES   and Level 3 Communications  NYSE LVLT   All are highly ranked in the Sabrient Ratings Algorithm 

If you prefer to play a bounce and maintain a bullish bias  the Sector Rotation model suggests holding Healthcare  Financial  and Technology  in that order  But if you prefer a defensive stance on the market  the model suggests holding Utilities  Consumer Goods  Staples Noncyclical   and Healthcare  in that order 

IMPORTANT NOTE  I post this information each week as a free look inside some of our institutional research and as a source of some trading ideas for your own further investigation  It is not intended to be traded directly as a rules based strategy in a real money portfolio  I am simply showing what a sector rotation model might suggest if a given portfolio was due for a rebalance  and I may or may not update the information each week  There are many ways for a client to trade such a strategy  including monthly or quarterly rebalancing  perhaps with interim adjustments to the bullish neutral defensive bias when warranted    but not necessarily on the days that I happen to post this weekly article  The enhanced strategy seeks higher returns by employing individual stocks  or stock options  that are also highly ranked  but this introduces greater risks and volatility  I do not track performance of the ETF and stock ideas mentioned here as a managed portfolio 
Disclosure  Author has no positions in stocks or ETFs mentioned 
Disclaimer  This newsletter is published solely for informational purposes and is not to be construed as advice or a recommendation to specific individuals  Individuals should take into account their personal financial circumstances in acting on any rankings or stock selections provided by Sabrient  Sabrient makes no representations that the techniques used in its rankings or selections will result in or guarantee profits in trading  Trading involves risk  including possible loss of principal and other losses  and past performance is no indication of future results ",2015-07-28,Scott Martindale,https://www.investing.com/analysis/lackluster-earnings-reports-put-eager-bulls-back-into-waiting-259656,259656
123189,344704,BDX,Becton Dickinson   Co  Company s Stock In Value,opinion,This article is going to look at blue chip dividend growth stock Becton Dickinson   Co  BDX  through the lens of FAST Graphs   fundamentals analyzer software tool  which shows the company currently in value  The dividend growth investor might want to research this company further for a possible candidate for their portfolio   BD is a leading global medical technology company that develops  manufactures and sells medical devices  instrument systems and reagents  The Company is dedicated to improving people s health throughout the world  BD is focused on improving drug delivery  enhancing the quality and speed of diagnosing infectious diseases and cancers  and advancing research  discovery and production of new drugs and vaccines  BD s capabilities are instrumental in combating many of the world s most pressing diseases  Founded in 1897 and headquartered in Franklin Lakes  New Jersey  BD employs approximately 29 000 associates in more than 50 countries throughout the world  The Company serves healthcare institutions  life science researchers  clinical laboratories  the pharmaceutical industry and the general public   Earnings Determine Market Price  The following earnings and price correlated  clearly illustrates the importance of earnings  The Earnings Growth Rate Line or True Worth  Line  orange line with white triangles  is correlated with the historical stock price line  On graph after graph the lines will move in tandem  If the stock price strays away from the earnings line  over or under   inevitably it will come back to earnings   Earnings   Price Correlated Fundamentals at a Glance A quick glance at the historical earnings and price correlated FAST Graphs  on Becton Dickinson   Co shows a picture of a company that is in value based upon the historical earnings growth rate of 10 8   orange circle  and a current PE of 14 5  Analysts are forecasting the earnings growth to continue at about 9 5   and when you look at the forecasting graph below  the stock appears in value   it s inside of the value corridor of the five orange lines   based on future growth   Becton Dickinson   Co  Historical Earnings  Price  Dividends and Normal PE Since 1998 Performance Table Becton Dickinson   CoThe associated performance results with the earnings and price correlated graph  validates the principles regarding the two components of total return  capital appreciation and dividend income  Dividends are included in the total return calculation and are assumed paid  but not reinvested  When presented separately like this  the additional rate of return a dividend paying stock produces for shareholders becomes undeniably evident  In addition to the 8 1  capital appreciation  green circle   long term shareholders of Becton Dickinson   Co  assuming an initial investment of  1 000  would have received an additional  436 40 in dividends  blue highlighting  that increased their total return from 8 1  to 9  per annum versus 4   red circle  in the S P 500 The following graph plots the historical PE ratio  the dark blue line  in conjunction with 10 year Treasury note interest  Notice that the current price earnings ratio on this quality company is as low as it has been since 1998 A further indication of valuation can be seen by examining a company s current price to sales ratio relative to its historical price to sales ratio  The current price to sales ratio for Becton Dickinson   Co is 2 02 which is historically low  Looking to the FutureExtensive research has provided a preponderance of conclusive evidence that future long term returns are a function of two critical determinants 1  The rate of change  growth rate  of the company s earnings2  The price or valuation you pay to buy those earningsForecasting future earnings growth  bought at sound valuations  is the key to safe  sound  and profitable performance The Estimated Earnings and Return Calculator Tool is a simple yet powerful resource that empowers the user to calculate and run various investing scenarios that generate precise rate of return potentialities  Thinking the investment through to its logical conclusion is an important component towards making sound and prudent commonsense investing decisions The consensus of 21 leading analysts reporting to Capital IQ forecast Becton Dickinson   Co s long term earnings growth at 9 5   orange circle   Becton Dickinson   Co has medium long term debt at 34  of capital  red circle   Becton Dickinson   Co is currently trading at a P E of 14 5  which is inside the value corridor  defined by the five orange lines  of a maximum P E of 18  If the earnings materialize as forecast  Becton Dickinson   Co s True Worth  valuation would be  126 80 at the end of 2017  brown circle on EYE Chart   which would be a 12 3  annual rate of return from the current price  yellow highlighting  Earnings Yield EstimatesDiscounted Future Cash Flows  All companies derive their value from the future cash flows  earnings  they are capable of generating for their stakeholders over time  Therefore  because Earnings Determine Market Price in the long run  we expect the future earnings of a company to justify the price we pay Since all investments potentially compete with all other investments  it is useful to compare investing in any prospective company to that of a comparable investment in low risk Treasury bonds  Comparing an investment in Becton Dickinson   Co to an equal investment in 10 year Treasury bonds  illustrates that Becton Dickinson   Co s expected earnings would be 5 9  purple circle  times that of the 10 Year T Bond Interest   See EYE chart below   This is the essence of the importance of proper valuation as a critical investing component Summary   ConclusionsThis report presented essential  fundamentals at a glance  illustrating the past and present valuation based on earnings achievements as reported  Future forecasts for earnings growth are based on the consensus of leading analysts  Although  with just a quick glance you can know a lot about the company  it s imperative that the reader conducts their own due diligence in order to validate whether the consensus estimates seem reasonable or not Disclosure   No position at the time of writing Disclaimer  The opinions in this document are for informational and educational purposes only and should not be construed as a recommendation to buy or sell the stocks mentioned or to solicit transactions or clients  Past performance of the companies discussed may not continue and the companies may not achieve the earnings growth as predicted  The information in this document is believed to be accurate  but under no circumstances should a person act upon the information contained within  We do not recommend that anyone act upon any investment information without first consulting an investment advisor as to the suitability of such investments for his specific situation  A comprehensive due diligence effort is recommended ,2012-09-13,F.A.S.T. Graphs,https://www.investing.com/analysis/becton-dickinson---co:-company's-stock-in-value-136263,136263
123213,344728,BDX,Who Will Profit In The Global War Against Kidney Disease ,opinion,As the emerging market nations of the world become more affluent  trillions more will be spent on health care in these lands  especially China and India  Ironically  the greater level of riches in these countries will lead to more cases of lifestyle ailments  especially the various types of kidney diseases  As such  companies ranging in size from Becton  Dickinson   Co   BDX  to Amgen  AMGN  to PLC Systems  OTC  PLCSF  are well positioned to profit from this trend in health care  According to studies  the global consumer class should reach one billion  India already has the largest middle class in the world  Economic development is also increasing across the continent of Africa  With the larger middles class will be more health care expenditures  China  as the second largest economy in the world and biggest consumer so many commodities  presents a very compelling case for investing in the global crusade against kidney disease  The People s Republic of China is seeking to develop more of a consumer economy in China  At present  about 40  of the gross domestic product of China is dependent upon exports to the United States and Great Britain  By contrast  about 70  of the gross domestic product of the United States is based on domestic consumer spending  Beijing wants to see health care spending increase in the world s most populous country  Looming large in China  and other emerging market nations  is kidney disease  According to the World Health Organization   kidney disease is increasing dramatically and the cost of treating this enormous epidemic represents an enormous burden on healthcare systems worldwide   There are many factors contributing to the worldwide expansion of kidney disease  The rising affluence around the world leads to richer diets  The more disposable income that a consumer has  the more is spent on restaurant fare and processed foods  Too much of that leads to diabetes and other kidney diseases  According to  The Rise in Chronic Kidney Disease   a report by the World Health Organization  240 million people in the world have diabetes today  The report furthers that   This figure is projected to rise to 380 million by 2025  largely due to population growth  aging  urbanization  unhealthy eating habits  increased body fat and a sedentary lifestyle  By 2025  the number of people with diabetes is expected to more than double in South East Asia  the Eastern Mediterranean and Middle East  and Africa  It is projected to rise by nearly 20  in Europe  50  in North America  85  in South and Central America and 75  in the Western Pacific region  The top five countries with the highest prevalence of diabetes in order include India  China  the United States  Russia and Japan  Worldwide more than 50  of people with diabetes are unaware of their condition and are not treated   What investors should be aware of is what Becton Dickinson  Amgen  and PLC Systems have to offer in upside potential in combating kidney disease As a Dividend Aristocrat  Becton  Dickson   Co  presents a blue chip way to invest for international sales in medical technology  With almost 40 000 employees  about two thirds of Becton  Dickinson s sales are to overseas customers  Many of its products are used in the various facets of detecting and treating kidney disease  Amgen is one of the biggest biotechnology firms with sales of  17 5 billion in 2012 from a broad array of products that fight kidney disease and other ailments  As examples  its protein based therapeutic products such as Aranesp and Epogen fight anemia in chronic kidney disease  Pretty much a pure kidney play  PLC Systems is a small cap focused on the cardiac and vascular market  Its top product is RenalGuard  which expeditiously removes contrast dyes that are toxic for kidneys  Studies have proven that RenalGuard is effective in preventing Contrast Induced Nephropathy  There is a RenalGuard study underway to support a planned Premarket Approval filing with the United States Food   Drug Administration  Depending on the risk tolerance level of the investor  these three companies offer an array of methods for profiting in gains against kidney disease  Due to its small cap status  PLC Systems offers the most upside  As a Dividend Aristocrat  Becton  Dickson   Co  offer more modest gains  although it is up almost 30  for 2013  It is much the same story with Amgen  up more than 16  for the year ,2013-07-08,John Murphy,https://www.investing.com/analysis/who-will-profit-in-the-global-war-against-kidney-disease-174510,174510
